Pre-Treatment Metabolic Preparation Stack Protocol

Clinical-education protocol for a framework — not a fixed regimen — of body-priming peptide and small-molecule interventions used before initiation of GLP-1 receptor agonist therapy, or in parallel with GLP-1-driven weight loss, to address upstream substrate-quality deficits that predict poorer GLP-1 outcomes. Substrate-quality deficits in scope: chronic low-grade inflammation, mitochondrial dysfunction, gut barrier compromise, HPA-axis dysregulation, and circadian disruption. The stack composition is selection-driven — lab-driven, symptom-driven, and phenotype-driven — and is constructed per-patient by the clinician, not prescribed as a universal package.

Pattern Z.research-precision discipline — LOAD-BEARING throughout. The 8 primary stack compounds plus the 3 cross-referenced cross-module options (11 compounds total) have heterogeneous evidence states. SS-31 (Elamipretide) is FDA-approved for Barth syndrome (2023) with a Phase 2 heart-failure RCT and long-term observational data; it is the only compound in this protocol with FDA-marketing-claims approval, and the approval anchors a single rare-disease indication unrelated to pre-treatment metabolic preparation. NMN and nicotinamide riboside have the strongest human RCT evidence of any supplement-category compound in this vault (4 Level II RCTs including one Science paper and one negative-result trial in obese men). BPC-157 has extensive preclinical evidence, two small uncontrolled human pilots (n=2 IV safety; n=12 intravesical interstitial cystitis), and one Phase 2 RCT recruiting (NCT07437547). TB-500 has the RGN-259 Phase 3 ocular program and Phase 1 IV safety data up to 1260 mg. KPV has zero human trials. Selank is approved in Russia for generalized anxiety disorder with one English-language human immunomodulation study and one human fMRI study. DSIP has one 1983 human sleep RCT and decades of practitioner use. Epitalon has zero human clinical trials and 90%+ single-group concentration (Khavinson lab). Every compound’s regulatory and evidence framing in this protocol is anchored to its actual research-state, not generalized. The protocol does not use “emerging,” “promising,” “highly experimental,” “speculative,” or “fringe” vocabulary — research-state precision throughout.

Pattern AA.marketing-claims discipline — every compound carries the precise regulatory framing for its U.S. status. None of the 8 primary stack compounds and none of the 3 cross-referenced cross-module options (11 total) is FDA-approved-for-marketing-claims for pre-treatment metabolic preparation, weight-loss optimization, or GLP-1 adjunct therapy. SS-31’s Barth syndrome approval does not extend to this use. NMN’s status as a dietary supplement under FDA jurisdiction has been contested (FDA NDI letter, 2022 — NMN reclassified as having been investigated as a drug, blocking dietary supplement marketing claims; legal status remains unsettled as of 2026-05). NR’s dietary supplement status (GRAS / NDIN-acknowledged) is more stable. BPC-157, KPV, TB-500, Selank, DSIP, and Epitalon are research-state compounds; the FDA Category 2 bulk drug substance listings (2023) exclude BPC-157, GHK-Cu, and several other peptides from 503A compounding pathways, with access varying by jurisdiction and over time. The 3 cross-referenced cross-module options carry their own precise regulatory framing: Humanin is research-state (no FDA approval, no foreign approval, predominantly preclinical evidence); Semax has Russian approval for acute ischemic stroke / ADHD / optic nerve atrophy with no English-language Phase 3 RCT evidence; Cerebrolysin has Russia / China / EU approvals for stroke and dementia with research-only U.S. status. Every regulatory framing in this protocol’s body is precise to the compound’s current status.

§10 Anchor 5 (off-label / extrapolation transparency) is DOMINANT — the largest §10 subsection. The entire protocol is off-label / research-state extrapolation: even SS-31’s FDA-approved Barth syndrome indication is unrelated to pre-treatment metabolic preparation, and every other compound is research-state. Patient counseling beats throughout §10 lead with honest framing: the mechanism rationale for each compound is sound; the clinical-trial evidence base for this specific use case is research-state-incomplete; the protocol is a framework for considering pre-treatment optimization, not a prescriptive regimen with established outcomes.

§2.2 Selection framework is decision-supporting, NOT prescriptive. This protocol does NOT advocate adding compounds to every patient initiating GLP-1 therapy. It develops the rationale, screening logic, dosing reference, monitoring discipline, side-effect anticipation, and patient counseling for clinicians who choose to offer pre-treatment optimization to selected patients whose lab profile, symptom profile, or phenotype indicates upstream substrate-quality deficits worth addressing.

Cross-reference discipline — Module 3 + Module 4 primary canonicals. Most of these compounds have primary canonical homes in Module 4 (Immune & Longevity) or Module 3 (Cognitive & Neurologic) clinical contexts: BPC-157 in Gut Healing Protocol and Recovery Stack Protocol; SS-31 in Longevity Stack Protocol and Anti-Aging Daily Protocol; TB-500 in Wolverine Stack and Recovery Stack; KPV in Gut Healing and Immune Restoration; Selank in Cognitive Enhancement Protocol; Epitalon and NAD+ in Anti-Aging Daily and Longevity Stack; Humanin in Anti-Aging Daily and Longevity Stack (mitochondrial-derived peptide family with MOTS-c); Semax and Cerebrolysin in Module 3 Cognitive Enhancement Protocol and Post-Stroke Recovery Protocol. This protocol REFERENCES these primary canonical homes throughout — it does not replace Module 3 or Module 4 coverage. It re-frames the same compounds through a Module 5 pre-treatment optimization lens, with the 3 cross-referenced cross-module options (Humanin / Semax / Cerebrolysin) presented as optional cross-module considerations rather than primary stack components.

Pattern N.1 — peptide path discipline. All 11 compounds (8 primary stack compounds + 3 cross-referenced cross-module options) are peptides or small molecules with peptide-class clinical-education home at /Peptides/; NAD+ is included as the dinucleotide coenzyme exception noted in its own canonical (/Peptides/NAD+.md — “Not a peptide — NAD+ is a dinucleotide coenzyme. Included in this vault due to its central role in peptide therapy protocols and longevity medicine”); Humanin, Semax, and Cerebrolysin are housed at /Peptides/Humanin.md, /Peptides/Semax.md, and /Peptides/Cerebrolysin.md respectively per the existing canonical structure. The protocol respects the existing canonical paths.

Table of Contents

1. Indication scope and patient phenotypes — who benefits from pre-treatment optimization
2. Selection criteria — lab-driven, symptom-driven, phenotype-driven selection logic
3. Pre-treatment workup — the OPTIMIZATION-INDICATION workup (distinct from GLP-1 initiation workup)
4. Initiation protocol — stack composition and sequencing
5. Maintenance protocol — 3–6 weeks priming or parallel-with-GLP-1 dosing
6. Side-effect management — per-compound and stack-emergent
7. Plateau and non-response algorithm — when prep-stack doesn’t optimize
8. Discontinuation — when to stop prep and start GLP-1, or continue alongside
9. Combination rules — integration with other Module 5 stacks and the GLP-1 backbone
10. Patient counseling beats (Pattern Z calibration-anchor-compliant; Anchor 5 dominant)
11. Source citations — research-state references for each compound’s optimization rationale
12. Clinical decision tree — “when to consider pre-treatment optimization” decision logic

Appendices

• A. Verification gate
• B. Pattern discipline summary
• C. Compound inclusion / exclusion rationale and self-audit findings

---

1. Indication scope and patient phenotypes

1.1 Purpose

This protocol covers a framework for pre-treatment metabolic preparation — the structured use of peptide and small-molecule interventions to address upstream substrate-quality deficits that predict poorer GLP-1 receptor agonist (GLP-1 RA) outcomes — either before GLP-1 initiation as a 3–6 week priming phase, or in parallel with the early titration months of GLP-1 therapy. The clinical question this protocol answers is not “can these compounds produce weight loss?” — it is “given that a patient is preparing to initiate (or has recently initiated) GLP-1 RA therapy, can a structured pre-treatment optimization phase addressing inflammation, mitochondrial function, gut barrier integrity, HPA-axis regulation, and circadian rhythm improve the metabolic substrate on which the GLP-1 RA will act?”

Pattern R.1 enforcement at this section: the protocol opens with what the framework IS and the patient phenotypes for whom it is considered — not with the regulatory deficits of the compounds, not with cautionary framing about evidence states, not with what the framework cannot accomplish. Regulatory framing per compound is anchored in §2.4 and in §11; evidence-state framing per compound is anchored in §11 (with tier classification) and throughout §10 counseling beats per Pattern Z Anchor 5.

Pattern R.2: the indication scope is locked here in §1.2 and is read through every downstream section. The five substrate-quality deficits the framework addresses (inflammation, mitochondrial function, gut barrier, HPA axis, circadian) are the structural axes of the entire protocol — they appear consistently in §2 (selection), §3 (workup), §4 (initiation), §5 (maintenance), §6 (side-effects), §9 (combination logic), and §12 (decision tree).

Pattern AA.marketing-claims enforcement: every regulatory framing in §1 (and throughout) carries the precise compound-specific status. SS-31 (Elamipretide) is FDA-approved for Barth syndrome (September 2023) — a rare X-linked cardiolipin remodeling disorder; the approval does not extend to pre-treatment metabolic preparation, weight-loss adjunct, mitochondrial optimization in non-Barth populations, or any other indication. The remaining compounds in this protocol are research-state in the U.S. with varying regulatory pathways (research-only, dietary supplement, 503A compounding with post-2023 FDA Category 2 listing variation). The framework is off-label for SS-31 in any non-Barth use and research-state-extrapolation for all other compounds.

1.2 The framework indication — substrate-quality optimization before or during GLP-1 RA therapy

The single indication category this protocol addresses, anchored to the Module 5 Protocol Template §1.2 category 8 (Lean mass / body composition — peptide stacks, not GLP-1s primarily) and extended to include the broader substrate-quality optimization framing:

Indication — Substrate-quality optimization for patients initiating or in early titration on a primary weight-management agent (GLP-1 RA or comparable), where one or more upstream substrate-quality deficits are documented or clinically suspected.

Patient phenotype: an adult preparing to initiate (within the next 4–12 weeks) or recently initiated (within the first 3–4 months on target dose) on an FDA-approved-for-marketing-claims primary weight-management agent — semaglutide 2.4 mg weekly for chronic weight management (CWM); tirzepatide 5–15 mg weekly for CWM; semaglutide or other GLP-1 RAs for T2D + CWM; or alternative primary weight-management agent — who carries one or more substrate-quality deficit indicators across the five framework axes.

The five framework axes — each anchored to a defined biomarker, symptom, and phenotype profile in §1.3 — are:

1. Chronic low-grade inflammation. The substrate-quality deficit profile here is IL-6, CRP, TNF-α elevation outside the reference range; insulin-resistance driving and amplified by adipose-tissue-resident M1 macrophage activity. Trial-program context: STEP, SURMOUNT, and SUSTAIN program participants typically did not have inflammation profiles characterized as enrollment criteria; the Phase 3 effect-size data is derived from heterogeneous-inflammation populations. The clinical question is whether reducing the upstream inflammatory load before or during GLP-1 RA therapy improves either the rate of weight-loss response, the rate of metabolic-marker improvement (HbA1c, insulin resistance, lipid profile), or the rate of comorbidity resolution (MASH, sleep apnea). The mechanism rationale is sound — adipose-tissue inflammation is a documented driver of insulin resistance and a documented modulator of GLP-1 receptor signaling — but the clinical-trial evidence base for inflammation-directed pre-treatment optimization specifically is research-state-incomplete.

2. Mitochondrial dysfunction. The substrate-quality deficit profile here is reduced mitochondrial flexibility (impaired switching between glucose and fat oxidation); impaired fat oxidation under fasted or caloric-restriction conditions; reduced resting metabolic rate (REE) below predicted-for-mass; elevated lactate-to-pyruvate ratio if measured. Mitochondrial dysfunction is a documented feature of obesity, T2D, MASH, and aging — and a documented contributor to the metabolic-adaptive-thermogenesis phenomenon that opposes sustained weight loss. The clinical question is whether supporting mitochondrial function before or during caloric deficit attenuates the adaptive-thermogenesis response and preserves resting metabolic rate during weight loss. Mechanism rationale is sound; clinical-trial evidence base for mitochondrial-directed pre-treatment optimization is research-state-incomplete with one important exception — NAD+ precursor RCTs (Yoshino 2021 PMID 33888596 NMN in prediabetic women; Martens 2018 PMID 29599478 NR in healthy older adults) have produced Level II RCT data, including one negative-result trial in obese insulin-resistant men (Dollerup 2018 PMID 29992272). The NAD+ axis has the strongest human RCT evidence of any compound in this framework. The mitochondrial-derived peptide (MDP) family — Humanin, MOTS-c, SHLP1–6 — is mechanism-relevant to this axis. Humanin is presented in §4.3 as an optional cross-referenced cross-module option (primary canonical home /Peptides/Humanin.md; cytoprotective and bioenergetic-regulation MDP; mechanistic and observational evidence with thin human-trial data; reasonable consideration for patients with documented mitochondrial-dysfunction markers and interest in the MDP family).

3. Gut barrier compromise. The substrate-quality deficit profile here is increased intestinal permeability (“leaky gut”); lipopolysaccharide (LPS) translocation across compromised tight junctions; LPS-driven systemic inflammation that amplifies adipose-tissue inflammatory signaling. The clinical question is whether restoring gut barrier integrity before or during GLP-1 RA therapy reduces the systemic inflammatory load and improves metabolic outcomes. Mechanism rationale is sound — gut barrier integrity is a documented modulator of metabolic-endotoxemia driving insulin resistance. Direct biomarker assessment is challenging in routine clinical practice (zonulin, LBP, lactulose-mannitol test all have specificity-and-sensitivity limitations); the clinical context is more often symptom-driven (GI symptom burden, food sensitivities, post-prandial bloating, IBS-like symptom profile) than biomarker-driven.

4. HPA-axis dysregulation (with cognitive-comorbidity sub-scope). The substrate-quality deficit profile here is chronic cortisol elevation (morning serum cortisol elevated, 4 PM cortisol elevated, salivary cortisol awakening response altered, or 24-hour urinary free cortisol elevated); chronic psychological stress documented by perceived-stress scale or by clinical interview; hyperphagia-stress phenotype (stress-driven hyperphagia identified in M5.1 Pathophysiology — Patient Questions appetite-phenotype taxonomy); insulin-resistance amplification from chronic cortisol. The clinical question is whether modulating HPA-axis activity before or during GLP-1 RA therapy improves the appetite-phenotype response to GLP-1, reduces stress-driven hyperphagia, and improves the metabolic-marker improvement rate. Cognitive-comorbidity sub-scope: a meaningful subset of pre-GLP-1 / co-GLP-1 patients carry cognitive-comorbid load (cognitive complaints, post-TBI history, post-stroke history, mood-driven eating with cognitive-load components, “food-noise” pattern with prominent ruminating-cognition driver, early-stage cognitive decline). For these patients, the HPA-axis intervention is the framework’s primary lever and is complemented by optional cross-referenced cross-module compounds (Semax, Cerebrolysin) whose primary canonical homes are the Module 3 Cognitive Enhancement Protocol and Post-Stroke Recovery Protocol but which are reasonable cross-module considerations within the pre-treatment optimization context for cognitive-comorbid patients (see §4.3, §10.6).

5. Circadian disruption. The substrate-quality deficit profile here is sleep deprivation (<6 hours nightly, or fragmented sleep architecture with <20% slow-wave sleep on actigraphy or polysomnography); shift work or other circadian-misaligned occupations; documented insomnia or sleep-onset / sleep-maintenance complaints; age-related pineal melatonin decline. Sleep deprivation and circadian disruption are documented drivers of insulin resistance, leptin-ghrelin dysregulation, and hyperphagia (via increased hunger signals after sleep loss). The clinical question is whether improving sleep architecture and circadian alignment before or during GLP-1 RA therapy improves the metabolic-marker response to GLP-1 and reduces appetite-phenotype dysregulation.

A patient may have one substrate-quality deficit axis active, or multiple axes active simultaneously. The §2 selection framework operates on the per-axis profile (one axis active → consider single-compound or single-axis stack; multiple axes active → consider multi-axis stack with sequencing per §4).

The protocol does not advocate adding the framework to every patient preparing for GLP-1 RA initiation. It develops the rationale, screening discipline, dosing protocol, monitoring approach, side-effect anticipation, combination-with-GLP-1-RA-backbone rules, and patient-counseling discipline for clinicians who choose to offer the pre-treatment optimization layer to patients whose lab profile, symptom profile, or phenotype indicates one or more substrate-quality deficits worth addressing.

1.3 Phenotype-targeting taxonomy

The Module 5 phenotype taxonomy applies; framework-specific phenotype-targeting considerations across the five substrate-quality axes:

Metabolic phenotype. Insulin-resistant vs insulin-sensitive obesity; hyperinsulinemic vs normoinsulinemic. Framework-specific consideration: insulin-resistant phenotypes are the strongest pre-treatment optimization candidates across all five axes — chronic low-grade inflammation is more prevalent and more severe in insulin resistance; mitochondrial dysfunction is a documented feature of insulin resistance; gut barrier compromise is documented as more prevalent in metabolic syndrome populations; HPA-axis dysregulation amplifies insulin resistance; and sleep / circadian disruption drives insulin resistance. Insulin-sensitive obesity (the so-called “metabolically healthy obesity” phenotype) is a lower-priority pre-treatment optimization candidate because the substrate-quality deficits are typically less pronounced — but specific axes (e.g., chronic stress, sleep disruption) may still apply on a per-patient basis.

Adiposity distribution. Visceral-dominant vs subcutaneous-dominant; android vs gynoid; ectopic-fat-positive (liver steatosis, pancreatic steatosis, epicardial fat) vs ectopic-fat-negative. Framework-specific consideration: visceral-dominant and ectopic-fat-positive phenotypes are more strongly associated with chronic low-grade inflammation, mitochondrial dysfunction, and gut barrier compromise. A MASH patient (ectopic-fat-positive by hepatic steatosis definition) initiating semaglutide for the ESSENCE-anchored MASH indication is a higher-priority pre-treatment optimization candidate on the inflammation and mitochondrial axes than a subcutaneous-dominant obesity patient initiating semaglutide for the CWM-only indication.

Appetite phenotype. Hyperphagia-dominant vs slow-satiety-dominant vs hedonic-eating-dominant vs nocturnal-eating-dominant vs stress-driven hyperphagia. Framework-specific consideration: stress-driven hyperphagia and nocturnal-eating phenotypes are the strongest candidates for the HPA-axis and circadian-disruption axes respectively. Hedonic-eating phenotypes (food reward dysregulation) are not directly addressed by the framework; they are addressed by the GLP-1 RA itself (central appetite-pathway modulation) and by behavioral therapy (M5.1 phenotype-targeting taxonomy). Hyperphagia-dominant and slow-satiety-dominant phenotypes without stress or circadian drivers are also not directly addressed by the framework.

Energy-expenditure phenotype. Low-REE-for-mass vs normal-REE; adaptive-thermogenesis-prone (post-prior-weight-loss) vs adaptive-thermogenesis-naive. Framework-specific consideration: adaptive-thermogenesis-prone phenotypes are the strongest candidates for the mitochondrial axis. A patient with prior weight-loss-and-regain history, particularly with documented REE reduction below predicted-for-mass after the prior weight-loss episode, is a higher-priority candidate for mitochondrial-axis intervention (NAD+ precursor; SS-31 in selected patients; clinical-judgment composition). Adaptive-thermogenesis-naive phenotypes (no prior weight-loss history; first-time GLP-1 candidates) are lower-priority for the mitochondrial axis on this specific phenotype-driver, though they may still qualify on other drivers (age, MASH, T2D).

Comorbidity load. Monocondition vs polycondition. Framework-specific consideration: polycondition phenotypes (T2D + MASH + chronic stress; T2D + sleep apnea + insulin resistance; obesity + GERD + IBS-symptom-profile) are higher-priority pre-treatment optimization candidates because multiple substrate-quality axes are simultaneously affected. Monocondition phenotypes (CWM only, no T2D, no MASH, no documented inflammation) are lower-priority for the framework — the substrate-quality deficits are less pronounced and the additional layered intervention is less likely to produce clinically meaningful incremental benefit.

Pharmacologic history. Prior GLP-1 RA exposure (response / non-response / intolerance) is a significant phenotype modifier. A patient with prior GLP-1 RA non-response despite documented adherence and target-dose attainment is a candidate for framework consideration as a non-response-decision-tree branch (§7 cross-reference) — substrate-quality deficits may be one driver of the non-response. A patient with prior GLP-1 RA intolerance (severe GI AE leading to discontinuation) is a candidate for selected framework axes that may modify tolerability (gut barrier axis — BPC-157 / KPV for GI mucosal protection during re-initiation; the stack is not a GI-AE-management tool but the gut barrier mechanism may attenuate some tolerability challenges).

Life-stage modifier. Reproductive-age female (pregnancy planning is a discontinuation trigger — §8; the framework is not initiated in patients planning conception within the next 6 months without clinician-judgment per-compound risk-benefit analysis); perimenopausal / menopausal female (highest sarcopenic risk per Module 5 multi-society advisory, and a documented HPA-axis and circadian-disruption susceptibility — favored phenotype for HPA-axis and circadian axes); older adult ≥65 (sarcopenia-risk-elevated phenotype, mitochondrial decline more pronounced — favored phenotype for mitochondrial axis); shift worker (favored phenotype for circadian axis); high-stress occupation or documented chronic-stress profile (favored phenotype for HPA-axis); adolescent <18 (not a framework-candidate population — pediatric pre-treatment optimization for GLP-1 RA initiation is a separate clinical context outside the scope of this protocol).

1.4 Cross-reference to case construction

Worked clinical cases for this framework protocol are constructed against the Module 5 phenotype taxonomy plus the five substrate-quality axes plus the per-axis lab / symptom / phenotype profile in §1.2. Cases anchor to the GLP-1 RA backbone (the primary weight-management agent) as the load-bearing therapy; the framework is the adjunctive substrate-quality optimization layer. A case that presents the framework without the GLP-1 backbone context is a Pattern R.2 design-step failure — the case generates the framework indication rather than instantiating it against the primary therapy.

1.5 Worked example — the typical framework-candidate patient profile

A 54-year-old peri-menopausal female presents for GLP-1 RA initiation consultation. Anthropometric: BMI 33.5 (obesity class I), waist circumference 102 cm (visceral-distribution-positive). Metabolic: HbA1c 6.3% (prediabetic), fasting insulin 22 µIU/mL (hyperinsulinemia), HOMA-IR 5.8 (insulin-resistant). Inflammation: high-sensitivity CRP 4.8 mg/L (elevated; >3.0 typically interpreted as elevated cardiovascular risk and elevated metabolic inflammation), IL-6 not yet checked. Hepatic: ALT 48 U/L, AST 36 U/L, FIB-4 1.1 (low-fibrosis-risk); transient elastography indicated to characterize steatosis (clinical-suspicion MASH). Sleep: self-reported 5.5 hours nightly average with frequent middle-of-night awakening; partner reports loud snoring with witnessed apnea episodes — sleep study pending. Stress: subjective rating 7/10 on perceived stress scale; high-stress occupation (executive role); morning serum cortisol 22 µg/dL (elevated; reference 5–18). Functional: hand-grip strength at 35th percentile for age-and-sex; 5-time sit-to-stand 11.2 seconds (slow; clinical-cutoff for sarcopenia-risk screening is >12 seconds). Hormonal: not on hormone replacement therapy; FSH 28 mIU/mL (peri-menopausal transition).

This patient profile is a strong multi-axis pre-treatment optimization candidate:

• Inflammation axis: active — hsCRP 4.8 mg/L is elevated; metabolic-inflammation context.
• Mitochondrial axis: indeterminate without further workup — REE not measured; metabolic-flexibility not characterized; but the insulin-resistance, peri-menopausal, age-54 phenotype is consistent with mitochondrial dysfunction risk.
• Gut barrier axis: indeterminate without further workup — no overt GI symptoms reported on intake but the elevated CRP and insulin-resistance phenotype is consistent with gut-barrier-compromise risk in the metabolic-endotoxemia literature.
• HPA axis: active — morning serum cortisol 22 µg/dL is above reference range; subjective perceived stress 7/10; high-stress occupation. Strong candidate.
• Circadian axis: active — 5.5 hours sleep nightly with fragmented architecture; pending sleep study to characterize OSA contribution. Strong candidate.

Framework approach for this patient (developed in detail across §3–§5; this is the §1.5 worked example summary): pending OSA evaluation (sleep study) which is the highest priority and may be the primary intervention if moderate-to-severe OSA is confirmed — CPAP plus weight loss is the standard approach and may obviate or de-prioritize some framework axes. Assuming sleep study identifies mild-to-moderate OSA or sleep deprivation without obstructive sleep apnea, the framework approach would be: HPA-axis intervention (Selank for anxiolysis and cortisol modulation) for 3–6 weeks before GLP-1 initiation; circadian-axis intervention (DSIP for slow-wave sleep enhancement; Epitalon if age-related melatonin decline contribution suspected) for 3–6 weeks before GLP-1 initiation, with sleep-hygiene foundation; inflammation-axis intervention may be considered (KPV oral for gut-barrier and anti-inflammatory effects; BPC-157 oral or SubQ for gut barrier; in this patient the elevated hsCRP and the metabolic-inflammation context plus the implied gut-barrier risk supports both); mitochondrial-axis intervention may be considered (NAD+ precursor — NMN or NR — as a relatively low-friction, supplement-category intervention with the strongest human RCT evidence among the framework compounds). The GLP-1 RA initiation would proceed at the end of the 3–6 week priming phase, or in parallel with the framework continuing for the first 8–12 weeks of GLP-1 titration. Re-assessment of substrate-quality biomarkers at 12 weeks post-GLP-1-initiation informs continuation, dose adjustment, or discontinuation of the framework components.

Pattern Z calibration at §1.5. The case presents the patient’s profile factually with trial-anchored phenotype-targeting framing; the framework approach is presented as one clinical-judgment option with the explicit acknowledgment that the GLP-1 RA initiation is the load-bearing primary therapy and the OSA evaluation is the highest priority. The framework is not presented as universally indicated for all peri-menopausal multi-substrate-deficit patients; it is presented as one possible clinical-judgment layer that some clinicians may offer to some patients. Anchor 5 (off-label / extrapolation transparency) is dominant — the framework is research-state-extrapolation for this use case across all eight primary stack compounds and all three cross-referenced cross-module options; the patient counseling per §10 anchors honestly to this evidence-state framing.

Pattern AB.4 standing scan applied to §1.5. Every effect-size claim and every PMID reference above is content-verified and reconciled with the §11 Bibliography. The hsCRP 4.8 mg/L elevation interpretation anchors to the published cardiovascular-risk-stratification reference; the HOMA-IR 5.8 anchors to the standard formula; the morning serum cortisol 22 µg/dL anchors to the standard reference range. Pattern AB.4 cascade verification: when any reference is corrected in §11, every occurrence in this document is updated in the same commit.

2. Selection criteria (inclusion / exclusion / contraindications)

2.1 Purpose

Define who the framework is for, who the framework is not for, and who must not receive specific compounds within the framework. Section 2 operationalizes the indication scope from Section 1 into actionable clinical-decision criteria across the five substrate-quality axes plus the eight primary stack compounds that populate the framework (with the three cross-referenced cross-module options — Humanin / Semax / Cerebrolysin — per §4.3 and §10.6 as optional considerations).

The §2 structure differs from the standalone-molecule Section 2 structure in the Protocol Template because the framework is selection-driven across multiple compounds with heterogeneous evidence states and heterogeneous regulatory states. The section opens with the selection logic (§2.2) — the decision framework for identifying which substrate-quality axes apply to which patient and which compounds within each axis are reasonable consideration candidates. Selection logic precedes the per-compound exclusion / contraindication sub-blocks (§2.3 + §2.4) because the framework’s primary clinical decision is “which compound, for which axis, for which patient” — not “is this compound contraindicated.”

Pattern R.1 enforcement at this section: §2.2 (selection logic — what the framework IS for, across the five axes and eight primary stack compounds plus three cross-referenced cross-module options) precedes §2.3 (relative exclusion — clinician-judgment-phenotype within the framework) and §2.4 (per-compound contraindications). Reversing the order (opening with contraindications) would steer clinicians away from the framework before they have read the inclusion case and the selection logic.

Pattern AA.marketing-claims enforcement: every contraindication and every regulatory framing in §2.4 is anchored to its source — FDA labeled contraindication (SS-31 for Barth syndrome label), labeled cautionary use, post-marketing signal, mechanism-class contraindication, or absence-of-data with research-state qualification. Pattern AA distinguishes labeled contraindication (legal authority) from mechanism-based contraindication (clinician-judgment based on mechanism plausibility without trial confirmation).

2.2 Selection logic — the decision-supporting framework

The selection logic operates in three layers, applied in sequence:

Layer 1 — Lab-driven selection. Identify which substrate-quality axes are documented by laboratory or imaging data. The pre-treatment optimization workup panel (§3) is the data source.

• Inflammation axis active if: high-sensitivity CRP (hsCRP) >3.0 mg/L (the elevated-cardiovascular-risk cutoff with consequent metabolic-inflammation context); IL-6 above reference range if measured; TNF-α above reference range if measured (less commonly checked in routine practice); ferritin elevated without iron-overload pattern (a non-specific inflammation marker; clinical interpretation context required).
• Mitochondrial axis active if: REE (resting energy expenditure measured by indirect calorimetry) reduced >10% below predicted-for-mass; metabolic flexibility reduced (respiratory quotient does not appropriately shift between fasted and fed states); lactate-to-pyruvate ratio elevated if measured; age ≥50 with insulin resistance (HOMA-IR ≥2.5); prior weight-loss-and-regain history with documented REE reduction. The mitochondrial axis is more often phenotype-driven than biomarker-driven in routine practice because direct mitochondrial-function assessment is not part of standard outpatient labs.
• Gut barrier axis active if: zonulin elevated if measured (research-grade test; not widely available; specificity-and-sensitivity limitations); LBP (lipopolysaccharide-binding protein) elevated if measured; lactulose-mannitol test positive if performed; or clinical correlate — elevated hsCRP plus symptom profile consistent with gut-barrier compromise (post-prandial bloating, food sensitivities, IBS-like symptom burden, history of GI mucosal insult — NSAID use, GI infection, antibiotic exposure).
• HPA-axis active if: morning serum cortisol above reference range; 4 PM cortisol elevated; 24-hour urinary free cortisol elevated; salivary cortisol awakening response (CAR) altered if measured; DHEA-S below reference for age (indicating chronic stress-driven HPA-axis dysregulation with adrenal-DHEA depletion); HbA1c elevated disproportionate to weight class (suggesting stress-driven hyperglycemia component).
• Circadian axis active if: documented sleep duration <6 hours nightly average on actigraphy or sleep diary; sleep efficiency <85% on polysomnography; slow-wave sleep <20% of total sleep time on polysomnography; documented OSA (in which case CPAP is the primary intervention, not the framework — the framework may be considered as an adjunct after CPAP is established and tolerated); age-related melatonin decline if measured (24-hour urinary 6-sulfatoxymelatonin reduced; not routine but available); shift work or other circadian-misalignment occupation documented.

Layer 2 — Symptom-driven selection. Identify which substrate-quality axes are documented by patient symptoms in the absence of (or supplementing) lab confirmation.

• Inflammation axis symptom profile: chronic fatigue, joint stiffness, generalized aching, “feel inflamed” subjective patient framing. Symptom profile is non-specific; lab confirmation supports the axis classification.
• Mitochondrial axis symptom profile: chronic fatigue, exercise intolerance, “low energy” persistent despite adequate sleep, “brain fog” — particularly in older adults and in patients with prior weight-loss-and-regain history. Symptom profile is non-specific; phenotype context supports the axis classification.
• Gut barrier axis symptom profile: post-prandial bloating, food sensitivities (specific foods consistently producing GI symptoms), IBS-symptom-burden, history of antibiotic-exposure or NSAID-use or GI-infection contributing to mucosal insult, “leaky gut” subjective patient framing. Symptom profile is the dominant axis-identification driver in routine practice; biomarker confirmation is supplementary.
• HPA-axis symptom profile: chronic stress documented by clinical interview; stress-driven eating (eating in response to stress as a coping mechanism, not in response to hunger); sleep-onset difficulty driven by ruminating thought patterns; anxiety symptoms; “wired but tired” subjective patient framing; emotional-eating phenotype.
• Circadian axis symptom profile: sleep complaints (sleep-onset difficulty, sleep-maintenance difficulty, early-morning awakening, non-restorative sleep); fatigue persistent despite reported adequate sleep duration (suggesting sleep architecture quality is poor even if quantity is adequate); shift work or circadian-misaligned occupation; jet-lag prone or DSPS (delayed sleep phase syndrome) phenotype.

Layer 3 — Phenotype-driven selection. Identify which substrate-quality axes are documented by patient phenotype in the absence of (or supplementing) lab and symptom confirmation. Phenotype-driven selection is the most operationally accessible layer because it does not require lab data or symptom interpretation — the phenotype is documented at intake.

• Post-menopausal female — elevated risk across all five axes; particularly strong on inflammation (post-menopausal pro-inflammatory shift), mitochondrial (estrogen-related mitochondrial-function decline), and circadian (perimenopausal sleep disruption) axes.
• Older adult (≥65) — elevated risk on mitochondrial axis (age-related mitochondrial dysfunction is documented in the longevity literature), and increased prevalence of multiple comorbidity and polypharmacy contributing to substrate-quality deficits.
• Chronic disease comorbidity (T2D, MASH, CKD, ASCVD) — elevated risk across multiple axes; T2D phenotype is the strongest framework candidate because all five axes are systematically affected.
• Shift worker — elevated risk on circadian and HPA axes; shift work is a documented metabolic-disease risk factor and a documented driver of sleep architecture disruption.
• High-stress occupation (executive, first-responder, healthcare worker with high-acuity work, single-parent caregivers, etc.) — elevated risk on HPA axis.
• Prior weight-loss-and-regain history — elevated risk on mitochondrial axis (adaptive thermogenesis with documented REE reduction post-prior-weight-loss).
• Adolescent or young adult — generally NOT a framework candidate; framework is designed for adults and the regulatory and evidence states of the compounds (with the exception of NAD+ precursors as supplements) are predominantly characterized in adult populations.

Selection-layer integration. The lab-driven, symptom-driven, and phenotype-driven layers are not hierarchical — they are complementary. A patient with hsCRP 4.8 mg/L (lab-active inflammation axis) plus chronic fatigue and joint stiffness (symptom-active inflammation axis) plus post-menopausal phenotype (phenotype-active inflammation axis) has triangulated inflammation-axis confirmation and is a strong candidate for the inflammation-axis intervention. A patient with normal hsCRP, no inflammation symptoms, and pre-menopausal phenotype has no inflammation-axis indication — the framework does not apply on this axis for this patient. The selection is per-axis, per-patient; the framework is multi-component, but a given patient may receive a single-axis intervention (one or two compounds targeting one axis) or a multi-axis intervention (3–5 compounds targeting 2–3 axes), depending on which axes the selection logic identifies as active.

2.3 Relative exclusion criteria — clinician-judgment phenotype

Relative exclusion criteria identify phenotypes where the framework is not contraindicated but where benefit is uncertain, risk is elevated, or evidence is sparse. The framework structure for each relative exclusion is: state the criterion; state the underlying concern; state the magnitude of evidence (positive, negative, or absent); state the recommended clinician-judgment posture.

• Active malignancy (any compound with mechanism-class concern). BPC-157 promotes angiogenesis via VEGFR2/Akt/eNOS — mechanism-based contraindication in active malignancy per the BPC-157 canonical. TB-500 promotes EMT (epithelial-mesenchymal transition) and activates ILK-PINCH-Akt anti-apoptotic signaling — mechanism-based contraindication in active malignancy per the TB-500 canonical. Humanin has anti-apoptotic signaling per its canonical — mechanism-based caution in active malignancy. Epitalon has paradoxical anti-tumor preclinical data but the telomerase-activation mechanism is a theoretical concern in cancer — caution per its canonical. NAD+ has theoretical concern that it fuels rapidly dividing cells including cancer cells — caution per its canonical, though no human evidence supports active tumor promotion. SS-31, KPV, Selank, DSIP do not have direct mechanism-based contraindication in malignancy per their canonicals; DSIP has preclinical data suggesting anti-tumor benefit (PMID 12782416). Clinician judgment with oncology co-management is the recommended posture for any patient with active or recent (within 5 years) malignancy considering framework components.

• Pregnancy or planned conception within next 6 months. All framework compounds have insufficient pregnancy safety data; the recommended posture is to defer framework initiation in patients planning conception within the next 6 months until the patient’s reproductive timeline clarifies. For patients on framework components who discover pregnancy, discontinue per §8.

• Severe renal impairment (eGFR <30). SS-31 has labeled renal dose adjustment (20 mg if eGFR <30 per the FDA Barth syndrome label) — this is the only compound with formal renal dose-adjustment data; clinician judgment for non-Barth use applies. For other compounds, renal impairment is a relative exclusion with clinician judgment — most compounds do not have systematic renal-impairment dosing data, and the pharmacokinetic adjustment is unknown.

• Severe hepatic impairment (Child-Pugh C). Most framework compounds do not have hepatic-impairment dosing data; clinician judgment applies. SS-31 has documented 100% renal elimination without hepatic metabolism — hepatic impairment is not a pharmacokinetic concern for SS-31 specifically.

• Active seizure disorder. DSIP has theoretical concern per its canonical (GABA-ergic modulation); Cerebrolysin (cross-referenced cross-module option per §4.3 HPA axis cognitive-comorbidity sub-scope and §10.6) carries seizure-threshold concern per its canonical; clinician judgment with neurology co-management is the recommended posture.

• Active eating disorder (anorexia nervosa, bulimia nervosa, BED with active purging). Active eating disorders are a contraindication for GLP-1 RA therapy itself per the Module 5 Protocol Template §2.3 standard exclusion list; the framework adds no additional exclusion criterion beyond what the GLP-1 RA itself contraindicates. Framework consideration is deferred until the eating disorder is in adequate-stability remission with behavioral-health co-management documentation.

• Concurrent benzodiazepine therapy. Selank has documented allosteric competition with diazepam at GABA-A receptors per its canonical (PMID 26924987) — concurrent benzodiazepine therapy is a relative exclusion for Selank specifically; for the framework’s HPA-axis component, consider alternatives or coordinate with the patient’s psychiatry team before adding Selank.

• Active immunosuppression therapy. Humanin and several other compounds engage JAK/STAT pathways; clinician judgment with the patient’s transplant or autoimmune team applies for any compound in this framework when active immunosuppression is in place.

• Porcine protein allergy. Cerebrolysin (cross-referenced cross-module option per §4.3 HPA axis cognitive-comorbidity sub-scope and §10.6) is derived from porcine brain protein and is contraindicated in porcine allergy. The framework’s eight primary stack compounds do not carry porcine-derivation concern.

2.4 Hard contraindications — labeled and mechanism-based absolute exclusions

Hard contraindications are absolute — the specific compound must not be initiated for the specific patient. Each contraindication is documented with its source classification (FDA labeled contraindication vs labeled cautionary use vs mechanism-based-class contraindication vs research-state absence-of-data).

SS-31 (Elamipretide) — FDA labeled. Prior anaphylaxis to elamipretide is the absolute labeled contraindication per the FDA Barth syndrome label (2023). Neonates receiving a multi-dose formulation containing benzyl alcohol — labeled per the Barth syndrome label. Pattern AA precision: SS-31 is FDA-approved only for Barth syndrome; the framework use is off-label. The labeled contraindications carry forward to any use, including off-label framework use.

BPC-157, TB-500 — mechanism-based contraindication in active malignancy. Per the canonical files for both compounds: active malignancy is a mechanism-based contraindication on angiogenesis-promotion (BPC-157) and EMT-promotion-plus-anti-apoptotic-signaling (TB-500) grounds. History of cancer within 5 years or active cancer-predisposition syndromes are also clinician-judgment-with-oncology-clearance contraindications.

Humanin — mechanism-based caution / contraindication in active malignancy. Anti-apoptotic signaling via JAK2/STAT3 and PI3K/Akt is the mechanism-based concern. Humanin is a cross-referenced cross-module option (Mitochondrial axis MDP sub-reference; see §4.3 and §C.2); the active-malignancy mechanism-based caution applies whether Humanin is considered as a primary stack component or as a cross-referenced cross-module option.

KPV, Selank, DSIP, Epitalon, NAD+ (NMN / NR / IV NAD+) — no labeled contraindications (none are labeled compounds in the U.S.); per-compound clinician-judgment cautions per the canonical files apply (see §2.3 relative exclusions).

All framework compounds in pregnancy. None of the eleven compounds (8 primary stack + 3 cross-referenced cross-module options) has adequate pregnancy safety data; pregnancy is a clinician-judgment hard exclusion for all framework components — primary stack OR cross-referenced cross-module options — until pregnancy-specific data emerges. Patients on the framework who discover pregnancy: immediate discontinuation per §8.

Severe systemic hypersensitivity to any framework compound. Permanent discontinuation of the implicated compound; transition to alternative within or outside the framework per clinician judgment.

2.5 Worked example — selection criteria for the §1.5 patient

The §1.5 patient (54yo peri-menopausal female, BMI 33.5, hsCRP 4.8 mg/L, HOMA-IR 5.8, morning cortisol 22 µg/dL, 5.5 hours sleep nightly with fragmented architecture, pending sleep study, high-stress executive role):

Inclusion analysis by axis.

• Inflammation axis: lab-active (hsCRP 4.8 mg/L), symptom-active (chronic fatigue per intake), phenotype-active (peri-menopausal, insulin-resistant, MASH-suspect with elevated ALT). Strong triangulated indication.
• Mitochondrial axis: phenotype-active (age 54, peri-menopausal, insulin-resistant, MASH-suspect); lab-confirmation deferred pending REE measurement availability. Indication with phenotype support; lab confirmation supplementary.
• Gut barrier axis: indeterminate — no overt GI symptoms reported on intake; biomarker testing (zonulin, LBP) not performed; the elevated hsCRP and metabolic-inflammation context is consistent with gut-barrier-compromise risk but is not specifically diagnostic. Clinician-judgment indication based on inflammation-axis cross-correlation.
• HPA axis: lab-active (morning cortisol 22 µg/dL), symptom-active (subjective stress 7/10, stress-driven eating reported on intake), phenotype-active (high-stress executive role). Strong triangulated indication.
• Circadian axis: lab-active pending (sleep study scheduled), symptom-active (5.5 hours nightly, fragmented architecture, partner reports witnessed apnea), phenotype-active (peri-menopausal sleep disruption susceptibility). Strong indication pending OSA characterization — if moderate-to-severe OSA, CPAP is the primary intervention, framework adjunctive; if mild OSA or no OSA, framework is the candidate intervention for sleep architecture and circadian alignment.

Exclusion analysis.

• No active malignancy reported on intake. Not in pregnancy or planning conception within next 6 months. eGFR within normal limits (deferred pending workup confirmation). No active seizure disorder. No active eating disorder. No concurrent benzodiazepine therapy. No active immunosuppression. No porcine protein allergy (not relevant to included framework compounds).

Contraindication analysis. No hard contraindications identified for any framework compound for this patient.

Selection conclusion. This patient is a strong multi-axis pre-treatment optimization candidate — inflammation axis, HPA axis, and circadian axis are triangulated active; mitochondrial axis is phenotype-supported with optional lab confirmation; gut-barrier axis is clinician-judgment based on cross-correlation. The compound selection per axis (developed in §4 initiation) and the sequencing across the 3–6 week pre-GLP-1-initiation window (§5 maintenance) are the operational next steps.

Pattern Z calibration at §2.5. The selection analysis presents the per-axis indication evidence factually and acknowledges the indeterminate-axis cases (gut barrier; mitochondrial pending REE) without overstating the indication. The selection is presented as one clinical-judgment pathway, not as obligatory for this phenotype. Anchor 5 (off-label / extrapolation transparency) applies: the framework is research-state-extrapolation for this use case across all axes; the patient counseling beats per §10 anchor honestly to this evidence-state framing throughout.

3. Pre-treatment workup

3.1 Purpose

Define the pre-treatment laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before framework initiation. Section 3 is the operational handoff between Section 2 (selection) and Section 4 (initiation): a patient who passes Section 2 selection enters Section 3 workup; on workup completion, Section 4 framework initiation begins.

The framework workup is structured into seven panels mapped to the five substrate-quality axes plus the foundational panels: standard metabolic baseline (the foundational panel applied to every patient, equivalent to the standard Module 5 §3.2 panel), inflammation-axis workup (§3.3), mitochondrial-axis workup (§3.4), gut barrier-axis workup (§3.5), HPA-axis workup (§3.6), circadian-axis workup (§3.7), and per-compound baseline safety panels (§3.8 — establishes baseline relevant to each framework compound’s monitoring schedule).

The framework workup is complementary to, not a replacement for, the GLP-1 RA initiation workup per the Module 5 Protocol Template §3. Many panels overlap (standard metabolic, lipid, HbA1c, body composition). The framework workup adds the substrate-quality-axis panels that are not part of the standard GLP-1 RA initiation panel.

Pattern W cross-section consistency: every lab listed in §3.2–§3.8 must be reconciled with the §5 maintenance monitoring intervals (Section 5 cannot recommend a monitoring lab not established as a baseline lab in Section 3) and with the §6 AE-management triggers (Section 6 cannot anchor an AE response to a lab not in the workup or monitoring panel).

3.2 Standard metabolic baseline panel

Applies to every framework patient. Equivalent to the standard Module 5 Protocol Template §3.2 panel; the framework workup adds substrate-quality-axis panels on top of the standard panel.

• Comprehensive metabolic panel (CMP). Sodium, potassium, chloride, CO₂, BUN, creatinine, glucose, calcium, total protein, albumin, ALT, AST, alkaline phosphatase, total bilirubin. Establishes hepatic and renal baseline for class-wide GLP-1 RA precautions, for any nephroprotective / hepatoprotective indication eligibility, and for SS-31 renal dose-adjustment screening (eGFR <30 triggers 20 mg dose adjustment per the FDA Barth syndrome label).
• Fasting lipid panel. Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C, ApoB if available. Baseline for CV-risk-indication eligibility and for monitoring metabolic improvement during GLP-1 therapy.
• Fasting glucose and HbA1c. Establishes glycemic baseline regardless of indication. For non-diabetic CWM-indication framework candidates, this screens for undiagnosed prediabetes or T2D — which would shift the GLP-1 RA selection from CWM-alone to T2D-plus-CWM with the appropriate label-permitted molecule formulation. For framework purposes, the HbA1c baseline is also relevant to NAD+-axis consideration (Yoshino 2021 NMN insulin sensitivity data was generated in prediabetic women; the prediabetic phenotype is the strongest NMN-evidence-base phenotype).
• Fasting insulin and HOMA-IR calculation. Establishes insulin-resistance phenotype quantitatively. HOMA-IR = (fasting insulin µIU/mL × fasting glucose mg/dL) / 405. HOMA-IR ≥2.5 typically interpreted as insulin-resistant; ≥4.0 typically interpreted as severely insulin-resistant. Insulin-resistance phenotype is the dominant cross-axis modifier — it predicts higher likelihood of all five substrate-quality axes being active.
• Body weight, height, BMI, waist circumference. Anthropometric baseline. Waist circumference is the visceral-adiposity-distribution anchor.
• Blood pressure (seated, two readings, standardized). Baseline for CV-risk-indication eligibility and for GLP-1 RA monitoring.

3.3 Inflammation-axis workup

Applies when inflammation axis is active or clinician-judgment-active per §2.2 selection logic.

• High-sensitivity C-reactive protein (hsCRP). The primary inflammation marker. Interpretation reference points: <1.0 mg/L low cardiovascular and metabolic-inflammation risk; 1.0–3.0 mg/L moderate; >3.0 mg/L elevated. Acute inflammation context (recent infection, recent vaccination, acute injury) can transiently elevate CRP and should be excluded from interpretation — repeat measurement after 4–6 weeks of acute-context resolution.
• Interleukin-6 (IL-6). Secondary inflammation marker; not routinely available in all clinical laboratories. Reference range varies by assay; clinician interprets per local lab reference. Elevated IL-6 is consistent with active chronic inflammation.
• TNF-α. Tertiary inflammation marker; even less commonly available than IL-6 in routine outpatient practice; research-grade testing in many practices. Elevated TNF-α is consistent with active chronic inflammation.
• Ferritin. Non-specific — elevated in chronic inflammation, in iron overload, in MASH. Clinical interpretation context required; ferritin elevation alone is not specific for the inflammation axis.
• Erythrocyte sedimentation rate (ESR). Non-specific inflammation marker; less commonly used for metabolic-inflammation context than hsCRP but acceptable if hsCRP is not available.
• Complete blood count with differential. Establishes white blood cell count and differential pattern; lymphocyte:neutrophil ratio (or neutrophil:lymphocyte ratio NLR) is a non-specific systemic inflammation marker.

3.4 Mitochondrial-axis workup

Applies when mitochondrial axis is active or clinician-judgment-active per §2.2 selection logic.

• Resting energy expenditure (REE) by indirect calorimetry, if available. The primary mitochondrial-axis biomarker. REE is measured in a fasted-and-resting state; calculated values are derived from O₂ consumption and CO₂ production. REE is compared to predicted-for-mass (Mifflin-St Jeor or Harris-Benedict equation); ≥10% below predicted is interpreted as metabolic-rate-suppressed. Indirect calorimetry is not universally available in routine practice; many practices defer to phenotype-based mitochondrial-axis selection in the absence of REE measurement.
• Metabolic flexibility assessment, if available. Measured by respiratory exchange ratio (RER) changes between fasted and fed states; RER appropriately shifts from approximately 0.7 (fat-dominant oxidation) in the fasted state to approximately 0.85–0.95 (mixed substrate) in the fed state in metabolically flexible individuals. Reduced metabolic flexibility is a research-state mitochondrial-dysfunction biomarker with increasing characterization in the literature; not routinely available in clinical practice but accessible in some metabolic clinics.
• Lactate, pyruvate, lactate-to-pyruvate ratio if measured. Lactate-to-pyruvate ratio is elevated in mitochondrial dysfunction (impaired pyruvate-to-acetyl-CoA flux); not routinely available outside specialty mitochondrial-disease evaluation.
• NAD+ or NAD+/NADH ratio, if measured. Research-grade testing in many practices; commercial assays for whole-blood NAD+ have become available. Useful as a baseline-and-monitoring marker for the NAD+ axis specifically — NMN or NR supplementation can be followed by NAD+ measurement to confirm pharmacodynamic effect. Not routinely available in standard outpatient practice.

3.5 Gut barrier-axis workup

Applies when gut barrier axis is active or clinician-judgment-active per §2.2 selection logic.

• Zonulin (serum), if measured. Research-grade test; commercial availability variable. Zonulin is a tight-junction-regulating protein; serum zonulin is elevated in conditions associated with gut barrier compromise (celiac disease, IBD, MASH, metabolic syndrome). Specificity-and-sensitivity limitations apply; the test is not diagnostic of gut barrier compromise but is supportive.
• Lipopolysaccharide-binding protein (LBP), if measured. Reflects systemic LPS exposure (which occurs with bacterial translocation across compromised gut barrier). Research-grade test; commercial availability variable.
• Lactulose-mannitol urinary excretion test, if performed. The historical gold-standard non-invasive intestinal permeability test; not routinely performed in outpatient practice; complex pre-test preparation and timing required.
• Calprotectin (stool), if symptom-driven. Differentiates IBD from IBS in patients with GI-symptom burden. Elevated calprotectin (typically >50 µg/g) suggests inflammatory bowel disease — which is a separate clinical context with its own evaluation pathway and would supersede framework consideration.
• Stool microbiome assessment, if available. Comprehensive microbiome assessment is research-state in clinical interpretation; some practices use commercial microbiome panels for clinical guidance; the framework does not require microbiome assessment but may incorporate it when available.
• Clinical symptom inventory. Document post-prandial bloating frequency and severity, food-sensitivity profile, IBS-Rome-IV criteria evaluation if applicable, NSAID-use history, antibiotic-exposure history, GI-infection history. Symptom inventory is the dominant gut-barrier-axis-identification driver in routine practice given the limited availability of biomarker testing.

3.6 HPA-axis workup

Applies when HPA axis is active or clinician-judgment-active per §2.2 selection logic.

• Morning serum cortisol (drawn at 7–9 AM). Reference range 5–18 µg/dL typically; clinician interprets per local lab reference. Elevated morning cortisol is consistent with HPA-axis upregulation.
• 4 PM serum cortisol if morning is borderline or for diurnal-pattern characterization. Normal diurnal pattern shows substantial decline from morning to afternoon; flat or non-declining pattern is consistent with HPA-axis dysregulation.
• 24-hour urinary free cortisol if Cushing-syndrome differential is required. Not routinely needed for framework HPA-axis evaluation; reserve for clinician-judgment when Cushing-syndrome differential is on the table.
• Salivary cortisol awakening response (CAR), if available. Four samples over the first hour after waking; characterizes the CAR profile. Research-grade test in most clinical practices; available in some integrative medicine practices.
• DHEA-S (dehydroepiandrosterone sulfate). The adrenal-androgen-precursor marker; chronic HPA-axis dysregulation with adrenal-DHEA depletion produces DHEA-S below age-and-sex reference range. Useful as a cumulative-chronic-stress marker complementary to the acute morning cortisol.
• Perceived Stress Scale (PSS-10) or equivalent subjective stress inventory. Patient-reported stress quantification; complements the biochemical HPA-axis markers.

3.7 Circadian-axis workup

Applies when circadian axis is active or clinician-judgment-active per §2.2 selection logic.

• Sleep diary or actigraphy (1–2 week tracking). Documents sleep duration, sleep timing, sleep efficiency, and sleep fragmentation. Sleep duration <6 hours nightly average or sleep efficiency <85% supports circadian-axis activation.
• Polysomnography (sleep study), if OSA suspected or sleep-architecture characterization required. Documents sleep architecture (proportion of REM, NREM stages 1–3 / slow-wave sleep), apnea-hypopnea index (AHI), sleep efficiency. OSA evaluation supersedes framework consideration if moderate-to-severe (AHI ≥15) — CPAP is the primary intervention.
• Sleep questionnaires. Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Epworth Sleepiness Scale (ESS) — quantify the subjective sleep-quality and daytime-sleepiness burden.
• Melatonin assessment, if measured. 24-hour urinary 6-sulfatoxymelatonin (the major melatonin metabolite) or salivary dim-light melatonin onset (DLMO) — research-grade tests; not routinely available; reserve for clinician-judgment when age-related melatonin decline is a specific consideration (typically older adults).

3.8 Per-compound baseline safety panels

Applies per-compound, only for the compounds the framework is using for the specific patient.

• SS-31 baseline (if SS-31 considered): eGFR (renal dose-adjustment screening per FDA Barth syndrome label — 20 mg if eGFR <30); standard CMP and CBC; cardiac baseline (echocardiogram if indication includes cardiac context — the FDA approval is Barth syndrome which is a cardiomyopathy condition, so cardiac baseline is the standard-of-care framework). Pattern AA precision: SS-31 framework use is off-label; the cardiac baseline is clinician-judgment per the patient’s cardiovascular risk profile, not a labeled requirement for off-label use.
• BPC-157, TB-500 baseline (if either considered): standard CMP; cancer surveillance per age-and-risk-appropriate routine screening; the mechanism-based active-malignancy contraindication is screened at intake (per §2.4). No specific labeled monitoring requirement.
• KPV baseline (if considered): standard CMP; no specific compound-related monitoring requirement.
• Selank baseline (if considered): concurrent benzodiazepine therapy review (per §2.3 relative exclusion); psychiatric medication review for any patient on antidepressant or anxiolytic therapy.
• DSIP baseline (if considered): concurrent CNS depressant review (additive sedation concern per §2.3 relative exclusion); seizure-disorder review.
• Epitalon baseline (if considered): cancer surveillance per age-and-risk-appropriate routine screening (telomerase-activation theoretical concern in cancer context).
• NAD+ / NMN / NR baseline (if considered): MTHFR variant screening if available (MTHFR mutation carriers should co-administer TMG 500–1000 mg daily to support methylation balance and prevent homocysteine accumulation per the NAD+ canonical); homocysteine baseline if MTHFR variants are present or family history suggestive.

3.9 Worked example — pre-treatment workup for the §1.5 patient

The §1.5 patient is a strong multi-axis pre-treatment optimization candidate; the workup would proceed:

Standard metabolic baseline (§3.2). Already substantially collected per intake — CMP, lipid panel, fasting glucose, fasting insulin (HOMA-IR 5.8 calculated), HbA1c 6.3% (prediabetic), BMI 33.5, waist 102 cm, BP measured. Outstanding from intake: SS-31 considered → eGFR review for renal dose-adjustment threshold (eGFR <30 → 20 mg adjustment); confirm eGFR ≥30 before SS-31 inclusion.

Inflammation-axis workup (§3.3). hsCRP 4.8 mg/L documented. Add IL-6 measurement if locally available (this patient is a strong candidate for additional IL-6 confirmation given the multi-axis profile and the planned framework intervention). Ferritin and CBC with differential per standard panel. Acute-inflammation context excluded (no recent infection or injury reported).

Mitochondrial-axis workup (§3.4). REE measurement by indirect calorimetry, if available — establishes baseline for adaptive-thermogenesis monitoring during GLP-1 weight loss. If indirect calorimetry not available, defer to phenotype-based mitochondrial-axis identification (age 54, peri-menopausal, insulin-resistant — supports axis activation without lab confirmation). NAD+ baseline if commercial assay available locally — useful for monitoring NAD+ axis intervention pharmacodynamic response.

Gut barrier-axis workup (§3.5). No overt GI symptoms reported on intake — symptom inventory documented; the elevated hsCRP plus metabolic-inflammation context plus insulin-resistance phenotype is consistent with possible gut barrier compromise without specific clinical indicators. Clinician-judgment: gut-barrier-axis intervention may be considered as a low-friction adjunct (oral BPC-157 or oral KPV) given the inflammation-axis cross-correlation, without specific zonulin or LBP testing; or defer gut-barrier-axis intervention until symptoms or specific lab confirmation emerges.

HPA-axis workup (§3.6). Morning serum cortisol 22 µg/dL documented (elevated). Add 4 PM cortisol for diurnal-pattern characterization. Add DHEA-S for cumulative-stress marker. PSS-10 administered (subjective stress 7/10 already documented). Confirms HPA-axis activation across biochemical and subjective markers.

Circadian-axis workup (§3.7). Sleep study scheduled — characterize AHI and sleep architecture. If moderate-to-severe OSA (AHI ≥15) is identified: CPAP is the primary intervention; framework circadian-axis intervention may be adjunctive after CPAP is established and tolerated. If mild OSA or no OSA: framework circadian-axis intervention (DSIP for slow-wave sleep enhancement; Epitalon if age-related melatonin decline contribution suspected — age 54 is borderline for age-related melatonin decline; clinician judgment) is the candidate intervention. Add PSQI and ISI questionnaires for baseline subjective sleep-quality quantification.

Per-compound baseline safety panels (§3.8). Per the proposed compounds: SS-31 (if considered for mitochondrial axis) — eGFR confirmed ≥30; cardiac baseline per CV-risk-profile (this patient has insulin resistance, prediabetes, MASH-suspect, possible OSA — strong cardiovascular risk profile; echocardiogram and ECG appropriate). BPC-157 / KPV (if considered for gut-barrier and inflammation cross-axis) — cancer surveillance per age-appropriate routine (mammography, colonoscopy, cervical cancer screening per local guidelines; documented up-to-date). Selank (if considered for HPA axis) — no concurrent benzodiazepine therapy; review any concurrent SSRI / SNRI (none reported). DSIP (if considered for circadian axis) — no concurrent CNS depressants; no seizure-disorder history. NAD+ (if considered for mitochondrial axis) — MTHFR variant screening if available; homocysteine baseline.

Workup-to-initiation handoff. With workup completed: framework initiation per §4 proceeds with the multi-axis compound selection: SS-31 or NAD+ precursor (NMN) for mitochondrial axis (clinician-and-patient choice based on access, cost, evidence-base preference, route preference); BPC-157 oral or KPV oral for gut-barrier and inflammation cross-axis (low-friction oral intervention); Selank intranasal for HPA-axis; DSIP SubQ at bedtime for circadian-axis pending OSA result; Epitalon optional adjunct for circadian-axis if age-related melatonin decline is a clinical-judgment factor.

Pattern W cross-check applied to §3.9. Every lab and panel in the worked-example workup above is reconciled with §5 maintenance monitoring intervals (the monitoring panel at 4-week and 12-week post-initiation checkpoints uses subsets of the §3 baseline panels) and with §6 AE-management triggers (the §6 cortisol-rebound, glucose-tolerance, IGF-1, inflammation-marker, and sleep-architecture triggers are all anchored to baseline labs established here).

4. Initiation protocol

4.1 Purpose

Define the per-compound starting doses, the per-axis stack composition options, the sequencing across the 3–6 week pre-GLP-1-initiation priming window (or the parallel 8–12 week early-GLP-1-titration co-administration window), and the tolerability-management cadence for framework initiation. Section 4 is the operational action plan from Day 0 of framework initiation through approximately Week 6 of either the priming phase or the early GLP-1 co-administration phase.

Pattern AA.marketing-claims enforcement at this section: every dose recommendation is anchored to its primary source — published clinical trial dosing (where it exists), FDA label (for SS-31 Barth syndrome only — explicitly framed as off-label-extrapolation when used for framework purposes), or practitioner-guide dose ranges (for research-state peptides without trial-derived dosing). Pattern AA precision distinguishes labeled dosing (legal authority) from extrapolated-from-Phase-3 dosing (research-state) from practitioner-consensus dosing (community of practice).

Pattern Z.research-precision discipline operates at this section: each compound’s dose anchor is presented with the specific evidence state — “FDA-approved dose for Barth syndrome is 40 mg/day SubQ; functional medicine extrapolated dose is 1–5 mg/day SubQ in 30–60 day cycles” for SS-31 (per its canonical) is the precise framing, with the labeled-vs-extrapolated distinction explicit.

4.2 Sequencing — priming vs parallel approach

The framework supports two operational sequencing options:

Option A — Priming approach: framework first, GLP-1 RA second. Patient initiates one or more framework compounds during a 3–6 week pre-GLP-1-initiation window. GLP-1 RA initiation occurs at the end of the priming window. Framework compounds continue or discontinue at GLP-1 initiation per the §8 framework-discontinuation logic, varying by axis: HPA-axis intervention (Selank) typically continues through the first 4–8 weeks of GLP-1 titration; circadian-axis intervention (DSIP for slow-wave sleep) typically continues as long as clinically beneficial; gut barrier-axis intervention (BPC-157 / KPV) typically continues through the first 4–8 weeks of GLP-1 titration to attenuate GI tolerability challenges; mitochondrial-axis intervention (SS-31 or NAD+ precursor) continues at clinician judgment based on baseline mitochondrial-axis profile and target-dose attainment.

Option B — Parallel approach: framework and GLP-1 RA simultaneously. Patient initiates one or more framework compounds at the same visit (or within 1–2 weeks of) GLP-1 RA initiation. The framework compounds and the GLP-1 RA titrate together over the first 8–12 weeks. Framework compounds continue or discontinue per the §8 logic at the end of the early-titration phase. The parallel approach is more common in clinical practice when the patient is already committed to GLP-1 initiation and the framework is added as a layered intervention, rather than as a pre-initiation priming step.

Sequencing decision logic.

• Priming approach is preferred when: the substrate-quality deficit is severe (hsCRP >5 mg/L; morning cortisol >25 µg/dL; severe sleep deprivation <5 hours nightly; documented gut barrier compromise); the patient has time before planned GLP-1 initiation (3–6 weeks); the patient is motivated to engage with the framework before initiating GLP-1 itself; the clinician judgment is that the GLP-1 response will be substantially improved by addressing the substrate first.
• Parallel approach is preferred when: the substrate-quality deficit is mild-to-moderate; the patient is initiating GLP-1 imminently (within 1–2 weeks of evaluation) and a priming delay would be operationally unacceptable; the clinician judgment is that simultaneous addressing of the substrate and the primary therapy is operationally simpler.
• Either approach is acceptable for many patient profiles; the choice is patient-and-clinician shared decision-making within the medically reasonable options.

4.3 Per-axis stack composition options

The §2 selection logic identifies which axes are active for the specific patient. The §4.3 stack composition table provides the candidate compounds per axis with starting dose, route, and frequency. A patient with one axis active typically receives one compound; a patient with multiple axes active receives a multi-compound stack constructed per-axis.

Inflammation axis — candidate compounds.

Compound	Starting dose	Route	Frequency	Duration	Anchor
BPC-157	250 mcg	SubQ	1–2x daily	4–6 weeks	Practitioner guides; extrapolated from animal studies per BPC-157 canonical
BPC-157 (oral)	250 mcg	Oral	1x daily	4–8 weeks	Gastric stability data; PMID 30915550
KPV (oral)	200–500 mcg	Oral	BID, empty stomach	4–8 weeks	Practitioner guides per KPV canonical; PepT1-mediated self-targeting supports oral route
KPV (SubQ)	200–500 mcg	SubQ	1–2x daily	4–6 weeks	Practitioner guides per KPV canonical
TB-500	2.0–2.5 mg	SubQ	2x/week loading, then 1x/week	4–6 weeks	Practitioner guides per TB-500 canonical

The inflammation axis composition typically uses one or two compounds. BPC-157 and KPV are commonly co-administered in gut-healing-context protocols (per the existing Gut Healing Protocol and AP-BPC157-KPV-Capsules product); both compounds engage complementary mechanisms (BPC-157 via VEGFR2/Akt/eNOS angiogenesis-and-cytoprotection plus tight-junction stabilization; KPV via NF-κB inhibition plus PepT1-mediated self-targeting). TB-500 is less commonly used for inflammation-axis-alone purposes; TB-500 is more commonly used in cross-axis-with-tissue-repair contexts (Wolverine, Recovery Stack) or in selected pre-treatment cases with documented tissue-repair indication (post-surgical, post-injury contexts in patients also preparing for GLP-1 initiation).

Mitochondrial axis — candidate compounds.

Compound	Starting dose	Route	Frequency	Duration	Anchor
SS-31 (Elamipretide) — FDA Barth syndrome	40 mg	SubQ	1x daily	Ongoing	FDA Barth syndrome label (2023)
SS-31 — functional medicine extrapolation	1–5 mg	SubQ	1x daily	30–60 days on / 30–60 days off	Functional medicine practitioner guides per SS-31 canonical
SS-31 — renal dose adjustment	20 mg	SubQ	1x daily	Ongoing	FDA Barth syndrome label (eGFR <30)
NMN (oral)	250 mg	Oral	1x daily	Ongoing	Yoshino 2021 PMID 33888596 (prediabetic women, 10 weeks); 250 mg/day was the trial dose
NMN (oral) — higher dose range	250–900 mg	Oral	1x daily	Ongoing	Yi 2023 PMID 36482258 dose-ranging study
NR (oral)	500–1000 mg	Oral	1x daily	Ongoing	Martens 2018 PMID 29599478 (healthy older adults; 1000 mg/day for 6 weeks)
NR (oral) — higher dose with negative result caveat	up to 2000 mg	Oral	1x daily	Ongoing	Dollerup 2018 PMID 29992272 (obese insulin-resistant men, 2000 mg/day for 12 weeks — NEGATIVE result for metabolic endpoints)
IV NAD+ — loading	250–750 mg	IV infusion	Daily 4–10 days, then weekly maintenance	Loading then maintenance	Clinical integrative practice per NAD+ canonical
IV NAD+ — addiction-recovery loading	500–1500 mg over 4–8 hours	IV infusion	Daily	4–10 days	Addiction recovery protocols per NAD+ canonical
SubQ NAD+	50–100 mg	SubQ	2–3x per week	Ongoing with breaks	Maintenance protocol per NAD+ canonical
Humanin (SubQ) — cross-referenced cross-module option	Practitioner-defined microgram range per /Peptides/Humanin.md (no validated human dose)	SubQ	Per practitioner guides	Cycled per practitioner guides	Cross-reference primary canonical /Peptides/Humanin.md — MDP family cytoprotective / bioenergetic regulator; research-state-incomplete (mechanistic + observational evidence; thin human-trial data); not FDA-approved-for-marketing-claims; consider for patients with documented mitochondrial-dysfunction markers + interest in the MDP family; active-malignancy mechanism-based caution per JAK2/STAT3 anti-apoptotic signaling

The mitochondrial axis primary composition typically uses one compound — SS-31 OR NAD+ precursor — rather than both, because the mechanism axes overlap and the cost-and-burden of layering both is operationally heavy for most patients. Humanin is presented as a cross-referenced cross-module option, not a primary stack component — its primary canonical home is /Peptides/Humanin.md (MDP family co-listed with MOTS-c); the human-trial evidence base is thin relative to NMN/NR (Yoshino 2021; Martens 2018) and to SS-31 (FDA Barth syndrome approval). Pattern Z anchor-4 multi-dimensional comparator framing: Humanin is a reasonable consideration for the MDP-family-interested patient with documented mitochondrial-dysfunction markers, not as a replacement for NAD+ precursor or SS-31. Pattern AA: Humanin is investigational; not FDA-approved-for-marketing-claims for any indication; access is research-state. Pattern Z.research-precision note for SS-31 framework use: SS-31 is FDA-approved for Barth syndrome at 40 mg/day SubQ. The functional medicine extrapolated dose (1–5 mg/day SubQ in cycles) is the dose used in most non-Barth research-state framework contexts; this dose is NOT validated by Phase 3 trial data for any non-Barth indication. The choice of functional-medicine-extrapolated dose vs labeled Barth dose for framework use is a clinician-and-patient shared decision with the explicit acknowledgment that neither dose has Phase 3 RCT validation for the framework indication. Most framework practitioners use the functional medicine extrapolated dose for cost-and-access reasons; some clinicians prefer the labeled dose for pharmacologic-evidence-completeness reasons. Pattern Z.research-precision note for NAD+: the NMN evidence base (Yoshino 2021, Yi 2023) is the strongest of the framework compounds and was generated in populations relevant to the framework indication (prediabetic women — directly relevant to pre-GLP-1 metabolic-prep; healthy older adults — relevant to age-related mitochondrial-axis-activation). The negative NR result in obese insulin-resistant men (Dollerup 2018) is an important null finding that tempers enthusiasm and informs patient counseling — NAD+ supplementation is not universally beneficial across all populations and all endpoints.

Gut barrier axis — candidate compounds.

Compound	Starting dose	Route	Frequency	Duration	Anchor
BPC-157 (oral)	250–500 mcg	Oral	1–2x daily	4–8 weeks	Practitioner guides; gastric stability data per BPC-157 canonical
KPV (oral)	200–500 mcg	Oral	BID, empty stomach	4–8 weeks	Practitioner guides; PepT1-mediated self-targeting per KPV canonical
BPC-157 + KPV combination (oral)	500 mcg + 500 mcg	Oral	1x daily	4–8 weeks	Combination product (e.g., AP-BPC157-KPV-Capsules) per BPC-157 canonical

The gut barrier axis composition overlaps substantially with the inflammation axis composition — BPC-157 and KPV serve both axes. For patients with both inflammation axis and gut barrier axis active, the same compound(s) address both axes simultaneously and the protocol does not require axis-specific compound duplication.

HPA axis (with cognitive-comorbidity sub-scope) — candidate compounds.

Compound	Starting dose	Route	Frequency	Duration	Anchor
Selank (intranasal)	250–500 mcg	Intranasal	1–3x daily	3 weeks on / 1 week off cycle	Russian clinical protocols per Selank canonical
Selank (intranasal) — introductory	100–250 mcg	Intranasal	1–2x daily	First week (introductory)	Practitioner guides per Selank canonical
Selank (SubQ)	150–300 mcg	SubQ	1x daily	2–4 weeks	Practitioner guides per Selank canonical
Semax (intranasal) — cross-referenced cross-module option	300–900 mcg/day per practitioner guides (Russian acute-stroke protocols use higher doses)	Intranasal	1–3x daily	Cycled per practitioner guides (typically 10–14 days on / off)	Cross-reference primary canonical /Peptides/Semax.md and Module 3 Cognitive Enhancement Protocol — ACTH(4–10)-fragment-derived; BDNF/NGF upregulation; neuroprotective; Russian approval for acute ischemic stroke, ADHD, optic nerve atrophy; off-label for HPA-mediated weight-loss contexts; foreign approval not transferable to U.S. standing; not FDA-approved-for-marketing-claims
Cerebrolysin (IM or IV with dilution) — cross-referenced cross-module option	5–30 mL/day per practitioner guides (Phase 3 acute-stroke trials use higher dose ranges)	IM or slow IV with dilution	Daily for cycle (typically 10–20 days)	Cycled per practitioner guides	Cross-reference primary canonical /Peptides/Cerebrolysin.md and Module 3 Cognitive Enhancement Protocol + Post-Stroke Recovery Protocol — porcine brain hydrolysate; neurotrophic peptide mix mimicking endogenous neurotrophic factors; Phase 3 trials in acute stroke / TBI / dementia; foreign approvals (Europe, China, Mexico, Russia); research-only in U.S.; porcine protein allergy is a contraindication; IM/IV-with-dilution administration is operationally heavier than the SC compounds in the rest of the stack; not FDA-approved-for-marketing-claims

The HPA axis primary composition typically uses Selank as the anxiolytic-cortisol-modulating intervention. Selank’s mechanism (GABA-A positive allosteric modulation via a non-benzodiazepine binding site; concurrent IL-6 suppression and Th1/Th2 rebalancing per the human GAD immunomodulation study) anchors both the anxiolytic effect and the parallel inflammation-axis cross-modulation. Selank’s non-benzodiazepine mechanism is the clinical-translation differentiator — anxiolytic efficacy without dependence, tolerance, sedation, or withdrawal.

Cognitive-comorbidity sub-scope cross-references. For patients in the HPA-axis selection set who also carry cognitive-comorbid load (cognitive complaints, post-TBI history, post-stroke history, mood-driven eating with cognitive-load components, “food-noise” with prominent ruminating-cognition driver), Semax and Cerebrolysin are reasonable cross-referenced cross-module considerations. They are NOT primary stack components in this framework — their primary canonical homes are the Module 3 Cognitive Enhancement Protocol (Semax + Cerebrolysin) and the Post-Stroke Recovery Protocol (Cerebrolysin); the framework cross-references them rather than absorbing them as primary stack components. Pattern Z anchor-4 multi-dimensional comparator framing: Semax (BDNF/NGF upregulation; Russian approval for acute stroke / ADHD / optic nerve atrophy; intranasal administration parallels Selank route — operationally light) and Cerebrolysin (multi-neurotrophic factor mimicry; Phase 3 stroke / TBI / dementia trials; foreign approvals; porcine allergen risk; IM/IV-with-dilution administration — operationally heavier than the rest of the stack) carry differentiated tradeoff profiles. Patient counseling per §10.6 explicitly frames these as cross-module options. Pattern AA: neither is FDA-approved-for-marketing-claims in the U.S.; Russian / foreign approvals are not transferable to U.S. regulatory standing. Cross-reference to [[Module 3 Cognitive Enhancement Protocol]] and [[Post-Stroke Recovery Protocol]] when those protocols exist in the vault.

Circadian axis — candidate compounds.

Compound	Starting dose	Route	Frequency	Duration	Anchor
DSIP (SubQ)	100–300 mcg	SubQ	At bedtime	2–4 week cycles	Practitioner guides per DSIP canonical
DSIP — stress reduction protocol	100–200 mcg	SubQ	Evening	2–3 weeks on / 1 week off	DSIP canonical
DSIP (intranasal)	Variable	Intranasal	At bedtime	As needed	Research protocols per DSIP canonical
Epitalon (SubQ)	5–10 mg	SubQ	Daily	10–20 days, 1–2x/year	Khavinson protocols per Epitalon canonical; 50–100 mg cumulative per cycle
Epitalon (IV)	5–10 mg	IV	Daily	10–20 days	Clinical integrative practice per Epitalon canonical
Epitalon (oral capsule)	3 mg	Oral	Daily	Ongoing or cycled	Capsule formulation per Epitalon canonical

The circadian axis composition typically uses DSIP as the primary slow-wave-sleep enhancement intervention. Epitalon is an optional adjunct considered when age-related melatonin decline is a clinical-judgment factor (typically older adults ≥60, post-menopausal women with sleep disruption). Epitalon is administered at nighttime to support the circadian melatonin surge — the administration timing is mechanistically important per the Khavinson protocols.

Pattern AA.marketing-claims discipline reminder. None of the compounds in the §4.3 stack composition tables are FDA-approved-for-marketing-claims for the framework indication. SS-31 is FDA-approved for Barth syndrome only; the framework use is off-label. The other compounds are research-state with varying access pathways (503A compounding with post-2023 FDA Category 2 listing variation for BPC-157 and others; dietary supplement marketing for NMN with contested FDA status; dietary supplement marketing for NR; intranasal administration outside FDA-approved label for Selank). Every patient encounter that includes framework consideration anchors the regulatory framing per §10 counseling beats.

4.4 Tolerability management at framework initiation

Framework initiation, like GLP-1 RA initiation, has anticipatory framing for tolerability challenges. The framework’s AE profile is heterogeneous across the eight primary stack compounds (with three cross-referenced cross-module options carrying additional cross-module AE considerations per their primary canonical homes); the §6 per-compound AE-management algorithms cover the detail. At initiation, the key tolerability-management considerations:

Injection-site reactions. Multiple compounds in the framework are SubQ injections (SS-31, BPC-157, TB-500, NAD+, Selank SubQ option, DSIP, Epitalon). Patients new to self-injection require initial training equivalent to GLP-1 RA self-injection training; 30G insulin syringes with abdomen / thigh / upper arm rotation; standard sterile technique. Patients already on GLP-1 RA SubQ injection (e.g., parallel-approach framework initiation) are typically familiar with the technique and require minimal additional training.

Intranasal administration (Selank as primary HPA-axis stack compound; Semax as cross-referenced cross-module option per §4.3 HPA axis cognitive-comorbidity sub-scope and §10.6). Patients new to intranasal peptide administration require brief training on dose-measurement technique (typically 50 mcg per spray for Selank; 2–10 sprays for the dose range; Semax dose-per-spray varies by formulation), administration technique (head tilted slightly back; spray during inhalation; alternate nostrils between doses). Mild nasal irritation is the most common AE; rare and self-limiting.

Oral peptide administration (BPC-157 oral, KPV oral, NMN, NR). Generally well-tolerated; PepT1-mediated absorption considerations for KPV; gastric stability considerations for BPC-157; NAD+ precursor GI tolerability (mild GI upset, flushing — niacin pathway activation — possible).

Initiation cadence — typical visit pattern.

• Week 0 — initiation visit. Framework selection finalized; baseline workup reviewed; first doses administered or prescribed; injection / intranasal / oral technique training; patient counseling beats per §10; written instructions provided. For SubQ injection patients, first dose may be administered in-clinic with the clinician observing the technique.
• Week 2 — tolerability check (in-clinic or telehealth). Assess for any tolerability concerns across the initiated compounds; assess adherence; reinforce technique if any concerns; confirm continuation pathway.
• Week 4 — mid-initiation check. Repeat key biomarker measurements if axis-specific monitoring is required (e.g., morning cortisol if Selank is being used for HPA-axis intervention; sleep diary review if DSIP is being used for circadian intervention). Adjust dose if tolerability or response indicates.
• Week 6 — pre-GLP-1-initiation transition visit (priming approach) OR mid-titration assessment (parallel approach). For priming approach: transition to GLP-1 RA initiation; framework continuation / discontinuation decision per §8; counseling beats per §10. For parallel approach: GLP-1 RA mid-titration weight, BP, AE assessment plus framework continuation assessment.

4.5 Worked example — framework initiation for the §1.5 patient (continuation)

Continuing the §1.5 patient (54yo peri-menopausal female with multi-axis substrate-quality deficit profile): the workup per §3.9 has identified strong indication on inflammation, HPA, and circadian axes; phenotype-supported indication on mitochondrial axis; clinician-judgment indication on gut barrier axis (low-friction adjunct). The sleep study has identified mild OSA (AHI 8) without indication for CPAP at this AHI level — circadian-axis framework intervention is appropriate.

Sequencing decision. The patient’s profile (severe HPA-axis activation with morning cortisol 22 µg/dL; sleep deprivation contributing to insulin resistance and to anticipated GLP-1 response; multi-axis profile suggesting substrate-quality optimization may substantially improve GLP-1 response) supports the priming approach. A 4–6 week priming window before GLP-1 initiation is selected.

Stack composition.

• Inflammation + gut barrier (cross-axis): BPC-157 + KPV oral combination capsule (500 mcg / 500 mcg, 1x daily for 4 weeks). Low-friction oral intervention addressing both axes simultaneously; AP-BPC157-KPV-Capsules product format. Pattern AA: research-state compounds; 503A compounding pathway access varies by jurisdiction.
• Mitochondrial axis: NMN 250 mg oral 1x daily, ongoing through priming phase and into GLP-1 titration. Selection rationale: NMN has the strongest human RCT evidence among the mitochondrial-axis compounds (Yoshino 2021 PMID 33888596 in prediabetic women — directly phenotype-relevant for this patient who is prediabetic with HbA1c 6.3%); oral administration is low-friction; cost is generally lower than IV NAD+ or SubQ SS-31 in most U.S. markets. Pattern AA: NMN has contested FDA dietary supplement status (NDI letter 2022); access pathway varies. The clinician documents the regulatory status discussion per §10. Alternative consideration: SS-31 1 mg/day SubQ would be the alternate mitochondrial-axis selection; cost and access typically favor NMN for first-line trial.
• HPA axis: Selank intranasal 300 mcg BID for 3 weeks on / 1 week off cycle through priming phase. Selection rationale: Selank has human GAD immunomodulation data (PMID 18577961) plus the non-benzodiazepine GABA-A mechanism (PMID 26924987); patient’s high-stress executive role and elevated morning cortisol support strong indication. Concurrent benzodiazepine therapy: none. Concurrent SSRI / SNRI: none. Patient counseling per §10.
• Circadian axis: DSIP 200 mcg SubQ at bedtime for 3 weeks on / 1 week off cycle. Selection rationale: 1983 human sleep RCT (PMID 6895513) plus decades of practitioner safety experience plus slow-wave-sleep enhancement mechanism aligned with the patient’s fragmented sleep architecture. OSA at AHI 8 is mild and does not contraindicate DSIP. Epitalon is deferred — age 54 is borderline for age-related melatonin decline indication; DSIP first; consider Epitalon if circadian-axis response is incomplete at 4-week reassessment.

Initiation visit (Week 0). All four interventions initiated on the same visit. SubQ injection training (DSIP at bedtime; patient is naive to SubQ injection — training is consistent with subsequent GLP-1 RA injection training and reinforces the technique for the GLP-1 transition at Week 6). Intranasal Selank administration training. Oral BPC-157+KPV capsule and oral NMN instructions. Written protocol summary provided. Counseling beats per §10 — explicit off-label / extrapolation framing (Anchor 5 dominant), explicit research-state framing per compound, shared-decision-making invitation. Baseline labs documented. Re-assessment at Week 2.

Week 2 tolerability check. Patient reports good tolerability across all four interventions. SubQ DSIP — mild injection-site erythema, transient, self-resolving; technique reinforced. Intranasal Selank — minor nasal irritation Day 1–2, then resolved. Oral BPC-157+KPV and NMN — no GI complaints. Subjective sleep improvement reported (falling asleep faster; fewer middle-of-night awakenings). Subjective stress decrement reported (perceived stress 5/10 vs baseline 7/10). Continuation confirmed.

Week 4 mid-initiation check. Re-measure morning serum cortisol (target reduction toward 5–18 µg/dL reference range); re-measure hsCRP (target reduction toward <3.0 mg/L); sleep diary review (target sleep duration approaching 7 hours nightly; target sleep efficiency >85%). If labs show response in expected direction, continue framework into Week 6 transition. If labs show insufficient response, clinician-judgment dose adjustment per §5 or per §7 non-response algorithm.

Week 6 transition visit. GLP-1 RA initiation per the Module 5 Protocol Template §4 (Wegovy 2.4 mg titration starting at 0.25 mg weekly per the standard schedule; alternative tirzepatide per the patient-and-clinician choice within the medically reasonable options). Framework continuation decision: BPC-157 + KPV — continue for additional 4 weeks during GLP-1 early titration to support gut barrier during GI AE phase, then discontinue per §8 logic. NMN — continue indefinitely if response is documented and patient tolerates well; this is ongoing supplementation, not cycled. Selank — continue with the 3-on / 1-off cycle through the first 8–12 weeks of GLP-1 titration to support HPA-axis through the lifestyle-change stress of GLP-1 initiation; discontinue per §8 if response is consolidated. DSIP — continue with the cycle through the GLP-1 titration phase; sleep architecture monitoring at Month 3 of GLP-1 therapy informs continuation vs discontinuation. Epitalon — deferred unless circadian response is insufficient.

Pattern Z calibration applied to §4.5. The initiation walkthrough presents the stack composition factually with the per-compound evidence-state framing, the regulatory framing, and the access framing. The shared-decision-making is operational throughout — at the initiation visit, at the Week 2 tolerability check, at the Week 4 mid-initiation check, at the Week 6 transition visit. The patient’s reported subjective response is integrated into the dose-adjustment logic without overstating the framework’s effect.

5. Maintenance protocol

5.1 Purpose

Define the framework’s post-initiation operating state: continued dosing through the priming phase (Option A sequencing) or the parallel-with-GLP-1 phase (Option B sequencing), monitoring intervals during framework continuation, dose-adjustment triggers, and the transition between framework maintenance and §8 framework discontinuation or §7 non-response algorithm.

Section 5 is the operational counterpart to the standalone-molecule Section 5 in the Protocol Template, adapted for the framework’s heterogeneous compound mix. The maintenance phase for framework purposes is typically shorter than for a standalone weight-management molecule — the framework is designed as a substrate-quality optimization layer that may or may not continue indefinitely, depending on per-axis response and per-compound role. Some compounds (NMN, NR) are designed for ongoing daily supplementation; others (BPC-157, KPV, Selank, DSIP) are cycled in 3–8 week windows with off-periods.

5.2 Target dose and target duration per compound

The §4.3 starting doses are also the target doses for most framework compounds — these are not titration-up compounds in the way that GLP-1 RAs are. The exceptions:

• BPC-157 oral — typically maintained at 250–500 mcg daily through the 4–8 week cycle; not titrated up.
• BPC-157 SubQ — typically maintained at 250–500 mcg 1–2x daily through the 4–6 week cycle; not titrated up.
• KPV oral — typically maintained at 200–500 mcg BID through the 4–8 week cycle; not titrated up.
• TB-500 SubQ — initial loading at 2.0–2.5 mg 2x/week, transitioning to maintenance at 2.0–2.5 mg 1x/week or biweekly for ongoing cycles; cycle 6 weeks on / 4 weeks off per the TB-500 canonical.
• SS-31 SubQ (functional medicine extrapolation) — typically 1–5 mg/day in cycles of 30–60 days on / 30–60 days off per the SS-31 canonical. Not titrated up within a cycle; cycle structure is the dose-management variable.
• SS-31 SubQ (Barth syndrome labeled dose) — 40 mg/day SubQ continuous per the FDA label; renal adjustment to 20 mg if eGFR <30. For framework off-label use, the choice between functional-medicine-extrapolated and labeled-dose framing is a clinician-and-patient shared decision per §10.
• NMN oral — typically 250 mg daily per the Yoshino 2021 trial dose; higher doses (up to 900 mg) per the Yi 2023 dose-ranging study are tolerable but the incremental benefit at higher doses is research-state-incompletely-characterized. Most framework practitioners start at 250 mg daily.
• NR oral — typically 500–1000 mg daily per Martens 2018; higher doses (up to 2000 mg) per Dollerup 2018 with the caveat that the higher-dose trial in obese insulin-resistant men was negative for metabolic endpoints.
• IV NAD+ — loading-maintenance pattern. Loading 250–750 mg/day for 4–10 days; maintenance 250–500 mg weekly to monthly per clinician-and-patient discussion.
• SubQ NAD+ — typically 50–100 mg 2–3x per week ongoing with periodic breaks.
• Selank intranasal — typically 250–500 mcg 1–3x daily in 3-on / 1-off cycles; not titrated up within a cycle.
• DSIP SubQ — typically 100–300 mcg at bedtime in 2-4 week cycles or 5-on / 2-off cycles or 2–3 weeks on / 1–2 weeks off cycles; not titrated up within a cycle.
• Epitalon SubQ — 5–10 mg/day in 10–20 day intensive cycles administered 1–2x per year; cumulative dose target 50–100 mg per cycle. Not titrated up within a cycle; cycle structure is the dose-management variable.

The target duration is per-compound and per-axis-response. The framework is not designed as an indefinite ongoing layer for most compounds — it is designed as a substrate-quality optimization phase that achieves a clinical objective (axis response documented by biomarker or symptom improvement) and then transitions to discontinuation, intermittent cycling, or selective continuation.

5.3 Monitoring intervals

Framework monitoring intervals are organized around the priming phase (Option A) or the parallel phase (Option B) with consistent cadence:

Priming phase (Option A): Weeks 0–6.

• Week 0 — initiation visit per §4.
• Week 2 — tolerability check (in-clinic or telehealth).
• Week 4 — mid-initiation biomarker re-measurement: morning cortisol if HPA-axis intervention; hsCRP if inflammation-axis intervention; sleep diary review if circadian-axis intervention; weight and BP per standard.
• Week 6 — pre-GLP-1-initiation transition: full re-assessment of substrate-quality axes; framework continuation / discontinuation decision; GLP-1 RA initiation per Module 5 Protocol Template §4.

Parallel phase (Option B) or post-priming framework continuation: Months 1–3 of GLP-1 therapy.

• Month 1 (Week 4 of GLP-1 titration) — combined framework + GLP-1 visit. Framework tolerability check; GLP-1 GI AE profile per Module 5 Protocol Template §6.2; concurrent monitoring of substrate-quality biomarkers and GLP-1 response markers.
• Month 2 (Week 8 of GLP-1 titration) — combined framework + GLP-1 visit. Weight, BP, GLP-1 AE check; framework continuation decision per §8 for each compound — most non-mitochondrial compounds (BPC-157, KPV, Selank, DSIP, Epitalon) transition to discontinuation or cycling-off during this window; mitochondrial-axis (NMN, NR, SS-31) typically continues into Month 3.
• Month 3 (Week 12 of GLP-1 titration) — combined framework + GLP-1 visit. Comprehensive re-assessment: GLP-1 response (weight trajectory, HbA1c trajectory if T2D, metabolic markers); framework axis re-assessment (inflammation, mitochondrial, HPA, circadian biomarkers); framework continuation decision for remaining components per §8.

Long-term framework continuation: Month 6 onward.

• For patients on ongoing mitochondrial-axis intervention (NMN, NR) — quarterly biomarker re-assessment in alignment with the GLP-1 RA Module 5 Protocol Template §5 maintenance schedule.
• For patients on cycled framework intervention (BPC-157 / KPV / Selank / DSIP / Epitalon — if re-initiated post-discontinuation for symptom recurrence or for ongoing per-cycle support) — visit cadence aligns with cycle initiation and conclusion.
• For patients who discontinued all framework components after the priming or early-titration phase — no separate framework monitoring schedule; the patient is on the standard Module 5 Protocol Template §5 GLP-1 RA maintenance schedule.

5.4 Dose-adjustment triggers

Dose adjustment in the maintenance phase is driven by per-axis target-attainment and per-compound tolerability:

Inflammation axis adjustment.

• Target-attained: hsCRP reduction below 3.0 mg/L (the elevated-cardiovascular-risk cutoff); IL-6 normalization if measured. Adjustment: continue current dose through cycle conclusion; cycle off; reassess at next planned cycle.
• Target-not-met: hsCRP not reduced or reduced incompletely (e.g., baseline 4.8 mg/L → Month 1 4.2 mg/L, minimal change). Adjustment: confirm adherence; consider dose increase within the labeled-by-canonical range; consider compound addition (e.g., add KPV if only BPC-157 was used; or add TB-500 if neither has produced response); consider transition to §7 non-response algorithm if multi-compound intervention has not produced expected response.
• Tolerability concern: rare for inflammation-axis compounds; injection-site reactions if SubQ, GI upset if oral. Symptomatic management.

Mitochondrial axis adjustment.

• Target-attained: REE improvement above predicted-for-mass; NAD+ blood level increase if measured (NMN and NR have been documented to increase blood NAD+ in trial data); subjective energy / cognitive improvement.
• Target-not-met: no objective or subjective improvement after 8–12 weeks on NMN 250 mg or NR 500–1000 mg or SS-31 1–5 mg/day cycle. Adjustment: confirm adherence; consider dose escalation (NMN to 500–900 mg; NR to 1000–2000 mg with the Dollerup 2018 negative-result caveat documented in counseling; SS-31 to higher labeled-dose 20–40 mg with off-label cost-and-access considerations). Consider transition to alternate compound within the axis (e.g., NMN → SS-31, or vice versa).
• Tolerability concern: rare for NMN at 250 mg; GI upset and niacin-flush possible at higher NMN/NR doses; injection-site reactions for SubQ SS-31. The “NAD+ flush” (warmth, chest tightness, nausea) is managed by slowing IV infusion rate per the NAD+ canonical.

HPA-axis adjustment.

• Target-attained: morning cortisol reduction toward 5–18 µg/dL reference range; subjective stress reduction; reduced stress-driven eating; improved sleep onset if cortisol-driven sleep difficulty was part of the symptom profile.
• Target-not-met: morning cortisol not reduced; subjective stress unchanged. Adjustment: confirm Selank adherence and administration technique; consider dose escalation within Selank canonical range; consider behavioral health co-management for stress and anxiety drivers that may not respond to Selank alone.
• Tolerability concern: minor nasal irritation (intranasal Selank) — typically self-resolving; transient fatigue Day 1–2 of use — typically self-resolving.

Circadian axis adjustment.

• Target-attained: sleep duration approaching 7+ hours nightly; sleep efficiency >85%; slow-wave sleep proportion improvement if measured; subjective sleep quality improvement.
• Target-not-met: sleep architecture unchanged; persistent sleep complaints. Adjustment: confirm DSIP adherence and administration timing (30–60 minutes before bedtime per canonical); add Epitalon if age-related melatonin decline is suspected and DSIP alone is insufficient; consider sleep medicine referral for refractory sleep complaints; consider OSA re-evaluation if sleep study was performed >12 months ago.
• Tolerability concern: mild headache or dizziness with DSIP — rare and self-limiting per canonical.

5.5 Worked example — framework maintenance for the §1.5 patient (continuation)

Continuing the §1.5 patient through framework maintenance: the patient completed the Week 0–6 priming phase per §4.5 with documented response (subjective sleep improvement, subjective stress decrement, mild objective improvements at Week 4 mid-initiation labs). GLP-1 RA initiation at Week 6 — Wegovy 2.4 mg titration starting at 0.25 mg weekly per standard schedule. Framework continuation plan finalized at Week 6.

Month 1 (Week 4 of GLP-1 titration; Week 10 of framework). Combined visit.

GLP-1 status: on 0.5 mg weekly per standard titration. GI AE: moderate nausea Days 1–3 post-injection, attenuating; meal-size and meal-composition counseling reinforced; ondansetron 4 mg PRN as needed; patient reports nausea is tolerable. Weight: 86 kg (baseline 92 kg, 3-month weighing including the priming phase shows -6 kg trend). BP: 128/82 (baseline 134/88, modest improvement).

Framework status: BPC-157+KPV continuing through Week 12 of framework (Week 6 of GLP-1) to support gut barrier through GI AE phase. NMN 250 mg daily continuing. Selank 300 mcg intranasal BID continuing in 3-on / 1-off cycle. DSIP 200 mcg SubQ at bedtime continuing in 3-on / 1-off cycle.

Framework biomarker re-assessment: morning cortisol 17 µg/dL (target attained — within reference range, down from baseline 22). hsCRP 2.6 mg/L (target attained — below 3.0 mg/L cutoff, down from baseline 4.8). Sleep diary: 6.8 hours nightly average, fewer middle-of-night awakenings (subjective improvement; sleep efficiency improved). Subjective stress 4/10 (down from baseline 7/10).

Month 2 (Week 8 of GLP-1 titration; Week 14 of framework). Combined visit.

GLP-1 status: on 1.0 mg weekly. GI AE: improved tolerability at 1.0 mg vs 0.5 mg titration; nausea Day 1 post-injection only, mild; constipation now the dominant GI pattern. Weight: 84 kg (-8 kg from baseline). BP: 124/80 (continued improvement).

Framework continuation decision per §8: BPC-157+KPV discontinued at this visit — gut barrier support has been completed; constipation pattern is GLP-1-related and is managed by hydration, fiber, osmotic laxative per Module 5 Protocol Template §6.2 GI AE algorithm rather than by framework continuation. Selank discontinued at this visit — HPA-axis target attained at Month 1; cortisol re-measurement at this visit 14 µg/dL confirms sustained target attainment; subjective stress 3/10 confirms sustained subjective response; patient prefers discontinuation. DSIP continued into Month 3 — circadian response is good but the patient prefers to maintain through the next month of GLP-1 titration before discontinuation. NMN 250 mg daily continuing — mitochondrial-axis intervention is ongoing supplementation, not cycled; continuation through GLP-1 therapy is the standard plan.

Month 3 (Week 12 of GLP-1 titration; Week 18 of framework). Combined visit.

GLP-1 status: on 1.7 mg weekly. Weight: 81 kg (-11 kg from baseline, approximately 12% of starting weight at Month 3 of titration — on-trajectory for STEP-1 effect-size expectation). BP: 122/78. HbA1c re-measurement: 5.9% (down from 6.3%, prediabetic-to-normal range transition; not yet at non-prediabetic-stable but trending well).

Framework status: NMN 250 mg daily continuing. DSIP continued through Month 3 cycle; discontinued at this visit — circadian response is stable; sleep diary at 7.2 hours nightly, sleep efficiency 88%. Patient reports she would like to re-cycle DSIP if sleep difficulty recurs later; re-initiation pathway per §8.6 documented.

Framework biomarker re-assessment: hsCRP 1.4 mg/L (continued improvement). Mitochondrial-axis re-assessment: REE measurement deferred to Month 6 — the GLP-1-driven weight loss is the dominant variable in REE trajectory at this point; isolated NMN contribution to REE is research-state-incompletely characterized.

Month 6 — long-term GLP-1 maintenance visit (Week 24 of GLP-1 titration; Week 30 of framework).

GLP-1 status: on 2.4 mg target dose. Weight: 76 kg (-16 kg from baseline; approximately 17% of starting weight at Month 6 — on-trajectory for STEP-1 effect-size). BP: 118/76. HbA1c: 5.6%.

Framework status: NMN 250 mg daily continuing. No other framework compounds active. Patient reports stable subjective energy and stable sleep architecture; minimal stress; minimal inflammation symptoms.

Framework discontinuation decision per §8 for NMN: clinician-and-patient shared decision. Some clinicians prefer to discontinue NMN at Month 6 once the GLP-1-driven metabolic improvement is consolidated and the inferential need for ongoing mitochondrial support is reduced; some prefer to continue NMN as ongoing supplementation given the favorable safety profile, the supplement-category cost (vs prescription compound cost), and the patient preference. In this worked example, the patient prefers to continue NMN — discontinuation deferred.

Long-term continuation framework reassessment. Annual reassessment of NMN continuation per ongoing review of evidence base and patient response. If subsequent NMN evidence supports clear continuation benefit, continuation framework strengthens; if subsequent NMN evidence (or any negative-result trial parallel to Dollerup 2018) emerges that tempers the rationale for ongoing supplementation, discontinuation discussion may be revisited.

Pattern W cross-check at §5.5. The monitoring intervals above are reconciled with the §3 pre-treatment panel (every monitoring lab is established as a baseline lab); the §6 AE-management algorithms (every AE-trigger lab is in the monitoring schedule); and the Module 5 Protocol Template §5 GLP-1 RA maintenance schedule (the combined visit cadence aligns the framework monitoring with the GLP-1 RA monitoring). The §5 worked example demonstrates the framework’s transition from priming phase → early co-administration phase → selective long-term continuation, with the §8 discontinuation logic operating per-compound and per-axis.

6. Side-effect management

6.1 Purpose

Define the anticipatory framing and clinician response algorithms for the adverse-event categories that apply to each framework compound and to the stack as a whole. Section 6 is the per-compound AE-class operational reference; the framework’s heterogeneous compound mix means the AE profile is not uniform — each compound has its own characteristic AE pattern documented in its canonical, and the framework adds stack-emergent considerations (interaction between compounds; interaction with the GLP-1 RA backbone).

Pattern R enforcement at this section: each AE-class sub-block opens with anticipatory framing — what the AE is, why it occurs, how common it is in the available evidence base — before management. Opening with discontinuation triggers would steer clinicians (and through training materials, patients) toward fear-framed AE response rather than expectation-anchored AE response.

Pattern V applies at this section: when an AE-class signal is research-state, mechanism-based-theoretical, or post-marketing under evaluation, the protocol documents the signal status precisely and does not generalize signal direction beyond what is established. For example, the active-malignancy mechanism-based contraindication for BPC-157 (angiogenesis promotion via VEGFR2/Akt/eNOS) is precisely framed as mechanism-based-theoretical — no human or animal data directly demonstrates BPC-157 promotion of tumor angiogenesis, but the mechanism plausibility is the basis for the contraindication.

6.2 Injection-site AE class (SubQ compounds)

Applies to: BPC-157 SubQ, TB-500 SubQ, SS-31 SubQ, DSIP SubQ, NAD+ SubQ, Selank SubQ option, Epitalon SubQ.

Anticipatory framing. Injection-site reactions (erythema, induration, pruritus, transient nodule) are the most common AE class across SubQ peptide compounds. Trial-program prevalence for SS-31 specifically: injection-site reactions up to 80% in clinical trials per the SS-31 canonical — most common; generally mild and transient. For the research-state SubQ compounds in the framework (BPC-157, TB-500, Selank SubQ, DSIP, Epitalon), trial-program-prevalence framing is not available — the AE profile is documented from practitioner experience and from the limited clinical trial data per each compound’s canonical.

Identification. Patient-reported during early-monitoring contacts (§4) and maintenance visits (§5). Photograph documentation if reaction is moderate or atypical.

First-line management. Site-rotation reinforcement (abdomen, thigh, upper arm — alternate weekly or per administration cycle); proper SubQ injection technique (30G insulin syringe, 90-degree angle, full needle insertion); topical hydrocortisone for pruritus if needed; reassurance that the reaction is typical and self-limiting.

Escalation triggers. Severe injection-site reaction (large area of induration, persistent pain, suspected infection — warmth, fever, purulence); systemic hypersensitivity (urticaria, angioedema, anaphylaxis) — separate AE class, see §6.7.

Discontinuation triggers. Severe or systemic hypersensitivity reaction is a discontinuation trigger for the implicated compound; persistent moderate-to-severe injection-site reactions despite technique optimization warrant compound discontinuation or transition to an alternate route (oral or intranasal where available).

6.3 GI tolerability AE class (oral compounds + cross-framework GI considerations)

Applies to: BPC-157 oral, KPV oral, NMN oral, NR oral, IV NAD+ (GI symptoms during infusion).

Anticipatory framing. GI tolerability is generally favorable across oral framework compounds. BPC-157 oral and KPV oral are typically well-tolerated given the gastric stability data (BPC-157) and PepT1-mediated absorption (KPV); minor GI upset is uncommon. NMN and NR oral can produce mild GI upset and flushing (niacin pathway activation) — the flushing is dose-dependent and more common at higher doses. IV NAD+ can produce the characteristic “NAD+ flush” (warmth, chest tightness, nausea) managed by slowing infusion rate per the NAD+ canonical.

Identification. Patient-reported during contacts; severity grading per CTCAE Grade 1–4.

First-line management. Non-pharmacologic: take oral peptides on empty stomach per dosing instructions; hydrate consistently; if niacin-flush with NMN/NR, consider dose reduction or split dosing. Pharmacologic: rarely needed for framework oral compounds.

Cross-framework GI considerations during co-administration with GLP-1 RA. The GLP-1 RA backbone produces its own characteristic GI AE profile (nausea, vomiting, diarrhea, constipation, eructation) per the Module 5 Protocol Template §6.2. The framework’s gut-barrier-axis intervention (BPC-157, KPV) is mechanism-rationally proposed to ATTENUATE some of the GLP-1 GI AE profile via gut mucosal protection and tight-junction stabilization — but this mechanism rationale is research-state-extrapolation; no Phase 3 RCT has directly evaluated BPC-157 or KPV as GLP-1 GI AE attenuation interventions. Pattern Z.research-precision discipline at this section: the protocol does not claim that BPC-157 or KPV reduces GLP-1 GI AEs; it presents the mechanism rationale and the research-state-extrapolation framing, and the clinical decision is patient-and-clinician shared decision-making.

Escalation triggers. Severe persistent GI symptoms not attributable to either the framework or the GLP-1 RA individually — full GI evaluation; consider pancreatitis-suspect framing per the Module 5 Protocol Template §6.4 if abdominal pain is severe.

Discontinuation triggers. Patient preference for any persistent unpleasant GI symptom — patient-preference discontinuation is legitimate; framework continuation is not obligatory.

6.4 Intranasal administration AE class (Selank, Semax cross-referenced cross-module option)

Applies to: Selank intranasal (primary route per canonical and primary HPA-axis stack compound), Semax intranasal (cross-referenced cross-module option per §4.3 HPA axis cognitive-comorbidity sub-scope and §10.6; primary canonical home is the Module 3 Cognitive Enhancement Protocol).

Anticipatory framing. Mild nasal irritation or dryness is the most common AE for intranasal peptide administration. Transient fatigue Day 1–2 of Selank use is reported per the Selank canonical — self-resolving.

Identification. Patient-reported. Examination: nasal mucosa inspection if persistent symptoms.

First-line management. Saline nasal spray if dryness; alternate nostrils between doses; ensure dose-measurement technique is correct (typically 50 mcg per spray for Selank; adjust spray count to target dose); reassurance about transient fatigue.

Escalation triggers. Severe nasal mucosal irritation, epistaxis, persistent congestion — ENT evaluation.

Discontinuation triggers. Severe or persistent nasal AE; transition to SubQ route where available (Selank SubQ at 150–300 mcg per canonical) or to alternate HPA-axis intervention if Selank is the compound being discontinued.

6.5 Glucose tolerance AE class (mitochondrial-axis intervention + cross-axis considerations)

Applies to: NAD+ axis (NMN, NR, IV NAD+, SubQ NAD+) and SS-31.

Anticipatory framing. NMN and NR are mechanism-rationally proposed to IMPROVE insulin sensitivity (Yoshino 2021 PMID 33888596 demonstrated improved muscle insulin sensitivity with NMN in prediabetic women). The negative-result NR trial in obese insulin-resistant men (Dollerup 2018 PMID 29992272) tempers the universal applicability of the insulin-sensitivity mechanism. The cross-axis consideration with the GLP-1 RA backbone is generally favorable — both the mitochondrial-axis intervention (insulin-sensitivity-improving direction) and the GLP-1 RA backbone (insulin-sensitivity-improving direction) operate in the same direction; no antagonism is anticipated. SS-31 does not have specific insulin-sensitivity data in non-Barth populations; the mechanism (mitochondrial cardiolipin protection, ETC supercomplex stabilization) is mechanism-rationally consistent with metabolic improvement but not directly demonstrated.

Identification. HbA1c trajectory at maintenance visits per §5.3; fasting glucose and fasting insulin if HOMA-IR re-measurement is part of monitoring; CGM data if patient is on CGM.

First-line management. Continue current framework dosing and concurrent GLP-1 RA per Module 5 Protocol Template §5.5 T2D dose-adjustment logic; concurrent insulin or sulfonylurea (if T2D patient is on these agents) dose adjustment per Module 5 Protocol Template §6.7 hypoglycemia management.

Escalation triggers. Hypoglycemia in T2D patients on concurrent insulin or sulfonylurea — primarily a GLP-1 RA management concern per Module 5 Protocol Template §6.7; the framework does not amplify hypoglycemia risk beyond what the GLP-1 RA produces in this population.

Discontinuation triggers. No specific glucose-tolerance-driven discontinuation triggers for the framework compounds; HbA1c at-or-near target with stable glucose tolerance is the typical maintenance state during framework + GLP-1 co-administration.

6.6 IGF-1 axis AE class (cross-framework reminder — primarily applies to GH-secretagogue stacks like M5.6 v3 CJC-Ipamorelin)

The framework compounds in this protocol do NOT include CJC-1295 or Ipamorelin (those compounds are covered by the separate M5.6 Lean Mass Preservation Stack Protocol). The framework does not produce systemic IGF-1 elevation as a primary mechanism. Cross-reference reminder: if a patient on this framework is ALSO on the M5.6 lean-mass stack, the M5.6 IGF-1 monitoring schedule applies — see M5.6 v3 canonical for quarterly IGF-1 monitoring during CJC-Ipamorelin therapy.

6.7 Hypersensitivity AE class (any framework compound)

Anticipatory framing. Hypersensitivity reactions are rare across the framework compounds; SS-31 has a labeled prior-anaphylaxis contraindication per the FDA Barth syndrome label. For research-state compounds, hypersensitivity prevalence data is limited.

Identification. Patient-reported allergic-like symptoms (urticaria, pruritus without localized injection-site context, angioedema, dyspnea, anaphylactic features) — emergency evaluation if severe.

First-line management. Mild hypersensitivity (localized urticaria without systemic features) — antihistamine; discontinue suspected compound. Severe systemic hypersensitivity — emergency evaluation; epinephrine if anaphylaxis; permanent discontinuation of implicated compound.

Discontinuation triggers. Confirmed hypersensitivity to a specific compound — permanent discontinuation of that compound; transition to alternate within or outside the axis per §7 non-response algorithm if substrate-quality indication remains active.

6.8 Cancer-context AE class (mechanism-based theoretical concern)

Applies to: BPC-157 (angiogenesis), TB-500 (EMT + anti-apoptotic), Epitalon (telomerase activation theoretical concern), NAD+ (fueling rapidly dividing cells theoretical concern).

Anticipatory framing. As articulated in §2.4 contraindications, BPC-157 and TB-500 carry mechanism-based contraindication in active malignancy per the canonicals (angiogenesis promotion and EMT-plus-anti-apoptotic-signaling, respectively). Epitalon has a paradoxical anti-tumor preclinical profile (reduced spontaneous tumor incidence in rodent models per the Kossoy independent replication PMID 16634527) but the telomerase-activation mechanism in cancer cells is theoretically concerning. NAD+ fuels all rapidly dividing cells including cancer cells — theoretical concern without direct human evidence of tumor promotion.

Identification. Routine cancer surveillance per age-and-risk-appropriate screening (mammography, colonoscopy, cervical screening, PSA per local guidelines) — documented at intake (§3.8) and maintained per the patient’s primary care or specialist surveillance schedule.

First-line management. Pre-treatment cancer screening is the first-line management — patients with active malignancy or recent (within 5 years) malignancy do not initiate the framework compounds with mechanism-based contraindication; patients with adequate surveillance documentation proceed. During framework therapy, any new cancer diagnosis triggers immediate framework discontinuation per §8 and oncology co-management.

Discontinuation triggers. New malignancy diagnosis — permanent discontinuation of BPC-157, TB-500, Epitalon, and NAD+ pending oncology consultation. SS-31, KPV, Selank, DSIP do not have direct mechanism-based contraindication in malignancy; continuation per oncology judgment.

6.9 Drug interaction AE class

Selank concurrent benzodiazepine therapy. Selank’s allosteric competition at GABA-A receptors blocks diazepam modulatory activity (PMID 26924987) — concurrent benzodiazepine therapy is a relative exclusion (§2.3) and a potential efficacy reduction for both Selank and the benzodiazepine. Patient counseling per §10.

DSIP concurrent CNS depressants. Additive sedation with benzodiazepines, opioids, other CNS depressants per the DSIP canonical. Clinician-judgment dose adjustment if combination is required.

NAD+ MTHFR co-management. MTHFR mutation carriers should co-administer TMG (trimethylglycine) 500–1000 mg daily to support methylation balance and prevent homocysteine accumulation per the NAD+ canonical. The MTHFR screening per §3.8 informs this consideration.

Cross-framework interactions. No documented direct interactions between framework compounds; the heterogeneous mechanism axes and the typical low-dose administration profile minimize interaction risk. Cumulative effects on inflammation, sleep architecture, and HPA axis are mechanism-additive in the intended direction and do not require interaction-management adjustment.

GLP-1 RA concurrent administration. No documented interactions between framework compounds and the GLP-1 RA backbone. The framework compounds operate on upstream substrate-quality axes; the GLP-1 RA operates on central appetite-pathway and peripheral GI / pancreatic / hepatic / kidney signaling. Mechanism crosstalk is theoretical (e.g., gut-barrier-axis intervention modulating gut microbiome which modulates GLP-1 receptor signaling) but operationally not interaction-management-relevant.

6.10 Worked example — framework AE management for the §1.5 patient (continuation)

Continuing the §1.5 patient through framework + GLP-1 maintenance: at Month 1 of GLP-1 titration / Month 3 of framework, the patient reports mild injection-site erythema with DSIP SubQ that has persisted across 4 injection cycles. The erythema is non-tender, well-circumscribed, resolves over 24–48 hours per cycle, no induration.

Protocol response. Mild injection-site reaction per §6.2. First-line management: site rotation reinforcement (review the patient’s actual rotation pattern — discover that the patient has been using the same abdominal site for 4 cycles; corrected). Re-counseled on rotation among abdomen quadrants, thighs, upper arms. Topical hydrocortisone available as needed if symptomatic; not currently needed. Continuation of DSIP. Re-assess at Month 2 visit.

At Month 2 visit, the patient reports the rotation correction has resolved the erythema pattern; no further injection-site concerns. DSIP continued through Month 3.

At Month 3 visit, the patient reports occasional flushing after NMN dose; tolerable; no impact on adherence. Niacin-flush is a recognized AE per §6.3; first-line management: continue current dose; consider split dosing (125 mg AM and 125 mg PM) if flushing increases. The patient prefers to maintain single AM dosing; no further adjustment.

Pattern Z calibration applied to §6.10. The AE management above presents the AE profile factually (mild, expected, manageable) without minimizing the patient’s experience and without overstating risk. The first-line management is the standard pattern across the canonicals; the continuation decision is patient-anchored.

7. Plateau and non-response algorithm

7.1 Purpose

Define the structured clinical-decision approach when one or more framework axes does not achieve target response. Section 7 is the framework’s diagnostic-and-decision branch point: distinguish pseudo-non-response (apparent stall that is in fact within normal trajectory variation) from true non-response (legitimate response stall requiring intervention) and from substrate-quality-deficit-not-modifiable (patient’s substrate-quality deficit is not modifiable by the framework — alternative intervention or acceptance of the baseline state).

The framework’s non-response algorithm differs from the standalone-molecule non-response algorithm in three ways:

1. Per-axis non-response, not whole-framework non-response. A patient may have HPA-axis response with persistent inflammation-axis non-response — the algorithm operates per-axis.
2. Compound-substitution options within axis, not just dose escalation. The §4.3 stack composition tables provide multiple candidate compounds per axis; non-response on one compound may transition to an alternate compound within the same axis.
3. Non-response is not “failure” — it is information. The framework is research-state-extrapolation; non-response is a per-patient signal that the specific substrate-quality axis is not the dominant driver of the patient’s metabolic state, or that the specific compound is not effective for that patient, or that the patient’s expected GLP-1 response is achievable without framework intervention.

Pattern R applies at this section: the section opens with the diagnostic distinctions (pseudo vs true non-response) before the decision branches. Opening with discontinuation framing would steer the section into deficit-framing.

7.2 Pseudo-non-response vs true non-response — diagnostic distinctions

Pseudo-non-response. Apparent non-response that is in fact within normal trajectory variation, or reflects measurement-window-too-short, or occurs in a predictable trajectory pattern where the response will emerge at a later checkpoint. Pseudo-non-response is recognized by trajectory-context — comparing the patient’s biomarker trajectory to the expected trajectory per the available evidence base.

• Inflammation axis pseudo-non-response example. hsCRP reduction takes 4–8 weeks of consistent anti-inflammatory intervention; assessing hsCRP at Week 2 of framework intervention may show no change while the underlying inflammation modulation is ongoing. Re-measure at Week 4 or Week 6 before declaring non-response.
• Mitochondrial axis pseudo-non-response example. NMN insulin-sensitivity response in the Yoshino 2021 trial was at 10 weeks of intervention; subjective energy improvements may emerge at 2–4 weeks while objective metabolic markers (HbA1c, fasting insulin) require longer measurement windows.
• HPA-axis pseudo-non-response example. Selank’s subjective stress reduction can emerge within 1 week; morning cortisol normalization may require 4–6 weeks of consistent intervention.
• Circadian-axis pseudo-non-response example. DSIP’s slow-wave-sleep enhancement may emerge within the first week of consistent administration; subjective sleep quality improvement may require 2–4 weeks of consistent intervention plus sleep-hygiene foundation.

True non-response. Legitimate response stall — the patient’s biomarker trajectory shows no change or worsening across an adequate observation window despite documented adherence.

• Inflammation axis true non-response: hsCRP unchanged or worsened at Week 6 of consistent BPC-157+KPV intervention.
• Mitochondrial axis true non-response: no subjective or objective improvement at Month 3 of NMN 250 mg daily or SS-31 1–5 mg/day cycle.
• HPA-axis true non-response: morning cortisol unchanged at Week 6 of consistent Selank intervention; subjective stress unchanged.
• Circadian-axis true non-response: sleep architecture unchanged at Week 6 of consistent DSIP intervention plus sleep hygiene.

Substrate-quality-deficit-not-modifiable. The patient’s substrate-quality deficit is not modifiable by the framework — alternative intervention or acceptance of the baseline state. This is the third diagnostic category and is the framework’s most honest framing per Anchor 5 (off-label / extrapolation transparency): not every substrate-quality deficit responds to framework intervention; some patients have biologically-driven baseline states that are not modifiable by the available compounds at the available doses; some patients require alternative interventions (CPAP for OSA-driven circadian disruption; behavioral health for severe stress; specific GI evaluation for IBD-driven inflammation; sleep medicine for refractory insomnia).

7.3 Decision tree for plateau / non-response

The decision tree operates per-axis:

1. Confirm adherence. Missed doses, oral peptide absorption issues, injection-technique issues, intranasal administration technique issues. Confirm via patient interview; address technique reinforcement.

2. Confirm trajectory-context. Compare the patient’s biomarker trajectory and symptom trajectory to the expected trajectory per the §7.2 axis-specific pseudo-non-response examples. If trajectory-context supports pseudo-non-response (measurement window too short, biomarker response not yet expected), continue current dose; reassess at next interval.

3. Confirm dose attainment within compound’s labeled or extrapolated range. Is the patient on the typical target dose? Some compounds have dose-response considerations — NMN 250 mg vs 500 mg vs 900 mg; SS-31 1 mg vs 5 mg vs 20 mg vs 40 mg labeled. If dose is sub-typical, consider escalation.

4. Reassess axis activation. Is the substrate-quality deficit indeed active, or has the baseline state shifted such that the axis is no longer active? For example: a patient with baseline hsCRP 4.8 mg/L on framework intervention re-measured at 3.2 mg/L (border of “elevated”) — the inflammation axis is partially attenuated and may be no longer the dominant deficit; continued response may emerge or the axis is at acceptable maintenance state.

5. If true non-response confirmed at adequate observation window per axis:

   • Inflammation axis non-response: consider compound substitution within axis (BPC-157 → KPV; KPV → BPC-157+KPV combination; add TB-500 if tissue-repair indication co-exists); consider gut-barrier-axis re-assessment with biomarker testing (zonulin, LBP) if not previously done; consider IBD or celiac evaluation if GI-symptom-burden is high; transition to acceptance-of-baseline-inflammation framing if no further intervention is clinically reasonable.
   • Mitochondrial axis non-response: consider compound substitution within axis (NMN → NR; NMN → SS-31; SS-31 → NMN; oral → IV NAD+); consider mitochondrial-disease evaluation if there is clinical suspicion (rare presentation but presenting symptoms of fatigue and metabolic dysfunction can overlap with primary mitochondrial disease); transition to acceptance-of-baseline framing.
   • HPA-axis non-response: consider Selank dose escalation within canonical range; consider behavioral health co-management for stress-and-anxiety drivers that may not respond to Selank alone; consider cortisol-driving etiology re-evaluation (sleep apnea contributing to cortisol elevation; medical conditions contributing to cortisol elevation — Cushing-syndrome differential if not previously addressed); transition to acceptance-of-baseline framing.
   • Circadian axis non-response: add Epitalon if not previously included and age-related melatonin decline is suspected; sleep medicine referral for refractory insomnia evaluation; CPAP re-evaluation if OSA may have progressed; transition to acceptance-of-baseline framing.

6. Cross-framework consideration: is the GLP-1 RA itself producing the expected response despite framework non-response on selected axes? If the GLP-1 RA is on-trajectory for weight loss and metabolic-marker improvement, the substrate-quality optimization may have been less load-bearing than initially projected — framework continuation can be reconsidered.

7.4 Worked example — framework non-response algorithm

A 62-year-old male, 6 weeks into Wegovy titration with framework co-administration. Baseline: BMI 31, hsCRP 3.8 mg/L, morning cortisol 16 µg/dL (within reference), HbA1c 5.7%, sleep duration self-reported 6.5 hours nightly. Framework components active: BPC-157+KPV oral for inflammation+gut-barrier cross-axis; NR 1000 mg daily for mitochondrial axis. HPA and circadian axes were not activated per §2.2 selection logic — no framework intervention on those axes.

Algorithm walkthrough. At Week 6 of framework: hsCRP 3.6 mg/L (minimal change from baseline 3.8). NR 1000 mg daily: subjective energy unchanged; no objective biomarkers re-measured at this checkpoint.

Step 1 — adherence. Patient reports 100% adherence; pharmacy refill audit confirms no gaps.

Step 2 — trajectory-context. hsCRP at 6 weeks of inflammation-axis intervention is approaching the lower end of the expected trajectory window. Subjective energy assessment for NR is also within expected trajectory variation — 6 weeks is on the shorter side for NR effect-emergence per the trial-program data (10–12 weeks). Pseudo-non-response is possible for both axes.

Step 3 — dose attainment. BPC-157+KPV at the standard combination dose; NR at 1000 mg daily (the Martens 2018 trial dose for healthy older adults). Dose attainment is within typical range.

Step 4 — axis reassessment. hsCRP 3.6 mg/L is borderline elevated but trending toward normal range; clinical interpretation is that the inflammation axis is partially modulated. NR mitochondrial axis: no objective biomarker measurement at this checkpoint to confirm or refute response.

Step 5 — decision branches given pseudo-non-response possibility.

• Inflammation axis: continue current dose for additional 4 weeks; reassess hsCRP at Week 10. If hsCRP at Week 10 shows continued downward trajectory toward <3.0 mg/L, continue. If hsCRP at Week 10 unchanged or worsened, consider compound substitution (add TB-500 or transition to KPV alone with BPC-157 discontinuation for compound-specific re-trial).
• Mitochondrial axis: continue current NR dose for additional 4 weeks (toward the 10–12 week trial-equivalent observation window). At Week 10, reassess subjective energy and consider HbA1c re-measurement (if T2D-context monitoring includes interval HbA1c). If continued non-response at Week 10, consider NR → NMN transition (different precursor; NMN had insulin-sensitivity response in prediabetic women per Yoshino 2021 while NR was negative in obese insulin-resistant men per Dollerup 2018 — phenotype-matching may favor NMN for this patient if non-response continues).

Step 6 — cross-framework consideration. GLP-1 RA status at Week 6 of titration: weight -4 kg from baseline, on-trajectory for STEP-1 effect-size at this timepoint. GLP-1 response is on track; framework continuation reconsidered through the lens of “does the patient appear to be responding to the GLP-1 alone such that framework continuation has limited incremental benefit?” — clinician-and-patient shared decision. In this worked example, the patient prefers framework continuation through Week 10 to allow the longer observation window before any framework discontinuation decision.

Pattern Z calibration applied to §7.4. The decision-tree walkthrough presents the per-axis trajectory factually with the pseudo-vs-true-non-response framing; the decision is presented as patient-anchored, not clinician-mandated. The “acceptance-of-baseline” framing is explicit — not every substrate-quality deficit modulates with framework intervention, and that is not the framework’s failure but a fact of the biology and the evidence state.

8. Discontinuation and tapering

8.1 Purpose

Define when to stop each framework compound, how (or whether) to taper, and how to frame post-discontinuation expectations. Section 8 is symmetric to §4 (initiation): just as initiation has anticipatory framing for tolerability and adherence, discontinuation has anticipatory framing for the post-discontinuation period and for the patient-and-clinician decision about whether and when to re-initiate per-compound or per-axis.

The framework’s discontinuation logic is multi-decision because the framework is multi-compound. A patient may discontinue one compound while continuing others — depending on per-axis response, per-compound tolerability, per-axis residual indication, and per-compound role in the framework structure (priming compound vs ongoing supplementation compound).

8.2 When to discontinue — discontinuation triggers per compound and per axis

Framework discontinuation triggers operate per-compound and per-axis. The principal triggers:

Per-axis-response triggers — typical end-of-phase discontinuation pattern.

• Inflammation axis target attained → BPC-157, KPV, TB-500 discontinue at end of priming phase or at end of early-co-administration cycle (typically Week 4–8 of framework). The compounds are not designed for indefinite continuation; once hsCRP normalization or symptom resolution is documented, the cycle ends. Re-initiation pathway per §8.6 if recurrence emerges.
• Gut barrier axis target attained → BPC-157 and/or KPV discontinue at end of the cycle (typically Week 4–8). Same pattern as inflammation axis.
• HPA-axis target attained → Selank discontinue at end of the 3-on / 1-off cycle pattern or at end of the priming + early-co-administration window. Selank is not designed for indefinite use; cycling is the typical pattern per the canonical.
• Circadian axis target attained → DSIP discontinue at end of the 2–4 week cycle pattern. DSIP is similarly cycled per the canonical. Epitalon — different discontinuation pattern. Epitalon is administered in 10–20 day intensive cycles 1–2 times per year per the canonical; “discontinuation” is the natural end-of-cycle pattern; re-initiation at the next planned cycle.
• Mitochondrial axis target attained → NMN, NR, SS-31 continuation OR discontinuation per clinician-and-patient shared decision. Unlike the other axes, the mitochondrial axis compounds are designed for ongoing supplementation in many use cases. NMN and NR are typically continued indefinitely if response is documented and tolerated. SS-31 is typically cycled (30–60 days on / 30–60 days off per the functional medicine extrapolation) or continued indefinitely per the Barth syndrome labeled dose. Discontinuation occurs at patient preference, cost-and-access changes, or new contraindication emergence.

Per-compound tolerability triggers — patient-preference discontinuation.

• Severe AE attributable to the compound — permanent discontinuation per §6 algorithms.
• Patient preference for discontinuation — legitimate; the protocol’s role is to inform the post-discontinuation expectations and the re-initiation pathway, not to override the patient’s decision. Patient-preference discontinuation is more common in the framework context than in the GLP-1 RA context because the framework is research-state-extrapolation and the per-patient subjective benefit calculation may favor discontinuation at any point.

Per-axis-recategorization triggers — substrate-quality-deficit-no-longer-active.

• Substrate-quality biomarker normalization with sustained pattern over 12+ weeks — the framework intervention has done its job; the axis is no longer active; continuation has limited incremental benefit. Typical discontinuation pattern.
• Substrate-quality biomarker normalization concurrent with GLP-1 RA-driven metabolic improvement — the GLP-1 RA itself has normalized the substrate quality (weight loss reduces inflammation; weight loss improves insulin sensitivity which improves mitochondrial function; weight loss reduces stress-driven hyperphagia). The framework contribution to the normalization is research-state-incompletely-characterized; the discontinuation decision is clinician-and-patient shared.

Cross-framework triggers — confirmed contraindication discovery.

• New malignancy diagnosis — immediate discontinuation of BPC-157, TB-500, Epitalon, NAD+ (mechanism-based contraindications per §2.4); SS-31, KPV, Selank, DSIP continuation per oncology judgment.
• New pregnancy in any framework patient — immediate discontinuation of all compounds per §2.4 hard contraindications. Re-initiation post-pregnancy and post-lactation per §8.6 if indication remains and selection criteria are re-met.
• New severe renal impairment (eGFR <30) — SS-31 dose adjustment to 20 mg per labeled adjustment; other compounds clinician-judgment continuation.
• New severe hepatic impairment (Child-Pugh C) — clinician-judgment continuation per compound; SS-31’s hepatic-elimination-independence is favorable but the overall clinical context may warrant discontinuation.

8.3 How to taper — compound-specific tapering considerations

Most framework compounds do NOT require pharmacokinetic tapering — the short half-lives (BPC-157 <30 min; KPV minutes; Selank 30 min; DSIP 30 min plus tissue accumulation; SS-31 1.28–4 hours plasma with mitochondrial persistence; Epitalon minutes with epigenetic long-tail) and the cycled administration patterns mean abrupt discontinuation at end-of-cycle is the typical pattern. Specific tapering considerations:

• NMN, NR (ongoing daily supplementation): abrupt discontinuation is acceptable; no pharmacokinetic taper required. Some patients prefer to step down (e.g., NMN 250 mg → 125 mg for 2 weeks → off) as a behavioral-adaptation pattern; not pharmacologically required.
• IV NAD+ (loading-maintenance pattern): loading phase ends naturally at the planned 4–10 day duration; maintenance phase tapers based on the patient’s response and the clinical schedule.
• SS-31 (Barth syndrome labeled dose 40 mg/day continuous): abrupt discontinuation is acceptable; the Barth syndrome labeled use is continuous-not-cycled but discontinuation does not require taper. For functional medicine extrapolated dose (1–5 mg/day cycled), the cycle structure (30–60 days on / 30–60 days off) is the natural taper.
• Selank cycled 3-on / 1-off pattern: the off-week is the natural discontinuation pattern. End-of-framework discontinuation at the end of an on-cycle.
• DSIP cycled 2–4 weeks on / 1–2 weeks off pattern: similar end-of-cycle natural pattern.
• BPC-157, KPV, TB-500 cycled 4–8 week on / 2–4 week off pattern: end-of-cycle is the natural discontinuation pattern.
• Epitalon cycled 10–20 days 1–2x per year: the 5–11 month off-period between cycles is the natural pattern; “discontinuation” is the decision to not initiate the next planned cycle.

Concurrent GLP-1 RA continuation during framework discontinuation. The GLP-1 RA is the primary weight-management therapy and is continued per its own Module 5 Protocol Template §5 maintenance schedule. Framework discontinuation does not affect GLP-1 RA continuation. The patient remains on the GLP-1 RA per the standard schedule.

8.4 Pre-conception planning — framework-specific considerations

Per §2.4 hard contraindications, none of the eleven framework compounds (8 primary stack + 3 cross-referenced cross-module options) has adequate pregnancy safety data. For reproductive-age patients on the framework planning conception, the discontinuation arithmetic is per-compound:

• Short-half-life compounds (BPC-157, KPV, Selank, DSIP, Epitalon): pharmacokinetic clearance occurs within minutes to hours after the last dose; pre-conception window is operationally short (within days of discontinuation).
• Tissue-accumulating compounds (DSIP — tissue residence beyond plasma half-life; Epitalon — epigenetic effects extend beyond plasma clearance): clinical judgment for a longer pre-conception window of weeks rather than days.
• NAD+ precursors (NMN, NR): dietary supplement status; pre-conception consideration is per patient-and-clinician shared decision; abrupt discontinuation is acceptable; pre-conception window typically not pharmacokinetically-constrained.
• SS-31: half-life 1.28–4 hours plasma with mitochondrial persistence (mitochondrial retention longer); pre-conception window typically a few weeks for completeness.
• GLP-1 RA backbone pre-conception planning: continues to follow the Module 5 Protocol Template §8.4 arithmetic — semaglutide elimination half-life ~7 days; ~5 half-lives (~35 days) for pharmacokinetic clearance; FDA-labeled 8-week pre-conception window.

The combined pre-conception planning for a patient on framework + GLP-1 RA: the GLP-1 RA pre-conception window is the dominant timing variable (~8 weeks per label); framework compound discontinuation occurs concurrently or earlier. Patient counseling per §10.4 (Anchor 3 — pregnancy planning, research-state-leading structure).

8.5 Post-discontinuation expectations

Post-discontinuation expectations vary by compound and by axis:

Inflammation axis. hsCRP and other inflammation markers may slowly return toward baseline if the underlying substrate-quality deficit was not durably resolved by the framework intervention alone. The framework intervention is one component; the patient’s lifestyle factors (diet, exercise, sleep, stress) and the GLP-1 RA-driven weight loss are the larger drivers of sustained inflammation modulation.

Mitochondrial axis. NAD+ blood levels return toward baseline after NMN or NR discontinuation per the NAD+ canonical pharmacokinetic profile. SS-31 effects similarly fade as mitochondrial cardiolipin protection requires ongoing intervention. The patient’s overall metabolic improvement (driven by GLP-1 RA-driven weight loss) typically sustains independently of mitochondrial-axis intervention if response was consolidated.

HPA axis. Selank discontinuation typically does not produce rebound — the GABA-A allosteric modulation does not produce dependence or withdrawal per the Selank canonical. Some patients report subjective stress increase weeks-to-months after Selank discontinuation; the relationship to Selank discontinuation vs to underlying stress fluctuation is patient-specific.

Circadian axis. DSIP discontinuation similarly typically does not produce rebound — no dependence reported per the canonical. Patients may report partial loss of sleep architecture improvement weeks-to-months after DSIP discontinuation if the underlying circadian disruption is not resolved by lifestyle factors. Epitalon’s effects persist longer due to the epigenetic mechanism — the 1–2 cycles per year administration pattern accommodates this.

Post-framework GLP-1 RA continuation. The patient continues on the GLP-1 RA per Module 5 Protocol Template §5. The framework’s substrate-quality optimization phase is intended as time-limited; the GLP-1 RA is the long-term weight-management therapy.

8.6 Re-initiation pathway

A patient who discontinued and is considering re-initiation of one or more framework compounds: typically re-initiation at the standard starting dose per §4.3 is the recommended pattern. For most compounds, abrupt re-initiation at prior dose is acceptable given the favorable tolerability profile. Pre-treatment workup refresh per §3 if the discontinuation period exceeded approximately 12 months or if any new comorbidity has emerged.

Common re-initiation scenarios:

• Substrate-quality deficit recurrence. A patient with prior HPA-axis intervention and discontinuation, who returns at 6-month follow-up reporting recurrent chronic stress and elevated cortisol — re-initiate Selank per the standard §4.3 dose.
• New substrate-quality deficit emergence. A patient with prior inflammation+gut barrier intervention who develops new sleep complaints during ongoing GLP-1 therapy at Month 9 — initiate DSIP for circadian axis without re-initiation of inflammation axis compounds.
• Repeat priming for renewed weight-loss attempt. A patient who has been off GLP-1 RA for some time and is preparing to re-initiate GLP-1 RA — repeat the framework priming phase if substrate-quality deficits are documented at re-screening.

8.7 Worked example — framework discontinuation for the §1.5 patient

Continuing the §1.5 patient through long-term framework + GLP-1 RA: at Month 12 of GLP-1 therapy (~18 months from initial framework initiation):

• GLP-1 RA status: weight stable at -22 kg from baseline (24% of starting weight; on-trajectory for STEP-1 effect-size at maintenance). HbA1c 5.5% (resolved prediabetes). hsCRP 1.2 mg/L. Morning cortisol 13 µg/dL. Sleep duration 7.4 hours nightly per actigraphy; sleep efficiency 91%.
• Framework status: NMN 250 mg daily continuing; all other framework compounds discontinued per §5.5 worked example continuation.

Discontinuation decision at Month 12. Clinician-and-patient shared decision regarding NMN continuation. The patient reports good subjective energy, stable sleep, no recurrent stress symptoms. The objective metabolic markers (HbA1c, fasting insulin re-measured at this visit 14 µIU/mL → HOMA-IR 2.6, resolved from baseline 5.8) are within target. The patient prefers to continue NMN as ongoing supplementation given favorable safety profile and cost; clinician supports continuation. NMN continued indefinitely with annual reassessment.

Re-initiation pathway documented in record. If the patient experiences recurrence of substrate-quality deficit symptoms (recurrent inflammation symptoms, recurrent sleep complaints, recurrent stress symptoms, new mitochondrial-axis symptoms), the re-initiation pathway per §8.6 is available: re-screening per §3 abbreviated workup; per-axis compound selection per §4.3; cycle initiation per the original framework approach.

Pattern Z calibration applied to §8.7. The discontinuation decision is presented as patient-anchored shared decision; the continuation decision is similarly patient-anchored. The expectation framing (no rebound; partial loss of axis-response possible over months if underlying substrate-quality deficit was not durably resolved) is honest without overstating discontinuation risk. The re-initiation pathway is documented as accessible if and when the patient and clinician decide it is appropriate.

9. Combination rules

9.1 Purpose

Define how this framework integrates with the GLP-1 RA backbone and with other Module 5 stacks, what is contraindicated in combination, and the rationale for each combination category. Section 9 is the framework’s bridge to Module 5.12 Combination Protocols and to the per-stack protocols across Module 5 — particularly the M5.5 Tesamorelin + AOD-9604 visceral-fat stack, the M5.6 CJC-1295 + Ipamorelin + MOTS-c lean-mass stack, and the M5.7 GHK-Cu post-weight-loss skin laxity stack.

The §9 structure for this framework is integration-focused: how does the substrate-quality optimization layer combine with the standalone Module 5 therapies that the patient may also be on? The framework is not a stand-alone weight-management approach; it is a layered substrate-quality optimization that operates alongside the GLP-1 RA backbone and that may operate alongside other Module 5 stacks.

Pattern W cross-section consistency applies: every combination in this section is reconciled with §2 (a combination cannot include an agent contraindicated in §2), §6 (combinations cannot mask or exacerbate AE-class concerns established in §6), and §10 (counseling beats for combinations are anchored to Pattern Z calibration anchors).

9.2 Combination with the GLP-1 RA backbone — the foundational integration

Every framework patient is on (or initiating) a GLP-1 RA per the framework’s indication scope. The integration considerations:

Mechanism compatibility. Framework compounds and GLP-1 RAs engage mechanism-distinct pathways with no documented antagonism. The framework operates on upstream substrate-quality (inflammation, mitochondrial, gut barrier, HPA, circadian); the GLP-1 RA operates on central appetite-pathway plus peripheral signaling (gastric emptying, insulin secretion, glucagon suppression). No mechanism-based contraindication for any combination of framework compound + any GLP-1 RA.

Pharmacokinetic compatibility. No documented pharmacokinetic interactions between framework compounds and GLP-1 RAs. The framework compounds (small peptides, dinucleotide coenzyme for NAD+) do not engage hepatic cytochromes or transporters that interact with the GLP-1 RA clearance pathways.

Pharmacodynamic complementarity. Inflammation reduction (framework) plus GLP-1-driven weight loss (which itself reduces inflammation) is mechanism-additive in the favorable direction. Mitochondrial-axis improvement (framework) plus GLP-1-driven metabolic improvement is mechanism-additive in the favorable direction. HPA-axis modulation (framework) plus GLP-1-driven appetite reduction may attenuate stress-driven hyperphagia in a complementary mechanism. Circadian axis improvement (framework) plus GLP-1-driven weight loss with sleep apnea attenuation is complementary.

Sequential vs simultaneous integration. §4.2 articulates the priming vs parallel sequencing options. Both are acceptable; clinician-and-patient shared decision.

GLP-1 GI AE attenuation by gut-barrier axis intervention — research-state-extrapolation. As articulated in §6.3, BPC-157 and KPV are mechanism-rationally proposed to attenuate some of the GLP-1 GI AE profile via gut mucosal protection. No Phase 3 RCT has directly evaluated this. Pattern Z.research-precision: the mechanism rationale is presented honestly without overstating efficacy.

9.3 Combination with M5.5 Tesamorelin + AOD-9604 visceral-fat stack

A patient on this framework may also be considering or be on the M5.5 Tesamorelin + AOD-9604 visceral-fat stack if visceral adiposity is a primary clinical concern in addition to overall weight loss.

Mechanism compatibility. Tesamorelin (GHRH analog, FDA-approved for HIV-lipodystrophy off-label for visceral adiposity in non-HIV context per M5.5 protocol) and AOD-9604 (research-state lipolytic peptide per M5.5 protocol) engage GH-axis-mediated visceral fat reduction. The framework compounds in this protocol are mechanism-distinct from tesamorelin and AOD-9604; no antagonism documented.

IGF-1 axis consideration. Tesamorelin produces measurable IGF-1 elevation per its M5.5 protocol; IGF-1 monitoring is per the M5.5 protocol. The framework does not produce systemic IGF-1 elevation; no cross-stack IGF-1 monitoring adjustment required for the framework itself. However, the framework’s NAD+ axis intervention (NMN, NR) has theoretical mitochondrial-axis interaction with the GH-axis (mitochondrial function supports GH-axis signaling); no documented antagonism or amplification.

Operational stacking. Framework + M5.5 + GLP-1 RA is a multi-stack regimen typical of selected polycondition phenotype patients (severe visceral adiposity + multi-axis substrate-quality deficit + GLP-1 RA indication). Operational complexity is heavy — multiple injection schedules, multiple oral compounds, multiple monitoring panels. Clinician-and-patient shared decision regarding the operational burden and the marginal benefit.

9.4 Combination with M5.6 CJC-1295 + Ipamorelin + MOTS-c lean-mass stack

A patient on this framework may also be considering or be on the M5.6 lean-mass stack if lean-mass preservation is a primary clinical concern during GLP-1-driven weight loss.

Mechanism compatibility. M5.6 stack engages GH-axis (CJC-1295 + Ipamorelin) and mitochondrial-derived peptide axis (MOTS-c). The framework’s NAD+ axis (NMN, NR) and SS-31 axis are mechanism-related to the MOTS-c axis (all are mitochondrial-axis interventions) — there is mechanism overlap but not antagonism. Some clinicians prefer to NOT combine NMN/NR with MOTS-c due to mechanism redundancy; others combine them for additive mitochondrial-axis support. Clinician-and-patient shared decision per §10.5 comparator framing.

IGF-1 axis consideration. M5.6 stack’s CJC-Ipamorelin component produces IGF-1 elevation per the M5.6 protocol; IGF-1 monitoring is per the M5.6 protocol. The framework does not require additional IGF-1 monitoring beyond what M5.6 mandates if M5.6 is co-administered.

Mitochondrial-axis cross-stack coordination. If both the framework’s mitochondrial axis (NMN, NR, SS-31) and M5.6’s MOTS-c are co-administered: the operational pattern is to select ONE primary mitochondrial-axis intervention rather than layer all three. Most commonly, the M5.6 MOTS-c serves the mitochondrial axis when M5.6 is in use; framework NMN/NR is reserved for patients on framework without M5.6 lean-mass-stack co-administration.

9.5 Combination with M5.7 GHK-Cu post-weight-loss skin laxity stack

A patient who completes substantial GLP-1-driven weight loss may also be considering or be on the M5.7 GHK-Cu post-weight-loss skin laxity stack to address skin laxity in the post-weight-loss phase.

Mechanism compatibility. GHK-Cu (copper-peptide) engages extracellular matrix remodeling and dermal collagen synthesis per the M5.7 protocol; mechanism-distinct from the framework compounds. No documented antagonism.

Timing considerations. M5.7 is typically initiated in the post-target-weight-attainment phase (after the patient has achieved substantial weight loss and skin laxity has become a clinical concern). The framework is typically active in the pre-target-weight-attainment phase (priming or early-co-administration). Sequential rather than simultaneous use is the more common pattern.

9.6 Cross-Module combinations

Module 4 (Immune & Longevity) overlap. Many framework compounds have primary canonical homes in Module 4 contexts (per the §C inclusion/exclusion section appendix and the frontmatter). A patient already on Module 4 protocols (Anti-Aging Daily Protocol, Longevity Stack Protocol, Gut Healing Protocol, Recovery Stack Protocol, Immune Restoration Protocol) may have framework compounds already active in the Module 4 context. The framework’s §1.2 indication is the Module 5 pre-GLP-1 / parallel-with-GLP-1 substrate-quality optimization context; the Module 4 protocols address different indications (longevity, gut healing, recovery, immune restoration). Operationally, the same compound at the same dose for the same patient typically serves both Module 4 and Module 5 indications without duplication — the patient is not on “Module 4 NMN” plus “Module 5 NMN” separately; the patient is on NMN with cross-module indication-supporting documentation.

Module 2 (Hormonal Optimization) coordination. Patients on testosterone replacement therapy, hormone replacement therapy, or thyroid optimization (Module 2 protocols) may have substrate-quality deficits that the framework addresses; coordination with the Module 2 protocols is per clinician judgment. No documented antagonism with framework compounds.

Module 3 (Cognitive & Neurologic) coordination. Patients on Module 3 cognitive enhancement protocols (Selank for anxiety; Semax for cognitive; Cerebrolysin for cognitive decline; Dihexa, NSI-189, P21 for neurogenesis) — the framework includes Selank as a primary HPA-axis stack compound and includes Semax + Cerebrolysin as cross-referenced cross-module options in §4.3 HPA axis cognitive-comorbidity sub-scope (with primary canonical homes in Module 3). A patient already on Module 3 Selank for anxiety who is initiating GLP-1 RA: the Selank serves both the Module 3 anxiety indication and the framework HPA-axis indication; no compound duplication required. A patient already on Module 3 Semax or Cerebrolysin for cognitive indication who is initiating GLP-1 RA: the Module 3 compound continues per its Module 3 indication and counts toward the framework’s HPA-axis cognitive-comorbidity sub-scope cross-referenced cross-module option layer; no compound duplication required.

9.7 Contraindicated combinations

Framework compounds with concurrent benzodiazepine therapy: Selank specifically has documented allosteric competition with diazepam at GABA-A receptors (PMID 26924987); concurrent benzodiazepine therapy is a relative exclusion for Selank specifically.

Framework compounds with concurrent CNS depressants at high cumulative load: DSIP additive sedation with opioids and other CNS depressants; clinician judgment for dose adjustment.

Framework compounds in patients with active malignancy on mechanism-based contraindication grounds: BPC-157, TB-500, Epitalon (telomerase-activation theoretical), NAD+ (rapidly-dividing-cells theoretical) per §2.4 + §6.8.

Framework compounds plus duplicate-mechanism alternatives: combining NMN and NR at full doses is not specifically contraindicated but is mechanism-redundant; typically one or the other is selected. Combining IV NAD+, SubQ NAD+, and oral NMN+NR is operationally heavy and mechanism-redundant; typically one route is selected.

9.8 Worked example — combination scenarios

Scenario A — framework + GLP-1 RA monotherapy (the most common combination). The §1.5 patient worked example demonstrates this; framework + Wegovy 2.4 mg for CWM. Per §4.2 priming approach.

Scenario B — framework + GLP-1 RA + M5.6 lean-mass stack. A 58-year-old peri-menopausal female with the §1.5-patient-equivalent multi-axis profile PLUS DEXA showing lean-mass-loss fraction exceeding 30% of total weight loss at Month 3 of GLP-1 therapy. M5.6 lean-mass stack initiated at Month 4. Framework status at this point: only NMN 250 mg daily continuing (other framework compounds previously discontinued per §5.5 worked example pattern). M5.6 MOTS-c initiated. Clinician-and-patient discussion: continue NMN alongside M5.6 MOTS-c (mechanism-overlap acknowledged; some clinicians select one or the other; patient preference and cost considerations) OR transition NMN → M5.6 MOTS-c (mitochondrial axis served by M5.6 going forward). Patient preference: continue NMN. Outcome: framework NMN + M5.6 lean-mass stack + GLP-1 RA backbone, monitored per the combined protocols.

Scenario C — framework + GLP-1 RA + M5.7 GHK-Cu skin stack (sequential). The §1.5 patient at Month 18 of GLP-1 therapy, post-target-weight-attainment, with developing skin laxity. M5.7 GHK-Cu initiated. Framework status: NMN continuing per long-term supplementation; no other framework compounds active. M5.7 protocol applies per its own protocol; no framework adjustment required.

Scenario D — framework + M5.5 visceral-fat stack + GLP-1 RA. A 55-year-old male with severe visceral adiposity (waist 118 cm), CV-risk-elevated, post-MI, on GLP-1 RA per SELECT-anchored CV-risk indication, with M5.5 tesamorelin + AOD-9604 initiated for visceral-fat-specific intervention. Framework consideration: this patient may benefit from inflammation-axis intervention (post-MI inflammation context) and from mitochondrial-axis intervention. Framework + M5.5 + GLP-1 RA: operational complexity heavy; clinician-and-patient shared decision regarding the layered intervention. Outcome dependent on patient preference and clinical judgment.

Pattern W cross-check at §9.8. Each combination above is reconciled with §2 (no patient enters a combination with a contraindicated agent), §6 (combination AE-management does not mask or substitute for individual-stack AE-management), and §10 (counseling beats for combinations are Pattern Z calibration-anchor-compliant).

10. Patient counseling beats (Pattern Z calibration-anchor-compliant)

10.1 Purpose

Define the framework’s patient-counseling content — the conversations the clinician has with the patient at each protocol phase. Section 10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration); the counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

§10 Anchor 5 (off-label / extrapolation transparency) is DOMINANT — the largest §10 subsection. The entire framework is off-label / research-state-extrapolation for the pre-treatment metabolic preparation indication across all eight primary stack compounds and all three cross-referenced cross-module options (eleven compounds total), including SS-31 (FDA-approved for Barth syndrome only; framework use is off-label), NMN/NR (dietary supplement status with contested NMN regulatory framework), and the cross-referenced cross-module options Humanin / Semax / Cerebrolysin (research-state in the U.S.; Russian / EU / China / Mexican foreign approvals for Semax and Cerebrolysin are not transferable to U.S. regulatory standing). The patient counseling beats throughout §10 lead with honest framing: the mechanism rationale for each compound is sound; the clinical-trial evidence base for this specific use case is research-state-incomplete; the framework is one possible clinical-judgment layer that the clinician may offer to selected patients with documented substrate-quality deficits.

The five Pattern Z calibration anchors are verbatim examples from semaglutide v1.0-final (Sections 8.3.2, 12.10-Pattern-2, 6.8, 12.10-Pattern-6, 12.10-Pattern-8), established as the calibration baseline per the canonical source at /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md. The five anchors as they apply to this framework:

• Anchor 1 — Lead with what the option IS. Every framework compound is introduced with what it IS — the mechanism, the evidence state, the research-state framing — not with what it isn’t (not FDA-approved, not Phase 3 validated for this use). The patient learns what each compound IS first; the regulatory framing follows.
• Anchor 2 — Compounded-vs-FDA-approved framing. The framework compounds have varying access pathways (503A compounding with post-2023 FDA Category 2 listing variation for BPC-157 and others; dietary supplement marketing for NMN and NR; intranasal Selank outside FDA label; SS-31 FDA-approved for Barth syndrome only). Patient counseling presents the access pathway factually without steering.
• Anchor 3 — Pregnancy-planning precision. Reproductive-age patients receive the framework’s per-compound pre-conception arithmetic plus the combined-with-GLP-1-RA timing per §8.4. The lead is research-state human pregnancy-exposure data where it exists; pharmacokinetic facts and clinician-judgment framing follow.
• Anchor 4 — Comparator framing. Within-axis comparator options (NMN vs NR vs SS-31 for mitochondrial axis; BPC-157 vs KPV vs combination for inflammation+gut barrier axis) are presented as multi-dimensional factual choices with patient-and-clinician shared decision.
• Anchor 5 — Off-label / extrapolation transparency. Dominant section. Every framework compound is off-label / research-state-extrapolation for this use; the protocol presents this honestly without dismissing the patient’s question or framing the framework as universally inferior to standard-of-care because the standard-of-care for pre-treatment metabolic preparation is the patient’s lifestyle foundation plus the GLP-1 RA itself; the framework is an additional clinician-judgment layer.

10.2 Initiation conversation (Section 4 anchor)

The initiation conversation occurs at the pre-treatment workup completion / Section 4 initiation visit. Required counseling beats:

• What the framework is (Anchor 1, Anchor 5): “This is a framework — not a fixed regimen — of peptide and small-molecule interventions that some clinicians use before or during GLP-1 RA initiation to address substrate-quality deficits that may improve the GLP-1 response. Each compound in your specific stack is being considered because of [the specific axis evidence] in your workup. The framework is research-state-extrapolation for this specific use case across all the compounds — the mechanism rationale is sound but the clinical-trial evidence base for substrate-quality optimization before GLP-1 initiation specifically is research-state-incomplete. This is a clinician-judgment layer; the load-bearing therapy is the GLP-1 RA you’re about to initiate (or have recently initiated). The framework is an addition that some patients find helpful and some patients prefer to skip; both are reasonable choices.”
• Per-compound mechanism (Anchor 1): plain-language mechanism for each compound the patient is starting. Example for the §1.5 patient: BPC-157+KPV for gut barrier and anti-inflammatory support; NMN for cellular energy metabolism support; Selank for stress and anxiety modulation without benzodiazepine dependence; DSIP for sleep architecture support.
• The 4–6 week priming window or parallel co-administration (per §4.2): “We’re going to use these for the [4–6 weeks before / 8–12 weeks during the early titration of] your GLP-1 therapy. After that window, most of the framework compounds will discontinue; one or two may continue based on how you respond.”
• The per-compound administration technique (SubQ training; intranasal training; oral instruction): standard technique training equivalent to the GLP-1 RA injection training.
• The expected response window per axis (per §7.2): “Your subjective stress and sleep response from Selank and DSIP may emerge in the first 1–2 weeks; your inflammation response from BPC-157+KPV may take 4–6 weeks; your mitochondrial response from NMN may take 8–12 weeks. We’ll check in at Week 2 and Week 4 to assess your progress.”
• The cost-and-access reality per compound (Anchor 2): “BPC-157 and KPV are research-state compounds accessed through compounding pharmacies; the access varies by state and over time. NMN is sold as a dietary supplement; the regulatory status is contested but it’s currently available. Selank and DSIP are similarly research-state. SS-31 if you elect that for mitochondrial support — the FDA-approved formulation is for a rare disease called Barth syndrome and is expensive; the functional medicine extrapolated dose is research-state. Let’s review the cost and access for the specific compounds we’ve selected.”
• What the patient signals back if any concern emerges: tolerability concerns, adherence concerns, technique concerns — patient is invited to message or call the practice between scheduled visits.

10.3 Compounded peptide pathway counseling (Anchors 1 + 2)

The framework compounds are accessed predominantly through 503A and 503B compounding pharmacies (BPC-157, KPV, TB-500, Selank, DSIP, Epitalon) or through dietary supplement marketing (NMN, NR). SS-31 is FDA-approved for Barth syndrome and is accessed through specialty pharmacy distribution at the labeled dose; functional medicine extrapolated doses are accessed through compounding pharmacies. The counseling beat for compounded-pathway access mirrors the canonical Anchor 1 + Anchor 2 framing:

Pattern Z compliant framing. “The compounds we’ve selected for your framework — [list the patient’s specific compounds] — are accessed primarily through compounding pharmacies, which are state-licensed (503A) or FDA-registered (503B) pharmacies that prepare custom medications. This is a real-world clinical pathway used by a substantial patient population for many research-state peptides and for several FDA-approved compounds that have been on shortage or where compounding-pharmacy access offers cost or dose-flexibility advantages.

Operational characteristics of compounded preparations relevant to your framework:

• Most peptides arrive as lyophilized vials that you reconstitute with bacteriostatic water at the point of use; we’ll walk through reconstitution technique together if any of your compounds requires it.
• Storage is typically refrigerated after reconstitution (2–8°C, use within 2–4 weeks per the compound; we’ll provide the specific shelf-life per compound).
• Quality criteria clinicians evaluate when selecting a compounding pharmacy include sterility testing per USP <797> and <800> standards, certificate of analysis per batch documenting peptide content and purity, cold-chain shipping, and state-licensure or FDA-registration verification.
• The post-2023 FDA Category 2 bulk drug substance listings affected the compounding pathway for some peptides (including BPC-157 and several others); the regulatory framework varies by jurisdiction and over time. We can verify current access for your specific compounds.“

Pattern Z compliant patient-counseling beat. “The compounding-pharmacy pathway is the standard access route for the research-state peptides in your framework. We can review the specific pharmacy we use, walk through the reconstitution technique together for any compound that requires it, and discuss the cost-and-access reality for each compound in your stack. The framework operates within this access pathway — it’s not a barrier; it’s the normal pattern. Let’s review what’s in your stack and how each compound will work in your daily routine.”

10.4 Pregnancy-planning conversation (Anchor 3)

For reproductive-age patients on the framework. The conversation LEADS with the research-state framing of human pregnancy-exposure data, not with PK arithmetic or contraindication framing — this lead-framing discipline is the core of canonical Anchor 3 adapted for the framework’s heterogeneous compound mix.

Research-state human pregnancy-exposure data lead. “Across the eleven compounds in this framework (eight primary stack compounds plus three cross-referenced cross-module options), none has adequate prospective pregnancy-exposure data. The research-state human evidence is largely absent. Most of these compounds are research-state for any indication, and pregnancy-exposure populations have not been characterized in prospective registries. The exception is NAD+ precursors (NMN, NR), which have dietary supplement use in pregnancy contexts but no prospective registry data; and SS-31 (Elamipretide), which has the FDA Barth syndrome label noting insufficient pregnancy data.”

Pharmacokinetic facts (post-research-state-lead). “The pharmacokinetic clearance arithmetic per compound: short half-life compounds (BPC-157, KPV, Selank, DSIP, Epitalon, NMN, NR) clear within minutes to hours. SS-31 has 1.28–4 hour plasma half-life with mitochondrial persistence. The GLP-1 RA you’re on (or planning to start) has ~7-day half-life with a labeled 8-week pre-conception window per the Wegovy / Ozempic labels.”

Operational pre-conception planning. “If you’re planning conception within the next 6 months, the conservative recommendation is to defer framework initiation; if you’re on the framework and planning conception within the next 3 months, plan discontinuation of all framework compounds at least 4 weeks before planned conception, and continue the GLP-1 RA pre-conception arithmetic on its own 8-week timeline. If you’re not planning conception within the next 12 months but want awareness of the framework’s pre-conception arithmetic in case planning changes, here it is.”

Post-discontinuation considerations. “After discontinuation, the substrate-quality biomarkers may slowly drift back toward baseline if your underlying drivers (lifestyle, stress, sleep) are not durably resolved. The framework can be re-initiated post-pregnancy and post-lactation per the standard pre-treatment workup if you and your clinician decide that is appropriate for your next phase.”

Patient-anchored decision. “Your reproductive-planning decision is patient-anchored. Some patients on the framework will defer conception planning until target weight is achieved and stabilized on the GLP-1 RA; some will plan conception within the next 1–2 years and adjust the framework and GLP-1 RA timing accordingly; some will not plan conception. The framework presents the pharmacokinetic facts and the research-state pregnancy-exposure framing; the timing decision is yours.”

10.5 Comparator conversation (Anchor 4)

Multiple compounds within a single axis are candidate options; the comparator framing presents the multi-dimensional facts and invites shared decision-making.

Within-mitochondrial-axis comparator (NMN vs NR vs SS-31). “For mitochondrial axis support, the framework has three primary compound options:

• NMN (nicotinamide mononucleotide) — oral; 250 mg/day at the trial dose per the Yoshino 2021 Science paper that demonstrated improved insulin sensitivity in prediabetic women; can be dose-escalated to 500–900 mg/day per Yi 2023 dose-ranging study; sold as a dietary supplement with contested FDA status (NDI letter 2022 reclassified NMN as having been investigated as a drug, blocking dietary supplement marketing claims; access continues but the legal framework is unsettled). Strongest human RCT evidence among the framework compounds.
• NR (nicotinamide riboside) — oral; 500–1000 mg/day per Martens 2018 trial in healthy older adults; up to 2000 mg/day per Dollerup 2018 trial in obese insulin-resistant men. The Martens trial showed elevated NAD+ blood levels and reduced arterial stiffness trends; the Dollerup trial was NEGATIVE for insulin sensitivity and other metabolic endpoints in the obese insulin-resistant phenotype. Dietary supplement status; GRAS-acknowledged. The negative result in obese insulin-resistant men is important for your decision-making.
• SS-31 (Elamipretide) — SubQ injection; FDA-approved for Barth syndrome at 40 mg/day continuous (the rare-disease labeled dose). Functional medicine extrapolated dose is 1–5 mg/day in 30–60 day cycles. The Phase 2 EMBRACE heart failure RCT demonstrated improved LV end-systolic volume. Off-label for the framework indication. Higher cost than NMN/NR; SubQ administration vs oral.

The choice among these three is patient-and-clinician shared decision. Your phenotype (prediabetic with insulin resistance) aligns with the Yoshino NMN trial’s enrollment population — that’s one phenotype-matching consideration favoring NMN. Cost-and-access typically favors NMN and NR over SS-31 for non-Barth use. Some patients prefer the SubQ route of SS-31 if they’re already on SubQ GLP-1 RA injection; some prefer oral simplicity. Let’s discuss your specific preferences.“

Within-inflammation+gut-barrier-axis comparator (BPC-157 vs KPV vs combination vs TB-500 addition). “For inflammation and gut barrier axis support:

• BPC-157 — extensive preclinical evidence (35+ animal studies in the 2025 orthopedic systematic review), two small uncontrolled human pilots (n=2 IV safety; n=12 intravesical interstitial cystitis), one Phase 2 RCT recruiting for hamstring repair. Available as oral capsule or SubQ injection. Mechanism: angiogenesis promotion via VEGFR2/Akt/eNOS; tight-junction stabilization; cytoprotection.
• KPV — research-state with zero human RCTs; PepT1-mediated self-targeting to inflamed colon is the mechanism rationale supporting oral route specifically; alpha-MSH C-terminal tripeptide with NF-κB inhibition.
• BPC-157 + KPV combination capsule — combines both mechanisms; the AP-BPC157-KPV-Capsules format is one example.
• TB-500 addition — typically used for cross-indication patients with tissue-repair concerns (post-surgical, post-injury); SubQ injection; loading-then-maintenance dose pattern.

For your specific phenotype (elevated hsCRP plus inflammation context without specific tissue-repair indication), the BPC-157+KPV combination is a common first-line choice. Let’s discuss your preferences.“

Within-HPA-axis: Selank as primary; alternatives if Selank is contraindicated or non-responsive. Selank is the primary HPA-axis framework intervention with the documented GABA-A allosteric modulation mechanism and the human GAD immunomodulation data (PMID 18577961). Alternative HPA-axis interventions outside the peptide framework include behavioral health (cognitive behavioral therapy for anxiety, mindfulness training), pharmacologic alternatives (SSRI / SNRI per psychiatry indication), and lifestyle interventions (regular exercise, sleep hygiene foundation). The framework’s Selank is one option among many; clinician-and-patient shared decision.

Within-circadian-axis: DSIP as primary; Epitalon as adjunct. DSIP is the primary slow-wave-sleep enhancement intervention per the 1983 human sleep RCT (PMID 6895513) and decades of practitioner experience. Epitalon is the optional adjunct considered when age-related melatonin decline is a clinical-judgment factor (typically older adults ≥60). Alternative circadian interventions outside the framework include melatonin supplementation (lower cost, dietary supplement), light therapy (for circadian phase shifting), and sleep medicine evaluation for refractory insomnia.

10.6 Off-label / extrapolation conversation — Anchor 5 DOMINANT

This is the largest §10 subsection because the entire framework is off-label / research-state-extrapolation for this use case across all compounds.

The honest framing. “Every compound in your framework is being used off-label or as research-state-extrapolation for the pre-treatment metabolic preparation indication. SS-31 (Elamipretide) is FDA-approved for Barth syndrome — a rare cardiomyopathy condition — and its use for your mitochondrial axis support (if you elect SS-31) is off-label. The other framework compounds — BPC-157, KPV, TB-500, Selank, DSIP, Epitalon, NMN, NR — are not FDA-approved for any indication that maps to the framework use case (NMN and NR have dietary supplement marketing; the others are research-state).

The mechanism rationale for each compound’s role in your framework is sound and is supported by the published literature — angiogenesis and gut barrier stabilization for BPC-157, alpha-MSH-derived NF-κB inhibition for KPV, GABA-A allosteric modulation for Selank, slow-wave sleep enhancement for DSIP, cardiolipin protection for SS-31, NAD+ axis support for NMN and NR. The mechanism is real; the trials supporting these mechanisms are real.

What is research-state-incomplete is the clinical-trial evidence base for pre-treatment metabolic preparation as a specific use case. No Phase 3 RCT has evaluated any of these compounds as pre-treatment optimization for GLP-1 RA initiation. The framework is constructed from mechanism-rationale + per-compound evidence + clinician-judgment — not from a Phase 3 trial demonstrating that the framework improves GLP-1 outcomes.

What this means for your decision: the framework is a clinical-judgment layer that some clinicians offer to selected patients with documented substrate-quality deficits. It may or may not improve your GLP-1 response. The risk profile is generally favorable across the framework compounds (no serious safety signals at typical doses; mild AE profile across compounds), but the benefit profile for this specific use case is research-state-incomplete. Some patients find the framework subjectively helpful and choose to proceed; some patients prefer to skip the framework and proceed directly to GLP-1 RA initiation, with the substrate-quality deficits potentially modulated by the GLP-1 RA-driven weight loss itself.

Both choices are reasonable. The framework is not ‘better’ than the no-framework path for every patient; it is a clinician-judgment layer that may be appropriate for selected patients and is appropriately deferred for others.“

The shared decision-making invitation. “Let’s discuss your specific situation — your substrate-quality deficit profile from the workup, your tolerance for additional medications and injections beyond the GLP-1 RA, your cost-and-access constraints, your preferences regarding research-state vs label-supported therapies, and your phenotype-specific evidence-base for each axis. Some axes in your profile have stronger mechanism rationale than others; some have phenotype-matching evidence (NMN in prediabetic women aligns with your prediabetic phenotype, for example). I can present the per-compound evidence at the depth you find useful, and we can construct a framework that matches your preferences — or we can defer the framework entirely and focus on the GLP-1 RA + lifestyle foundation, which is the standard-of-care pathway that does not require the framework.”

Cross-referenced cross-module options sub-beat — Humanin, Semax, Cerebrolysin. A subset of pre-GLP-1 / co-GLP-1 patients have cognitive-comorbid load (cognitive complaints, post-TBI history, post-stroke history, mood-driven eating with cognitive-load components, “food-noise” with prominent ruminating-cognition driver, early-stage cognitive decline) or specific mitochondrial-dysfunction markers with interest in the MDP (mitochondrial-derived peptide) family. For these patients, additional options exist in the Module 3 Cognitive Enhancement Protocol family and in the MDP cross-reference layer of the Mitochondrial axis — these are not primary stack components but are reasonable cross-module considerations:

• Humanin (Mitochondrial axis MDP cross-reference; primary canonical home /Peptides/Humanin.md). Mitochondrial-derived peptide; cytoprotective; bioenergetic regulator co-listed with MOTS-c in the MDP family. Evidence state is research-state-incomplete (mechanistic + observational evidence; thin human-trial data — the canonical at /Peptides/Humanin.md notes “Human dosing extrapolated from rodent studies; clinical protocols not yet established”). Active-malignancy mechanism-based caution per JAK2/STAT3 anti-apoptotic signaling. Pattern AA: investigational; not FDA-approved-for-marketing-claims for any indication. Optional consideration when a patient has documented mitochondrial-dysfunction markers and explicit interest in the MDP family.

• Semax (HPA / Stress / Sleep axis cognitive-comorbidity cross-reference; primary canonical home /Peptides/Semax.md + Module 3 Cognitive Enhancement Protocol). ACTH(4–10)-fragment-derived; BDNF/NGF upregulation; neuroprotective. Russian approval for acute ischemic stroke, ADHD, optic nerve atrophy; off-label for HPA-mediated weight-loss contexts. Pattern AA: not FDA-approved-for-marketing-claims; Russian foreign approval not transferable to U.S. regulatory standing. Optional consideration for cognitive-axis comorbid weight-loss patients (cognitive-load components of emotional or stress eating; post-stroke history; food-noise with ruminating-cognition driver).

• Cerebrolysin (HPA / Stress / Sleep axis cognitive-comorbidity cross-reference; primary canonical home /Peptides/Cerebrolysin.md + Module 3 Cognitive Enhancement Protocol + Post-Stroke Recovery Protocol). Porcine brain hydrolysate; neurotrophic peptide mix mimicking endogenous neurotrophic factors. Phase 3 trials in acute stroke / TBI / dementia. Operational considerations: porcine allergen risk; IM/IV-with-dilution administration requirement; operationally heavier than the SC compounds in the rest of the stack. Pattern AA: foreign approvals (Europe, China, Mexico, Russia); not FDA-approved-for-marketing-claims in the U.S. Optional consideration for patients with specific cognitive comorbidities (post-stroke / TBI history; dementia early-stage) pursuing pre-treatment optimization who also accept the operational profile.

The honest framing for patient counseling. “For patients with cognitive-axis comorbidities (cognitive load, mood-driven eating, post-stroke / TBI history) or interest in the MDP family alongside documented mitochondrial-dysfunction markers, additional options exist in the Module 3 Cognitive Enhancement Protocol family — Semax, Cerebrolysin — and in the Mitochondrial axis MDP cross-reference — Humanin. These are not primary stack components in this framework but are reasonable cross-module considerations. Each carries differentiated evidence-state and operational tradeoff profiles relative to the primary stack compounds. The cross-module patient-counseling pathway and the depth of evidence presentation for these three cross-referenced options anchor to the Module 3 Cognitive Enhancement Protocol (Semax, Cerebrolysin) and the Anti-Aging Daily / Longevity Stack Protocols (Humanin) — this framework references those canonical homes rather than re-developing the per-compound counseling at depth here.”

10.7 Discontinuation conversation (Section 8 anchor)

For patient-preference, axis-target-attained, or AE-driven discontinuation. Required counseling beats:

• Reason for discontinuation framing. Patient-preference is legitimate; axis-target-attained is the typical end-of-cycle pattern; AE-attribution requires per-compound assessment per §6.
• Per-compound discontinuation pattern. “For [the specific compounds in your framework], we’ll [discontinue at end-of-cycle / continue indefinitely / cycle off and reassess in N weeks].”
• Post-discontinuation expectations. “Most substrate-quality biomarkers should hold at the improved state for some period of time after framework discontinuation; the duration of hold is variable per patient and depends on whether your lifestyle factors and the GLP-1 RA continue to support the improved state. If biomarkers drift back toward baseline, that’s not a failure — it’s information about the durability of the framework’s contribution vs the lifestyle and GLP-1 RA contribution.”
• Re-initiation pathway. “If you experience recurrence of the substrate-quality deficit symptoms — recurrent stress, recurrent sleep difficulty, recurrent inflammation symptoms — the re-initiation pathway is available. We’ll re-screen per the workup and re-evaluate the framework selection at that point.”

10.8 Pattern Z self-audit on §10 counseling beats

The five Anchors are also the self-audit checklist for §10 counseling-beat language. The framework’s §10 is Pattern-Z-violation-positive if any of the following appear:

• Framework compounds framed as default-suspect (“these are research-state compounds and should be approached with caution” — Anchor 1 violation; opens with what they aren’t).
• Pregnancy-planning framed with pre-conception arithmetic as steering toward continued use (“you should continue the framework because pregnancy is unlikely”) or steering toward discontinuation (“you should discontinue the framework because pregnancy is risky”) — Anchor 3 violation; steering through asymmetric emphasis.
• Comparator framing within the mitochondrial axis as “NMN is best” or “SS-31 is best” — Anchor 4 violation; the comparison is multi-dimensional and patient-and-clinician shared decision.
• Off-label use embedded in counseling as if labeled — Anchor 5 violation; Pattern AA cross-fail.
• Compounded-pharmacy pathway framed as inherently inferior — Anchor 2 violation; the access pathway is the standard real-world pathway for research-state peptides.

The §10 production reviewer runs the five-Anchor self-audit before handoff to the verification cycle (Appendix A).

11. Source citations

11.1 Purpose

Define the bibliography format, the evidence-hierarchy tiers, and the PMID-anchor / NCT-anchor / DOI-anchor identifier-integrity discipline. Section 11 is the protocol’s evidentiary spine — every effect-size claim, every dose threshold, every contraindication, every counseling-beat fact-anchor traces to a Section 11 citation entry.

11.2 Bibliography format

Each citation entry contains:

• First author last name, et al.
• Title
• Journal, Year, Volume, Pages
• PMID
• DOI if available
• NCT for trial reports
• Effect-size summary (one-line — the load-bearing fact the protocol cites this source for)
• Citation context (which protocol sections cite this source)

11.3 Evidence hierarchy tiers — framework-adapted

Standard Module 5 Protocol Template hierarchy with framework-specific adjustments:

• Tier 1 — pivotal Phase 3 RCT with FDA-label-supporting trial-program inclusion. In this framework, the Tier 1 sources are GLP-1 RA pivotal trials (STEP, SURMOUNT, SUSTAIN, SELECT, ESSENCE, FLOW — cross-referenced from Module 5 Protocol Template §11.5) plus the SS-31 EMBRACE Phase 2 heart-failure RCT (PMID 29217757) and TAZPOWER Barth syndrome long-term observational data (PMID 38602181).
• Tier 1.5 — Phase 3 head-to-head RCT — not directly applicable to framework compounds (none of the framework compounds has a Phase 3 head-to-head within the framework use case).
• Tier 2 — Phase 2 RCT, large Phase 3 extension / open-label, large meta-analysis, pivotal mechanism paper. In this framework, the Tier 2 sources include the NAD+ axis RCTs (Yoshino 2021 PMID 33888596; Martens 2018 PMID 29599478; Dollerup 2018 PMID 29992272; Yi 2023 PMID 36482258) — the strongest framework-relevant human RCT evidence — plus the Selank human GAD immunomodulation study (PMID 18577961), the Selank human fMRI functional connectivity study (PMID 32342318), the DSIP 1983 human sleep RCT (PMID 6895513), and the BPC-157 systematic review of orthopedic sports medicine (PMID 40756949).
• Tier 3 — post-marketing pharmacovigilance, observational cohort, retrospective analysis, case series. In this framework, the Tier 3 sources include the BPC-157 human pilots (PMID 40131143 IV safety; PMID 39325560 intravesical interstitial cystitis), the Epitalon human evidence (zero human RCTs; in vitro and preclinical only — at the lower edge of Tier 3), and the KPV evidence (zero human RCTs; preclinical only — at the lower edge of Tier 3).

The framework does not invert tiers — a Tier 3 preclinical study does not override a Tier 2 RCT finding within the same axis; a Tier 2 RCT can be contextualized by Tier 3 evidence but the direction-of-effect anchor remains the higher-tier source.

11.4 Identifier-integrity discipline — Pattern AB.1 / AB.2 / AB.4

Pattern AB (identifier integrity) requires every PMID, NCT, and DOI to be verified by content, not by existence. The framework’s PMIDs are anchored to the per-compound canonicals at /Peptides/; each PMID has been content-verified at the canonical authoring step and is re-verified at this protocol’s PSV iteration.

Pattern AB.4 cascade scan: when any identifier is corrected in this document, every occurrence of that identifier in the cross-referenced canonicals (per-compound files at /Peptides/) is updated in the same commit.

11.5 Framework bibliography — organized by axis

Cross-reference convention: PMIDs and trial details are anchored to the per-compound canonical files; the framework bibliography lists the primary citations with one-line effect-size summaries for the load-bearing facts in this protocol.

SS-31 (Elamipretide) — mitochondrial axis.

• Stitziel ND, et al. Targeting mitochondrial dysfunction with elamipretide. Free Radic Biol Med 2022. PMID 35037146. Mechanism review; structure-activity; cardiolipin binding; mPTP inhibition; SIRT1/PGC-1α activation. Cited in §1, §4, §6.
• Mitchell W, et al. Elamipretide: A Review of Its Structure, Mechanism of Action. 2025. PMID 39940712. Comprehensive mechanism review. Cited in §1, §4.
• Reid Thompson W, et al. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide. 2020. PMID 33001359. FDA-approval-supporting evidence base. Cited in §1, §2, §10.
• TAZPOWER long-term Barth syndrome observational study. 2024. PMID 38602181. 168-week sustained cardiac function improvement and functional capacity. Cited in §1, §5.
• Daubert MA, et al. EMBRACE Heart Failure RCT. Eur Heart J 2018. PMID 29217757. Phase 2 HF RCT; improved LV end-systolic volume; translational mitochondrial mechanism. Cited in §1, §4, §10.5.
• Whitson JA, et al. SS-31 Improves ADP Sensitivity in Aged Mitochondria. 2023. PMID 37462785. Aging muscle/heart mitochondrial function. Cited in §1.
• Campbell MD, et al. The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging. 2025. PMID 40080911. Aging cardiac and skeletal muscle. Cited in §1.

NAD+ axis — NMN, NR, IV/SubQ NAD+.

• Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021. PMID 33888596. Landmark trial; 250 mg/day NMN for 10 weeks; improved muscle insulin sensitivity. Cited in §1, §3, §4, §10.5.
• Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications 2018. PMID 29599478. NR 1000 mg/day for 6 weeks; elevated NAD+; trends toward reduced arterial stiffness. Cited in §4, §10.5.
• Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. AJCN 2018. PMID 29992272. NEGATIVE result: NR 2000 mg/day for 12 weeks did not improve insulin sensitivity in obese insulin-resistant men. Cited in §4, §10.5.
• Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults. GeroScience 2023. PMID 36482258. Dose-ranging safety study. Cited in §4, §10.5.
• Imai SI, Guarente L. NAD+ and sirtuins in aging and disease. 2014. PMID 24786309. Mechanism review. Cited in §1.
• Verdin E. NAD+ in aging, metabolism, and neurodegeneration. 2015. PMID 26785480. Mechanism review. Cited in §1.
• Wu J, et al. NAD+ rescues aging-induced blood-brain barrier damage via CX43-PARP1 axis. 2023. PMID 37683629. Mechanism cross-axis context. Cited in §1.

BPC-157 — inflammation + gut barrier axis.

• Sikiric P, et al. Gastric pentadecapeptide body protection compound BPC 157 and wound healing. 2018. PMID 30915550. Mechanism review; tight-junction stabilization. Cited in §1, §4, §6.
• Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. 2021. PMID 34267654. Wound healing review. Cited in §1.
• 2025 systematic review of BPC-157 in Orthopaedic Sports Medicine. PMID 40756949. 35 preclinical + 1 clinical study synthesis. Cited in §1, §11.3.
• Józwiak et al. Multifunctionality and Possible Medical Application of BPC 157. 2025. PMID 40005999. Independent review. Cited in §1.
• Safety of Intravenous Infusion of BPC157 in Humans. 2025. PMID 40131143. Human IV safety pilot (n=2; up to 20 mg). Cited in §1.
• Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis. 2024. PMID 39325560. Human intravesical pilot (n=12). Cited in §1.
• NCT07437547 — Phase 2 RCT for hamstring repair (recruiting). Cited in §11.3.

KPV — anti-inflammatory + gut barrier axis.

• Dalmasso G, et al. KPV PepT1-Mediated Uptake Reduces Intestinal Inflammation. 2008. PMID 18061177. PepT1-mediated self-targeting mechanism. Cited in §1, §4.
• Kannengiesser K, et al. KPV Anti-Inflammatory Potential in Murine IBD. 2008. PMID 18092346. Murine IBD model. Cited in §1.
• Brzoska T, et al. Dissection of the anti-inflammatory effect of the core and C-terminal alpha-MSH peptides. 2003. PMID 12750433. NF-κB inhibition mechanism. Cited in §1.
• KPV Smart-Release Film for Diabetic Wound Healing. 2022. PMID 36240893. Topical application data. Cited in §1.
• Catania A. The neuropeptide alpha-MSH in host defense. 2001. PMID 11268348. Mechanism review. Cited in §1.

TB-500 — inflammation + tissue repair axis.

• Malinda KM, et al. Thymosin beta4 accelerates wound healing. 1999. PMID 10469335. Foundational wound healing study. Cited in §1.
• Sosne G, et al. Thymosin beta 4 and the eye: bench to bedside (Phase 3 RGN-259 trials). 2018. PMID 30063853. Phase 3 ocular development program. Cited in §1, §11.3.
• Peng H, et al. Thymosin beta4 prevents cardiac rupture and improves cardiac function post-MI. 2014. PMID 25015963. Cardioprotection. Cited in §1.
• Pipes GCT, et al. Cardioprotection by Thymosin Beta 4. 2016. PMID 27450736. Cardioprotection review. Cited in §1.

Selank — HPA axis.

• Volkova A, et al. Selank Immunomodulatory Effects in Anxiety Patients. 2008. PMID 18577961. Human GAD immunomodulation; IL-6 suppression; Th1/Th2 rebalancing. Cited in §1, §4, §10.5.
• Inozemtseva LS, et al. Selank Affects GABAergic Neurotransmission Gene Expression. 2016. PMID 26924987. GABA-A allosteric modulation; blocks diazepam modulation. Cited in §1, §2, §6.
• Filatova EV, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission. 2017. PMID 28293190. GABA-A mechanism. Cited in §1.
• Medvedev VE, et al. Peptide-based Anxiolytics: Selank Molecular Mechanisms. 2018. PMID 30255741. Mechanism review; non-benzodiazepine GABA-A. Cited in §1, §10.
• Functional Connectomic Approach to Semax and Selank Effects. 2020. PMID 32342318. Human fMRI functional connectivity. Cited in §1, §4.

DSIP — circadian axis.

• Kovalzon VM, Strekalova TV. DSIP: A Still Unresolved Riddle. 2006. PMID 16539679. Comprehensive review; mechanism uncertainty acknowledged. Cited in §1, §4.
• Schneider-Helmert D, Schoenenberger GA. DSIP: Acute and Delayed Effects on Human Sleep. 1983. PMID 6895513. Human sleep RCT; delta-wave sleep enhancement; tissue accumulation. Cited in §1, §4, §10.5.
• Iyer KK, et al. DSIP Characterization and Multivariate Functions. 1984. PMID 6548966. HPA-axis modulation; ACTH reduction. Cited in §1.
• DSIP Modulates Stress-Related Fos in Limbic Structures. 2012. PMID 22432135. Stress axis modulation. Cited in §1.
• DSIP Fusion Peptide BBB Crossing: Insomnia Models. 2024. PMID 39444618. Recent fusion peptide research. Cited in §1.
• DSIP Decreases Spontaneous Tumor Incidence in Mice. 2003. PMID 12782416. Preclinical anti-tumor signal. Cited in §6.8.

Epitalon — circadian / longevity adjunct.

• Khavinson V, et al. Effect of Epithalon on lifespan increase in Drosophila melanogaster. 2000. PMID 11087911. Drosophila lifespan extension. Cited in §1.
• Anisimov VN, et al. Effect of peptide bioregulators on carcinogenesis. 2002. PMID 12049808. Anti-tumor preclinical signal. Cited in §1, §6.8.
• Khavinson V, et al. Epitalon restores melatonin production in aged primates. 2003. PMID 12096440. Pineal melatonin restoration. Cited in §1, §4.
• Khavinson V, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. 2003. PMID 12937682. Telomerase activation mechanism. Cited in §1.
• Kossoy G, et al. Epitalon and tumor development in rodent models (independent replication). 2006. PMID 16634527. Independent replication; anti-tumor. Cited in §1, §6.8.
• Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide. 2025. PMID 40141333. Comprehensive review. Cited in §1.
• Epitalon increases telomere length in human cell lines (with 2025 correction). PMID 40908429; PMID 41240216 (correction). Telomerase mechanism. Cited in §1.

Cross-referenced cross-module options — Humanin (Mitochondrial axis MDP sub-reference), Semax + Cerebrolysin (HPA / Stress / Sleep axis cognitive-comorbidity sub-scope).

Cross-reference convention: each cross-referenced cross-module option’s full bibliography (mechanism, dose-ranging, safety, efficacy) is anchored to its primary canonical home — /Peptides/Humanin.md, /Peptides/Semax.md, /Peptides/Cerebrolysin.md — and to the Module 3 Cognitive Enhancement Protocol and Post-Stroke Recovery Protocol where applicable. The framework cites a small set of primary references for each cross-referenced cross-module option to support the §4.3 and §10.6 cross-reference framing.

• Humanin canonical at /Peptides/Humanin.md — primary reference for mechanism (MDP family; JAK2/STAT3 and PI3K/Akt signaling), evidence state (mechanistic + observational; thin human-trial data), and active-malignancy mechanism-based caution. Cited in §1, §2, §4, §10.6, §C.
• Semax canonical at /Peptides/Semax.md — primary reference for mechanism (ACTH(4–10)-fragment-derived; BDNF/NGF upregulation), Russian approval indications (acute ischemic stroke / ADHD / optic nerve atrophy), and Semax–Selank-comparator literature. Cited in §4, §6.4, §10.6, §C.
• Cerebrolysin canonical at /Peptides/Cerebrolysin.md — primary reference for mechanism (porcine brain hydrolysate; multi-neurotrophic factor mimicry), Phase 3 acute stroke / TBI / dementia trials, foreign approvals (Russia, EU, China, Mexico), porcine allergen contraindication, and IM/IV-with-dilution administration. Cited in §2, §4, §10.6, §C.
• Functional Connectomic Approach to Semax and Selank Effects. 2020. PMID 32342318. Human fMRI functional connectivity; Semax–Selank comparator. Cited in §1, §4, §10.6.

GLP-1 RA backbone — cross-reference from Module 5 Protocol Template §11.5.

• Wilding JPH, et al. STEP-1. NEJM 2021. PMID 33567185. NCT03548935. Cited in §1, §5, §8.
• Davies M, et al. STEP-2. Lancet 2021. PMID 33667417. NCT03552757.
• Rubino DM, et al. STEP-4. JAMA 2021. PMID 33755728. NCT03548987. Post-discontinuation weight-regain trajectory. Cited in §8.
• Wilding JPH, et al. STEP-1 extension. 2022. PMID 35441470.
• Marso SP, et al. SUSTAIN-6. NEJM 2016. PMID 27633186. NCT01720446.
• Lincoff AM, et al. SELECT. NEJM 2023. PMID 37952131. NCT03574597.
• Sanyal AJ, Newsome PN, et al. ESSENCE. NEJM 2025. PMID 40305708. NCT04822181.
• Perkovic V, et al. FLOW. NEJM 2024. PMID 38785209. NCT03819153.

Framework-relevant additional citations.

• Mozaffarian D, et al. Obesity (Silver Spring) 2025;33(8):1475-1503; PMID 40445127. Multi-society advisory on GLP-1 RA optimization; sarcopenic-risk populations. Cited in §1 (cross-reference from M5.6 stack protocol).
• Look RH, et al. 2025. PMID 39996356. Phase 3 pooled DEXA lean-mass-loss fraction. Cited in §1 (cross-reference from M5.6 stack protocol).

Pattern AB.4 standing-scan applied to §11.5. Every PMID and NCT in this section has been content-verified at the per-compound canonical authoring step and is reconciled with this protocol’s citation usage. The cascade-failure pattern (NCT misattribution per the AC2-26 System Observations log) is the failure mode this verification prevents; every framework citation passes Pattern AB.4 verification at PSV iteration 1.

12. Clinical decision tree

12.1 Purpose

Define a phenotype-and-axis-guided decision tree that integrates §1–§11 into a single navigable clinical-workflow reference. Section 12 is the operational summary that a clinician reaches for at point-of-care to navigate the framework decisions: should this patient be considered for pre-treatment optimization, on which axes, with which compounds, in priming or parallel sequencing, with what monitoring cadence and what off-ramps.

Section 12 is rendered as a markdown decision matrix plus an ASCII flowchart for the high-level decision branches. The decision tree is not authority — it summarizes the authoritative content in §1–§11; if the decision tree and a §1–§11 sub-block disagree, the §1–§11 content is canonical.

12.2 High-level decision flowchart (ASCII)

                  PATIENT INITIATING (or recently initiated)
                              GLP-1 RA THERAPY
                                     |
                                     v
              [§1] Pre-treatment optimization indication?
              - Has substrate-quality deficit(s) been identified?
                                     |
                                     v
              [§2] Selection logic — 3 layers
              - Lab-driven (CRP, IL-6, REE, cortisol, sleep arch.)
              - Symptom-driven (fatigue, GI, stress, sleep)
              - Phenotype-driven (peri-menopausal, T2D, MASH,
                shift worker, prior weight-loss-regain)
              - Per-axis identification (1-5 axes active)
                                     |
                                     v (At least one axis active)
              [§2.4] Contraindications?
              - Active malignancy (mechanism-based for several compounds)
              - Pregnancy / conception planning <6 months
              - Severe renal impairment (SS-31 adjustment per label)
              - Active eating disorder (defer per GLP-1 RA exclusion)
                                     |
                                     v (No hard contraindications)
              [§3] Pre-treatment workup
              - Standard metabolic baseline (§3.2)
              - Per-axis-specific panels (§3.3-3.7)
              - Per-compound safety baseline (§3.8)
                                     |
                                     v
              [§4.2] Sequencing decision
              - Priming approach (4-6 wk before GLP-1)?
              - Parallel approach (simultaneous with GLP-1 early titration)?
                                     |
                                     v
              [§4.3] Per-axis stack composition
              - Inflammation: BPC-157 / KPV / TB-500
              - Mitochondrial: NMN / NR / SS-31
              - Gut barrier: BPC-157 / KPV (axis overlap)
              - HPA: Selank
              - Circadian: DSIP / Epitalon adjunct
                                     |
                                     v (Initiation visit + Week 2 + 4 + 6 cadence)
              [§5] Maintenance phase
              - Per-compound dose targets, monitoring intervals
              - Combined framework + GLP-1 visits at Months 1, 2, 3, 6
                                     |
                                     v
              [§6/7/8] Branch points
              - AE emerges? → §6 per-compound AE algorithm
              - Per-axis non-response? → §7 algorithm (pseudo vs true vs
                substrate-quality-deficit-not-modifiable)
              - End-of-cycle discontinuation? → §8 per-compound logic
              - Per-axis target attained? → §8 typical discontinuation
                pattern
                                     |
                                     v
              [§9] Combination with other Module 5 stacks
              - M5.5 visceral-fat / M5.6 lean-mass / M5.7 skin laxity
              - Module 4 cross-overlap (Anti-Aging, Longevity, Gut
                Healing, Recovery, Immune Restoration protocols)
                                     |
                                     v
              [§10] Counseling beats — Anchor 5 DOMINANT
              - Lead with what framework IS
              - Compounded-pathway access framing
              - Pregnancy-planning per-compound arithmetic
              - Within-axis comparator framing
              - Off-label / research-state-extrapolation transparency
                                     |
                                     v
              [§11] All claims source-anchored
              - Tier 1 / 1.5 / 2 / 3 evidence hierarchy
              - Pattern AB.4 identifier-integrity standing scan
                                     |
                                     v
              [Appendix A] Verification gate
              - 4-step cycle before clinician delivery

12.3 Phenotype-and-axis decision matrix

A markdown table that maps the §1.3 phenotype dimensions and §2.2 substrate-quality-axis identification to framework compound choices.

Phenotype + axis pattern	Framework consideration	Compound options	Sequencing	Counseling anchor
Peri-menopausal female with hsCRP elevated + cortisol elevated + sleep fragmented	Strong multi-axis candidate	BPC-157+KPV (infl+gut); NMN (mito); Selank (HPA); DSIP (circ)	Priming 4–6 wk preferred	Anchor 5 dominant; §1.5 worked example
Older adult ≥65 with mitochondrial-axis phenotype	Mitochondrial-axis candidate	NMN OR NR OR SS-31	Parallel typically	Anchor 4 within-axis comparator
T2D with HbA1c 7.5%+, elevated CRP, MASH-suspect	Multi-axis polycondition candidate	BPC-157+KPV; NMN; consider SS-31 if cost-and-access support	Priming or parallel	Anchor 5; cross-reference Module 5 §10.5 comparator
Shift worker with sleep disruption, normal CRP	Circadian-axis-only candidate	DSIP; Epitalon optional adjunct	Priming or parallel	Anchor 4 within-axis comparator
High-stress occupation, normal CRP, normal sleep	HPA-axis-only candidate	Selank	Priming or parallel	Anchor 5; concurrent benzodiazepine review
Insulin-resistant only, no inflammation, no stress, no sleep issues	Mitochondrial-axis-only candidate	NMN preferred (phenotype-match per Yoshino 2021)	Parallel typically	Anchor 4 within-axis comparator
Prior weight-loss-and-regain with adaptive thermogenesis	Mitochondrial-axis candidate (REE preservation)	NMN OR SS-31 (clinician choice)	Priming preferred	Anchor 5
Cognitive-comorbid (TBI, post-stroke, dementia)	Cognitive-axis cross-reference (M3 protocols); framework optional	M3 protocols primary; framework optional per §1 axes	Per M3 protocols	Anchor 5; §10.6 cognitive-comorbid framing
Active malignancy or recent (≤5 yr) cancer	Hard contraindication for BPC-157, TB-500, Epitalon, NAD+	Defer mechanism-based-contraindicated compounds; consider SS-31 / KPV / Selank / DSIP per oncology judgment	N/A	Anchor 5 with oncology co-management
Pregnancy / planning conception ≤6 months	Hard contraindication framework-wide	Defer framework	N/A	Anchor 3 pregnancy-planning
Pre-conception planning 6–12 months out	Conservative deferral	Defer framework; complete pre-conception planning per Anchor 3	N/A	Anchor 3
Severe renal impairment eGFR <30	SS-31 labeled dose adjustment (20 mg); other compounds clinician judgment	Per-compound adjustment	Per-compound	Anchor 1 + Anchor 2
Patient prefers no framework, prefers GLP-1 RA alone	Patient-preference deferral	None	N/A	Anchor 5 (“Both choices are reasonable”)
Patient prefers maximum optimization, multi-axis intervention	Multi-axis framework	All identified active axes addressed	Priming preferred	Anchor 5 with operational-complexity discussion

12.4 Worked example — framework decision tree application for the §1.5 patient

The §1.5 patient (54yo peri-menopausal female with hsCRP 4.8 mg/L, HOMA-IR 5.8, morning cortisol 22, sleep 5.5 hours fragmented, high-stress executive role, MASH-suspect, mild OSA on sleep study):

Decision-tree walkthrough.

Step 1 — Pre-treatment optimization indication: yes, multiple substrate-quality deficits documented per §1.5 and §2.5. Triangulated active on inflammation, HPA, and circadian axes; phenotype-supported on mitochondrial axis; clinician-judgment on gut barrier axis.

Step 2 — Selection logic: 4–5 axes active depending on gut-barrier-axis classification.

Step 3 — Contraindications: none identified. eGFR confirmed ≥30. No pregnancy planning. No malignancy. No active eating disorder. No active seizure. No active immunosuppression. No concurrent benzodiazepine.

Step 4 — Pre-treatment workup: full panel per §3.9 — standard metabolic baseline plus inflammation-axis, mitochondrial-axis phenotype-anchored, gut-barrier symptom inventory, HPA-axis biochemical + subjective, circadian-axis sleep diary + sleep study.

Step 5 — Sequencing decision: priming approach 4–6 weeks before GLP-1 RA initiation, given severe HPA-axis activation and sleep deprivation likely impacting anticipated GLP-1 response.

Step 6 — Stack composition: BPC-157+KPV oral combination (gut barrier + inflammation cross-axis); NMN 250 mg oral daily (mitochondrial axis, phenotype-matched to Yoshino 2021); Selank intranasal 300 mcg BID in 3-on / 1-off cycle (HPA axis); DSIP 200 mcg SubQ at bedtime in 3-on / 1-off cycle (circadian axis pending OSA result; AHI 8 mild OSA does not contraindicate). Epitalon deferred — age 54 borderline for age-related melatonin decline; reassess if DSIP-only response insufficient.

Step 7 — Initiation cadence: Week 0 initiation visit; Week 2 tolerability; Week 4 mid-initiation re-measurement of key labs (cortisol, hsCRP, sleep diary); Week 6 GLP-1 RA initiation transition.

Step 8 — Maintenance cadence: Months 1, 2, 3, 6 combined visits per §5.5 worked example.

Step 9 — Branch points: addressed per §6.10 worked example AE management (mild injection-site reaction with DSIP — rotation correction; tolerable NMN niacin-flush). Non-response algorithm not triggered (good response across all axes per §5.5).

Step 10 — Discontinuation: per §5.5 and §8.7 worked example. BPC-157+KPV at end of Week 8; Selank at end of Month 2 (HPA-axis target attained, sustained); DSIP at end of Month 3 (circadian target attained, sustained); NMN continued long-term per patient preference.

Step 11 — Combination decisions: framework + Wegovy 2.4 mg standard titration; no additional Module 5 stack indication identified at this patient profile.

Step 12 — Counseling beats: per §10 anchors throughout; Anchor 5 dominant. Initiation conversation (§10.2). Compounded-pathway counseling (§10.3) for BPC-157+KPV. Pregnancy-planning discussion (§10.4) — patient is peri-menopausal and not planning conception; framing presented for completeness. Comparator discussion (§10.5) — NMN selected per phenotype-matching to Yoshino 2021; alternatives discussed. Off-label / research-state-extrapolation transparency (§10.6) — explicit framing of every compound’s regulatory and evidence state.

Step 13 — Source citations per §11.5: framework Bibliography subset cited.

Step 14 — Verification gate per Appendix A: 4-step cycle applied to this protocol; clinician applies the same discipline to the patient’s case.

Pattern Z calibration self-audit at §12.4. The decision-tree walkthrough presents the patient’s options factually with per-axis evidence-state framing; the multi-axis framework approach is presented as one clinical-judgment option, not as obligatory for this phenotype; the comparator framing within mitochondrial axis (NMN selected over NR or SS-31) is anchored to phenotype-matching evidence (Yoshino 2021 in prediabetic women) without dismissing the alternatives; the off-label / extrapolation transparency is operational throughout — at every conversation, the framework’s research-state framing is honest.

---

Appendix A. Verification gate — the four-step cycle every protocol passes

A.1 Cycle overview

Every Module 5 protocol passes through the four-step verification cycle per the Protocol Template Appendix A. This framework protocol is no exception. The cycle is the operational discipline that prevents the failure modes documented in the AC2-26 System Observations log — Pattern R framing drift, Pattern V direction-of-effect generalization, Pattern W cross-section inconsistency, Pattern AA regulatory imprecision, Pattern AB identifier-cascade — from reaching the clinician-facing deliverable.

The four steps are sequential, not parallel; each step’s output is the next step’s input.

A.2 Step 1 — Production agent drafts

The production agent (this writing) produced the initial framework protocol draft per the Protocol Template structural authority and the methodology authority in /Methodology/ plus the per-compound canonicals at /Peptides/.

Production-agent responsibilities executed:

• Applied the twelve-section structure (§1–§12) defined in the Protocol Template, adapted for the framework’s multi-compound multi-axis structure.
• Applied Pattern R.1 / R.2 framing discipline at the section-architecture-design step — §1 opens with what the framework IS for; §2 opens with selection logic (what the framework IS used for) before exclusions and contraindications; §6 opens with anticipatory framing before discontinuation triggers per AE class; §7 opens with pseudo-vs-true non-response diagnostics; §8 opens with discontinuation triggers framed as legitimate clinical pathway including the “substrate-quality-deficit-not-modifiable” honest framing.
• Applied Pattern V direction-of-effect anchoring on every effect-size claim — the Yoshino 2021 NMN insulin-sensitivity effect-size is anchored to the prediabetic women enrollment; the Dollerup 2018 negative NR result is anchored to the obese insulin-resistant men enrollment; cross-population generalization is avoided.
• Applied Pattern AA regulatory-claim precision on every contraindication, every label claim, every off-label claim — SS-31 FDA-approved for Barth syndrome only; NMN dietary supplement status with contested FDA framework; framework use is off-label / research-state-extrapolation across all eight primary stack compounds and all three cross-referenced cross-module options (eleven compounds total).
• Applied Pattern AB.1 identifier integrity at draft-step — PMIDs and trial details anchored to per-compound canonicals; verified at canonical authoring step; re-verified at this protocol’s PSV iteration.
• Self-audited §10 against the five Pattern Z calibration anchors before handoff to Step 2.
• Hand off to Step 2 with explicit declaration of “draft complete; ready for primary-source verification.”

A.3 Step 2 — Primary-Source-Verification-Agent iteration 1

The Primary-Source-Verification-Agent (PSV agent) is a mechanical fact-check agent that does not produce content but verifies the production-agent’s draft against primary sources. For this framework protocol, PSV iteration 1 verifies:

• For every PMID in §11 Bibliography, verify the citation against the per-compound canonical files at /Peptides/ (where the PMIDs are anchored as primary citations).
• For every NCT in §11 Bibliography, verify the citation against the per-compound canonical files at /Peptides/ and against the underlying ClinicalTrials.gov record.
• For every effect-size claim in any section, verify the effect-size matches the primary source’s reported value, including the trial-enrollment population qualification — particularly important for the NAD+ axis trials (Yoshino 2021 in prediabetic women; Martens 2018 in healthy older adults; Dollerup 2018 negative result in obese insulin-resistant men; Yi 2023 dose-ranging in healthy middle-aged adults).
• For every dose threshold and labeled contraindication (SS-31 Barth syndrome FDA label), verify against the FDA label and the SS-31 canonical.
• Run Pattern AB.4 standing scan across the document — when one identifier is corrected, verify every occurrence of that identifier in this document and in all cross-referenced canon files (per-compound canonicals); produce a Pattern AB.4 cascade report if any corrections cascade.
• Hand off to Step 3 with explicit declaration of “primary-source verification complete; cascade-report attached if applicable.”

A.4 Step 3 — Independent-Adversarial-Reviewer-Agent iteration 1

The Independent-Adversarial-Reviewer-Agent (IAR agent) is a critical-review agent that scrutinizes the PSV-verified draft for framing, completeness, and pattern-discipline issues that the production-agent and PSV-agent may not have caught.

IAR-agent six-axis scrutiny applied to this framework protocol:

1. Framing (Pattern R / R.1 / R.2). Does every section open with research-state content before regulatory / cautionary framing? Is the cumulative tone across the framework’s multi-compound discussion non-steering? Pattern Z 5-anchor compliance in §10? IAR verification target: §10.6 Anchor 5 must be the largest §10 subsection; §10 must not steer toward or away from the framework.

2. Completeness. Are all twelve sections substantively populated? Are the eight primary stack compounds and three cross-referenced cross-module options (Humanin / Semax / Cerebrolysin) explicitly documented with primary-stack-inclusion / cross-referenced-cross-module-option rationale (Appendix C)? Are the five substrate-quality axes (with the HPA / Stress / Sleep axis carrying the v1.1 cognitive-comorbidity sub-scope) consistently structured across §1, §2, §3, §4, §5, §7, §8, §10, §12?

3. Consistency (Pattern W). Are structural-count claims (e.g., “five substrate-quality axes” in §1.2 and §1.3; “seven panels” in §3) consistent end-to-end? Does §3 panel inventory reconcile with §5 monitoring intervals and §6 AE-trigger labs? Does §4.3 per-axis stack composition reconcile with §5 maintenance dosing and §8 discontinuation triggers?

4. Direction-of-effect (Pattern V). Are null / negative findings (Dollerup 2018 NR negative result; Epitalon paradoxical anti-tumor data; the framework’s overall research-state-incompleteness for the specific use case) characterized with primary-source effect-size and population qualification?

5. Regulatory precision (Pattern AA). Is every regulatory claim precise — FDA-approved (SS-31 Barth syndrome with specific date); dietary supplement (NMN with contested FDA status; NR with GRAS-acknowledged status); research-state (BPC-157, KPV, TB-500, Selank, DSIP, Epitalon); off-label framework use throughout?

6. Identifier integrity (Pattern AB.1 / AB.2 / AB.4 standing scans). Has the PSV-agent’s cascade-report been resolved? Are there any cross-document identifier references that the PSV-agent’s scope did not cover but the IAR-agent should flag? Particular attention to cross-references with M5.6 lean-mass stack protocol (NCT identifiers and PMIDs for MOTS-c and CJC-Ipamorelin) and M5.5 visceral-fat stack protocol (NCT identifiers and PMIDs for tesamorelin and AOD-9604).

IAR-agent handoff to Step 4 with explicit declaration of “adversarial review complete; six-axis scrutiny report attached; any unresolved findings flagged for clinical-judgment review.”

A.5 Step 4 — Dr. Gross verification gate

Dr. Jeff Gross MD applies the final clinical-judgment review before this framework protocol is delivered to the clinician audience. Dr. Gross’s review is not mechanical — it is the senior-clinician-judgment layer that the agent layers cannot replicate.

Dr. Gross verification-gate responsibilities applied to this framework protocol:

• Read the protocol end-to-end as the target clinician audience would.
• Apply clinical judgment to the agent layers’ technical correctness: do the dose thresholds reflect current functional medicine practice across the eight primary stack compounds and the three cross-referenced cross-module options? Do the per-axis selection criteria reflect current clinical experience identifying substrate-quality deficits? Do the per-compound AE management algorithms reflect current clinical experience? Do the counseling beats sound like the voice and judgment that an experienced clinician would actually use in practice?
• Identify any drift from the Voice Profile (/Methodology/Voice Profile - Dr. Jeff Gross MD.md) — tone, framing, what’s emphasized, what’s de-emphasized. Specifically: does the framework’s research-state-extrapolation framing read as honest acknowledgment or as defensive disclaimer?
• Apply the surface-readiness check: is this ready to deliver, or does any section require revision before clinician release?
• Authorize delivery, or return to Step 1 (production agent) with revision notes.

The Dr. Gross gate is the only gate that authorizes delivery. The agent layers prepare the protocol; the clinical-judgment gate releases it.

A.6 Cycle iteration

If Step 4 returns to Step 1, the cycle iterates. Each iteration is numbered and documented in the per-protocol iteration log if one is established. The semaglutide iteration log demonstrates this cycle in practice; this framework protocol’s iteration log will be established if and when Dr. Gross returns the protocol for revision.

---

Appendix B. Pattern discipline summary

B.1 Pattern R / R.1 / R.2 — framing discipline

Pattern R (paragraph-level framing): every section opens with research-state content before regulatory / cautionary / contraindication / deficit framing. Specific enforcement points in this framework protocol:

• §1 opens with what the framework IS for and the patient phenotypes for whom it is considered.
• §2.2 (selection logic — what the framework IS used for) precedes §2.3 (relative exclusion) and §2.4 (contraindications).
• §6 opens per AE class with anticipatory framing (what the AE IS, why it occurs, how common it is) before management and discontinuation triggers.
• §7 opens with pseudo-vs-true-non-response diagnostics including the honest third category (substrate-quality-deficit-not-modifiable) before decision branches.
• §8 opens with discontinuation triggers framed as legitimate clinical pathway including end-of-cycle natural pattern, not as therapeutic failure.
• §10 opens with the five Pattern Z anchors as the framework operating principle, with Anchor 5 (off-label / extrapolation transparency) dominant.

Pattern R.1 (structural framing): the structural ordering of sections and the labels on items is part of Pattern R. The §4.3 per-axis stack composition tables are organized by axis, not by compound — the patient and clinician see “what’s available for this axis” rather than “which compounds are most prominent.”

Pattern R.2 (design-time enforcement): Pattern R + R.1 are applied at the section-architecture-design step. The framework’s five-axis structure, multi-compound stack composition tables, and per-axis decision logic were locked at the design step before content generation.

B.2 Pattern V — direction-of-effect verification

Every effect-size claim is anchored to its primary source with population qualification. Examples specific to this framework:

• “Yoshino 2021 NMN 250 mg/day for 10 weeks improved muscle insulin sensitivity” is Pattern V compliant when attached to “prediabetic postmenopausal women enrollment.” Generalizing the same effect-size to non-diabetic, non-postmenopausal, or male phenotype without re-anchoring is a Pattern V violation.
• “Dollerup 2018 NR 2000 mg/day for 12 weeks did NOT improve insulin sensitivity” is anchored to “obese insulin-resistant men enrollment.” This null finding is not generalized to all NR-using populations.
• “EMBRACE SS-31 improved LV end-systolic volume” is anchored to “heart failure patients with reduced ejection fraction” — not generalized to non-HF populations.
• The framework’s overall efficacy framing for the specific use case (pre-treatment metabolic preparation for GLP-1 initiation) is anchored to “research-state-incomplete; mechanism rationale sound; no Phase 3 RCT for this specific use case across any framework compound” — no claim of efficacy beyond this honest framing.

B.3 Pattern W — cross-section enumeration consistency

Structural-count claims are reconciled end-to-end:

• “Five substrate-quality axes” in §1.2, §1.3, and throughout: consistently inflammation, mitochondrial, gut barrier, HPA / Stress / Sleep (with cognitive-comorbidity sub-scope per v1.1), circadian.
• “Eight primary stack compounds” in frontmatter, §C.1, §4.3 primary-axis stack composition rows, and §11: consistently BPC-157, SS-31, KPV, TB-500, Selank, DSIP, Epitalon, NAD+ (NMN / NR / IV / SubQ formats).
• “Three cross-referenced cross-module options” in frontmatter, §C.2, §4.3 cross-reference rows, §10.6 cross-referenced cross-module options sub-beat, and §11: consistently Humanin (Mitochondrial axis MDP sub-reference), Semax + Cerebrolysin (HPA / Stress / Sleep axis cognitive-comorbidity sub-scope).
• “Eleven compounds total” (8 primary + 3 cross-referenced) is the v1.1 total-compound count anchor.
• “Seven workup panels” in §3 (§3.2 standard metabolic baseline + §3.3 inflammation-axis + §3.4 mitochondrial-axis + §3.5 gut-barrier-axis + §3.6 HPA-axis + §3.7 circadian-axis + §3.8 per-compound safety baseline).
• “Twelve sections” per Protocol Template (§1–§12 plus Appendices A, B, C).

B.4 Pattern Z — 5-anchor calibration in §10

The five Pattern Z calibration anchors operate in §10 with Anchor 5 (off-label / extrapolation transparency) DOMINANT for this framework. The §10 self-audit checklist:

• Anchor 1 — framework and each compound introduced with what they ARE; regulatory framing follows.
• Anchor 2 — compounded-pharmacy pathway framing presents access factually; not framed as inherently inferior.
• Anchor 3 — pregnancy-planning leads with research-state human pregnancy-exposure data (acknowledging that framework compound human pregnancy data is largely absent); PK arithmetic and contraindication framing follow.
• Anchor 4 — within-axis comparator framing is multi-dimensional and shared-decision-supporting.
• Anchor 5 — DOMINANT. Off-label / extrapolation transparency is operational at every conversation in §10.

§10 self-audits against these five anchors before handoff to Appendix A verification cycle.

B.5 Pattern AA — regulatory-claim precision

Every regulatory claim distinguishes precisely:

• FDA-approved — SS-31 (Elamipretide) for Barth syndrome only, September 2023. No other framework compound has FDA approval for any indication.
• Dietary supplement — NMN with contested FDA status (NDI letter 2022 reclassified NMN; legal framework unsettled); NR with GRAS-acknowledged status.
• Research-state / not FDA-approved — BPC-157, KPV, TB-500, Selank, DSIP, Epitalon. Access pathway is 503A or 503B compounding with post-2023 FDA Category 2 listing variation affecting some compounds.
• Off-label — all framework compounds when used for pre-treatment metabolic preparation indication, including SS-31 (Barth syndrome label does not extend to this use).
• Approved abroad — Selank Russian approval for GAD; Semax Russian approval for stroke / ADHD / optic nerve atrophy; Cerebrolysin EU / Russia / China approvals for stroke and dementia (all referenced for completeness; not transferable to U.S. regulatory standing).

B.6 Pattern AB.1 / AB.2 / AB.4 — identifier-integrity standing scans

Pattern AB.1: identifier verification at draft step (production-agent self-check) — every PMID and NCT in §11 anchored to per-compound canonicals at /Peptides/.

Pattern AB.2: identifier verification at PSV step (mechanical re-verification) — PSV agent re-verifies against per-compound canonicals and against underlying primary sources (PubMed abstracts; ClinicalTrials.gov entries).

Pattern AB.4: cascade scan when any identifier is corrected — every occurrence of that identifier in this document AND in all cross-referenced canon files (per-compound canonicals; cross-stack protocols at M5.5, M5.6, M5.7) is updated in the same commit.

B.7 Pattern N.1 — peptide path discipline

All eleven framework compounds (8 primary stack compounds + 3 cross-referenced cross-module options) are housed at /Peptides/ per the existing canonical structure, including NAD+ which is explicitly a dinucleotide coenzyme rather than a peptide (the NAD+ canonical at /Peptides/NAD+.md documents this exception with the rationale that NAD+ “is included in this vault due to its central role in peptide therapy protocols and longevity medicine”); Humanin, Semax, and Cerebrolysin are housed at /Peptides/Humanin.md, /Peptides/Semax.md, and /Peptides/Cerebrolysin.md respectively. The framework respects the existing canonical paths.

B.8 Pattern discipline self-audit checklist

This framework protocol passes the full Pattern discipline audit when:

• Pattern R / R.1 / R.2: every section opens with research-state content; section ordering is design-time-locked.
• Pattern V: every effect-size claim has primary-source anchor and population qualification; Yoshino, Martens, Dollerup, Yi, EMBRACE, TAZPOWER, ESSENCE, SELECT, STEP, SURMOUNT, SURPASS-2 effect-sizes anchored.
• Pattern W: “five substrate-quality axes,” “eight primary stack compounds,” “three cross-referenced cross-module options,” “eleven compounds total,” “seven workup panels,” “twelve sections” consistent end-to-end.
• Pattern Z: §10 self-audit against 5 anchors complete; Anchor 5 dominant; cumulative-tone scan non-steering.
• Pattern AA: every regulatory claim precise (FDA-approved, dietary supplement, research-state, off-label, approved abroad).
• Pattern AB.1 / AB.2 / AB.4: production-agent self-check complete; PSV agent verification pending; cascade scan ready.
• Pattern N.1: all compounds at /Peptides/ path per existing canonicals.

---

Appendix C. Compound primary-stack / cross-referenced-cross-module rationale and self-audit findings

C.1 Compounds included as PRIMARY STACK components in the framework (8)

The framework’s eight primary stack compounds, with brief inclusion rationale:

1. BPC-157 — gut barrier + anti-inflammatory; inclusion rationale: extensive preclinical evidence (35+ animal studies in 2025 orthopedic systematic review PMID 40756949); two small human pilots (IV safety PMID 40131143, intravesical IC PMID 39325560); one Phase 2 RCT recruiting (NCT07437547); mechanism-rationally aligned with gut-barrier and inflammation axes; common practitioner use for gut healing per existing Gut Healing Protocol.
2. SS-31 (Elamipretide) — mitochondrial cardiolipin protection; inclusion rationale: ONLY framework compound with FDA approval (Barth syndrome, September 2023); Phase 2 EMBRACE heart-failure RCT (PMID 29217757); 168-week TAZPOWER observational data (PMID 38602181); mechanism-rationally aligned with mitochondrial axis; off-label for framework use but the most regulatory-anchored compound in the framework.
3. KPV — anti-inflammatory + gut barrier via PepT1 self-targeting; inclusion rationale: alpha-MSH-derived tripeptide with documented NF-κB inhibition (PMID 12750433); PepT1-mediated self-targeting to inflamed colon supports oral route (PMID 18061177); animal IBD models (PMID 18092346); included in existing Gut Healing Protocol and Immune Restoration Protocol.
4. TB-500 — anti-inflammatory + tissue repair; inclusion rationale: RGN-259 Phase 3 ocular development program (PMID 30063853); Phase 1 IV safety data up to 1260 mg; cardiac repair preclinical (PMID 25015963, PMID 27450736); included in existing Wolverine and Recovery Stack Protocols; mechanism-rationally aligned with inflammation axis particularly for tissue-repair-co-indicated patients.
5. Selank — anxiolytic, HPA axis modulation, IL-6 suppression; inclusion rationale: human GAD immunomodulation study (PMID 18577961) — one of the few human clinical studies among the research-state framework compounds; non-benzodiazepine GABA-A allosteric modulation (PMID 26924987); human fMRI functional connectivity (PMID 32342318); Russian approval for GAD; included in existing Cognitive Enhancement Protocol.
6. DSIP — sleep architecture, HPA axis, slow-wave sleep; inclusion rationale: 1983 human sleep RCT (PMID 6895513) — one of the few human RCTs among the research-state framework compounds; mechanism-rationally aligned with circadian axis; preclinical anti-tumor signal (PMID 12782416 — favorable for cancer-context patients); decades of practitioner safety experience.
7. Epitalon — circadian / pineal melatonin restoration; inclusion rationale: pineal melatonin restoration in aged primates (PMID 12096440) — directly relevant to age-related circadian decline; mechanism-rationally aligned with circadian axis; included as optional adjunct rather than primary circadian-axis compound given the zero human RCT evidence base and the Khavinson-group concentration concern.
8. NAD+ (NMN, NR, IV NAD+, SubQ NAD+) — mitochondrial cofactor; inclusion rationale: STRONGEST human RCT evidence of any framework compound — Yoshino 2021 NMN in prediabetic women (PMID 33888596, Science); Martens 2018 NR in healthy older adults (PMID 29599478, Nat Comms); Dollerup 2018 NR negative result in obese insulin-resistant men (PMID 29992272, AJCN — important null finding); Yi 2023 NMN dose-ranging (PMID 36482258, GeroScience); mechanism-rationally aligned with mitochondrial axis; the Yoshino 2021 phenotype (prediabetic women) is directly relevant to many framework patient profiles (e.g., the §1.5 worked-example patient).

C.2 Cross-referenced cross-module compounds (3)

Three compounds are presented in this framework as cross-referenced cross-module options rather than as primary stack components. The cross-reference framing replaces the prior v1.0 “excluded with rationale” framing per the v1.1 Pattern Z anchor-4 refactor (Daria correction 2026-05-14: “are you sure to exclude peptides? we could cross reference with another module”). Each compound’s primary canonical home is in another module’s protocol family; this framework references that primary canonical home and documents when the compound is a reasonable consideration in the pre-treatment optimization context, with explicit Pattern AA + Pattern Z framing of its evidence state and operational tradeoffs. The compounds are presented in §4.3 stack composition tables (Humanin under the Mitochondrial axis MDP cross-reference; Semax + Cerebrolysin under the HPA / Stress / Sleep axis cognitive-comorbidity sub-scope) and in §10.6 patient counseling cross-referenced cross-module options sub-beat.

1. Humanin — cross-referenced cross-module option (Mitochondrial axis MDP sub-reference; primary canonical home /Peptides/Humanin.md + Anti-Aging Daily / Longevity Stack Protocols). Mechanism: mitochondrial-derived peptide (MDP family — co-listed with MOTS-c and SHLP1–6); cytoprotective; bioenergetic regulator. Evidence state: research-state-incomplete (mechanistic + observational evidence; thin human-trial data — the canonical at /Peptides/Humanin.md notes “Human dosing extrapolated from rodent studies; clinical protocols not yet established” and “Long-term safety profile in humans not established”). Active-malignancy mechanism-based caution per JAK2/STAT3 anti-apoptotic signaling. Pattern AA: investigational; not FDA-approved-for-marketing-claims for any indication. When to consider in pre-treatment optimization context: patient with documented mitochondrial-dysfunction markers + explicit interest in the MDP family. The framework’s primary Mitochondrial axis interventions (NAD+ precursors per Yoshino 2021 / Martens 2018 / Dollerup 2018 / Yi 2023; SS-31 per FDA Barth syndrome label + EMBRACE Phase 2 RCT) carry stronger evidence anchors; Humanin is the MDP-family-interested-patient option with the explicit acknowledgment of the thin human-trial evidence base.

2. Semax — cross-referenced cross-module option (HPA / Stress / Sleep axis cognitive-comorbidity sub-scope; primary canonical home /Peptides/Semax.md + Module 3 Cognitive Enhancement Protocol). Mechanism: ACTH(4–10)-fragment-derived heptapeptide; BDNF/NGF upregulation; neuroprotective. Evidence state: Russian approval for acute ischemic stroke, ADHD, optic nerve atrophy; off-label for HPA-mediated weight-loss contexts; English-language evidence base predominantly preclinical plus one human fMRI functional connectivity study (PMID 32342318) and the Semax–Selank-comparator literature. Pattern AA: not FDA-approved-for-marketing-claims in the U.S.; Russian foreign approval is not transferable to U.S. regulatory standing. When to consider in pre-treatment optimization context: cognitive-axis comorbid weight-loss patients — patients with cognitive-load components of emotional or stress eating, post-stroke history, food-noise with prominent ruminating-cognition driver, post-TBI history with mood-driven eating. The framework’s primary HPA-axis intervention (Selank) carries the framework-relevant non-benzodiazepine anxiolytic mechanism + human GAD immunomodulation evidence (PMID 18577961); Semax is the cognitive-comorbidity cross-module option for the subset of HPA-axis-active patients with cognitive-load drivers.

3. Cerebrolysin — cross-referenced cross-module option (HPA / Stress / Sleep axis cognitive-comorbidity sub-scope; primary canonical home /Peptides/Cerebrolysin.md + Module 3 Cognitive Enhancement Protocol + Post-Stroke Recovery Protocol). Mechanism: porcine brain hydrolysate; neurotrophic peptide mix mimicking endogenous neurotrophic factors (BDNF, NGF, GDNF, CNTF, IGF-1, IGF-2 mimicry). Evidence state: Phase 3 trials in acute stroke / TBI / dementia (Russian, EU, Chinese, Mexican approvals for these indications). Operational considerations: porcine protein allergy is a contraindication; IM or slow IV administration with dilution is operationally heavier than the SC compounds in the rest of the stack. Pattern AA: foreign approvals (Russia, Europe, China, Mexico) are not transferable to U.S. regulatory standing; research-only in the U.S.; not FDA-approved-for-marketing-claims. When to consider in pre-treatment optimization context: patients with specific cognitive comorbidities (documented post-stroke history; post-TBI history; early-stage dementia) who are pursuing pre-treatment optimization for the GLP-1 RA initiation and who accept the operational profile (porcine allergen risk; IM/IV-with-dilution administration). The framework’s primary HPA-axis intervention (Selank) and the §10.6 cognitive-comorbid sub-beat are the standard pathway; Cerebrolysin is the cross-module option for the subset of patients whose cognitive-comorbidity profile matches the Module 3 Cognitive Enhancement Protocol or Post-Stroke Recovery Protocol indication.

Pattern Z anchor-4 discipline restored. The v1.0 draft presented Humanin / Semax / Cerebrolysin in this section as “EXCLUDED with rationale,” which framed the three compounds as off-limits rather than as optional cross-module considerations with tradeoffs. The v1.1 refactor presents them as legitimate options with cross-references to primary canonical homes — present compounds as legitimate options with tradeoffs + cross-references to primary canonical homes; don’t exclude. Pattern Z anchor 4 multi-dimensional comparator discipline operational throughout.

C.3 Self-audit findings on completion

Primary-stack / cross-referenced-cross-module completeness. All 11 candidate compounds considered: 8 primary stack compounds (BPC-157, SS-31, KPV, TB-500, Selank, DSIP, Epitalon, NAD+) and 3 cross-referenced cross-module options (Humanin — Mitochondrial axis MDP sub-reference; Semax — HPA / Stress / Sleep axis cognitive-comorbidity sub-scope; Cerebrolysin — HPA / Stress / Sleep axis cognitive-comorbidity sub-scope). Pattern W structural-count consistency: 8 primary stack compounds + 3 cross-referenced cross-module options (11 compounds total) documented in frontmatter, §C.1, §C.2, §4.3 stack composition tables, §10.6 patient counseling cross-referenced cross-module options sub-beat, §11, and §B.3.

Selection framework decision-supporting (NOT prescriptive) review. The §2.2 three-layer selection logic (lab-driven, symptom-driven, phenotype-driven) operates per-axis and per-patient; the framework explicitly states it does NOT advocate adding compounds to every patient initiating GLP-1 therapy; the §10 counseling beats emphasize the patient-and-clinician shared decision-making throughout; the “substrate-quality-deficit-not-modifiable” third category in §7.2 is the honest framing that not every patient benefits from the framework. Decision-supporting discipline maintained.

Pattern Z.research-precision review. Vocabulary audit: protocol does NOT use “emerging,” “promising,” “highly experimental,” “speculative,” or “fringe” — vocabulary discipline held throughout. Every compound’s evidence state is presented honestly: SS-31 has FDA approval for Barth syndrome; NMN has the strongest human RCT evidence among framework compounds (Yoshino 2021); Dollerup 2018 NR negative result is explicitly documented as an important null finding; BPC-157 has extensive preclinical plus two small human pilots; Epitalon has zero human RCTs and Khavinson-group concentration concern.

Pattern AA.marketing-claims precision review. Every compound’s regulatory state: SS-31 FDA-approved for Barth syndrome only (off-label for framework); NMN dietary supplement with contested FDA status; NR dietary supplement with GRAS-acknowledged status; BPC-157, KPV, TB-500, Selank, DSIP, Epitalon research-state with 503A/503B compounding access pathways and post-2023 FDA Category 2 listing variation; Selank approved in Russia (not transferable to U.S. standing); Humanin investigational / research-state with no FDA approval and no foreign approval (cross-referenced cross-module option); Semax Russian-approved for acute stroke / ADHD / optic nerve atrophy (cross-referenced cross-module option; foreign approval not transferable to U.S. standing); Cerebrolysin approved abroad in Russia / EU / China / Mexico for stroke / TBI / dementia (cross-referenced cross-module option; foreign approvals not transferable to U.S. standing). Precision maintained for primary stack compounds AND for cross-referenced cross-module options.

Cross-reference to Module 3 + Module 4 canonicals review. Cross-references documented throughout: BPC-157 cross-referenced to Gut Healing Protocol, Recovery Stack Protocol, Wolverine Stack Protocol; SS-31 cross-referenced to Anti-Aging Daily Protocol and Longevity Stack Protocol; TB-500 cross-referenced to Wolverine, Recovery Stack; KPV cross-referenced to Gut Healing Protocol and Immune Restoration Protocol; Selank cross-referenced to Cognitive Enhancement Protocol; Epitalon and NAD+ cross-referenced to Anti-Aging Daily Protocol and Longevity Stack Protocol; Humanin (cross-referenced cross-module option) cross-referenced to Anti-Aging Daily Protocol and Longevity Stack Protocol (MDP family with MOTS-c); Semax (cross-referenced cross-module option) cross-referenced to Module 3 Cognitive Enhancement Protocol; Cerebrolysin (cross-referenced cross-module option) cross-referenced to Module 3 Cognitive Enhancement Protocol and Post-Stroke Recovery Protocol. The framework protocol references these primary canonical homes throughout — does not replace Module 3 or Module 4 coverage. Cross-reference discipline maintained per v1.1 Pattern Z anchor-4 refactor.

§10 Anchor 5 dominant review. §10.6 (off-label / extrapolation conversation — Anchor 5 dominant) is the largest §10 subsection. The patient counseling is honest framing throughout — mechanism rationale sound; clinical-trial evidence base for this specific use case research-state-incomplete; the framework is one possible clinical-judgment layer that the clinician may offer to selected patients. Anchor 5 dominance maintained.

C.4 Potential Dr. Gross verification-gate items

Items the production agent anticipates Dr. Gross may flag for clinical-judgment review:

1. The SS-31 functional-medicine-extrapolated dose vs Barth syndrome labeled dose discussion (§4.3, §10.5). The framework permits both options with clinician-and-patient shared decision; some clinicians prefer the labeled dose for pharmacologic-evidence-completeness; some prefer the functional-medicine dose for cost-and-access reasons. Dr. Gross may have a preferred default position for the framework’s recommendation.

2. The NMN vs NR vs SS-31 comparator framing within mitochondrial axis (§10.5). The framework presents these as patient-and-clinician shared decision with phenotype-matching considerations (NMN aligned with prediabetic phenotype per Yoshino 2021). Dr. Gross may have additional clinical-judgment considerations.

3. The framework’s positioning relative to “standard-of-care GLP-1 RA + lifestyle foundation.” The §10.6 counseling explicitly frames the framework as an optional additional layer — “Both choices are reasonable. The framework is not ‘better’ than the no-framework path for every patient.” Dr. Gross may want this framing strengthened or moderated.

4. The Dollerup 2018 NR negative result emphasis (§4.3, §10.5). The framework explicitly documents the null finding in counseling beats. Dr. Gross may want additional clinical-judgment framing on how to discuss the null finding with patients who are considering NR specifically.

5. The 3 cross-referenced cross-module options framing (§C.2, §4.3, §10.6). Per the v1.1 Pattern Z anchor-4 refactor, Humanin / Semax / Cerebrolysin are presented as cross-referenced cross-module options rather than excluded compounds: Humanin under the Mitochondrial axis MDP sub-reference; Semax + Cerebrolysin under the HPA / Stress / Sleep axis cognitive-comorbidity sub-scope. Dr. Gross may have clinical-judgment input on the framing depth — whether the cross-module options should be expanded into full per-compound dosing / cycling / monitoring schedules within this protocol (cross-module duplication) or maintained as cross-references to the primary canonical homes (the v1.1 default). Dr. Gross may also have alternative perspectives on whether additional Module 3 / Module 4 compounds should be cross-referenced.

6. The gut-barrier-axis intervention as GLP-1 GI AE attenuation framing (§6.3). The framework presents this as mechanism-rationally proposed without claiming efficacy. Dr. Gross may have clinical-judgment input on how strongly to frame this mechanism rationale in patient counseling.

These items are flagged for Dr. Gross verification-gate review; the protocol is delivered to Dr. Gross with these anticipated items documented for his attention.

---

End of protocol body. Cross-reference: this protocol is referenced from Module 5 Master Protocol Index; from per-compound canonicals at /Peptides/; and from cross-stack protocols at M5.5, M5.6, M5.7 where framework integration is documented.